| DrugName | Drugbank ID | Top 3 targets (by SDisG) | Top 3 regulated pathways (by SDP) | SPCN | SDN | SDC |
| Desmopressin | DB00035 | GSK3B;HDAC1;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Amoebiasis; | 62.89 | 11.17 | 5.63 |
| Cetrorelix | DB00050 | GSK3B;CTSS;TLR2; | Fluid shear stress and atherosclerosis;Porphyrin and chlorophyll metabolism;Biosynthesis of amino acids; | 9.34 | 3.65 | 2.56 |
| Bifonazole | DB04794 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 285.03 | 21.14 | 13.48 |
| Lemborexant | DB11951 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 273.15 | 20.49 | 13.33 |
| Niraparib | DB11793 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;RNA transport;Th17 cell differentiation; | 278.57 | 21.31 | 13.07 |
| Clotrimazole | DB00257 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 273.84 | 21.05 | 13.01 |
| Nilotinib | DB04868 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 276.14 | 21.59 | 12.79 |
| Imatinib | DB00619 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 290.45 | 22.64 | 12.83 |
| Ruxolitinib | DB08877 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 271.02 | 21.56 | 12.57 |
| Zaleplon | DB00962 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Natural killer cell mediated cytotoxicity; | 279.70 | 22.15 | 12.63 |
| Ribociclib | DB11730 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 285.23 | 24.34 | 11.72 |
| Imiquimod | DB00724 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 260.90 | 23.76 | 10.98 |
| Delavirdine | DB00705 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;RNA transport;Th17 cell differentiation; | 253.13 | 20.48 | 12.36 |
| Dasatinib | DB01254 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 245.60 | 22.05 | 11.14 |
| Ponatinib | DB08901 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 277.47 | 23.74 | 11.69 |
| Letrozole | DB01006 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 275.81 | 23.00 | 11.99 |
| Fostamatinib | DB12010 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 224.15 | 20.72 | 10.82 |
| Pazopanib | DB06589 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;RNA transport;Th17 cell differentiation; | 275.49 | 22.67 | 12.15 |
| Dacomitinib | DB11963 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 282.80 | 24.23 | 11.67 |
| Sunitinib | DB01268 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 295.47 | 24.64 | 11.99 |
| Vemurafenib | DB08881 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 296.18 | 25.08 | 11.81 |
| Desloratadine | DB00967 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 284.95 | 24.03 | 11.86 |
| Osimertinib | DB09330 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 282.18 | 23.73 | 11.89 |
| Indoramin | DB08950 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway; | 278.61 | 21.38 | 13.03 |
| Regorafenib | DB08896 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 261.15 | 24.41 | 10.7 |
| Gefitinib | DB00317 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 258.41 | 22.91 | 11.28 |
| Erlotinib | DB00530 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 300.74 | 26.06 | 11.54 |
| Avanafil | DB06237 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 284.09 | 25.21 | 11.27 |
| Sorafenib | DB00398 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 277.39 | 25.17 | 11.02 |
| Vandetanib | DB05294 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 289.00 | 25.17 | 11.48 |
| Afatinib | DB08916 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 288.43 | 25.62 | 11.26 |
| Tofacitinib | DB08895 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;RNA transport; | 286.39 | 25.08 | 11.42 |
| Fedratinib | DB12500 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 282.33 | 25.23 | 11.19 |
| Midostaurin | DB06595 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 280.96 | 25.75 | 10.91 |
| Pemigatinib | DB15102 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 280.22 | 25.78 | 10.87 |
| Bosutinib | DB06616 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 264.31 | 24.61 | 10.74 |
| Crizotinib | DB08865 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 270.01 | 24.86 | 10.86 |
| Axitinib | DB06626 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 300.86 | 24.07 | 12.5 |
| Brigatinib | DB12267 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 258.14 | 24.61 | 10.49 |
| Capmatinib | DB11791 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 286.92 | 22.83 | 12.57 |
| Neratinib | DB11828 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 279.92 | 26.04 | 10.75 |
| Binimetinib | DB11967 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 269.29 | 25.05 | 10.75 |
| Lapatinib | DB01259 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 281.28 | 26.49 | 10.62 |
| Selumetinib | DB11689 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 273.40 | 25.96 | 10.53 |
| Ceritinib | DB09063 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 274.05 | 26.58 | 10.31 |
| Zinc-acetate | DB14487 | HDAC2;HDAC1;PARP1; | Mineral absorption;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 76.69 | 21.19 | 3.62 |
| Ondansetron | DB00904 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 246.84 | 21.32 | 11.58 |
| Duvelisib | DB11952 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 364.61 | 30.66 | 11.89 |
| Perampanel | DB08883 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 313.15 | 27.25 | 11.49 |
| Astemizole | DB00637 | JAK1;GSK3B;HDAC1; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;T cell receptor signaling pathway; | 296.29 | 25.99 | 11.4 |
| Flortaucipir-F-18 | DB14914 | JAK1;GSK3B;MAPK14; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 326.81 | 30.74 | 10.63 |
| Alprazolam | DB00404 | JAK1;GSK3B;HDAC2; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 311.40 | 28.05 | 11.1 |
| Risperidone | DB00734 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 284.46 | 26.15 | 10.88 |
| Bendazac | DB13501 | GSK3B;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 249.43 | 24.24 | 10.29 |
| Oxaprozin | DB00991 | GSK3B;HDAC2;HDAC1; | RNA transport;Th1 and Th2 cell differentiation;Human cytomegalovirus infection; | 283.69 | 27.76 | 10.22 |
| Suvorexant | DB09034 | JAK1;GSK3B;MAPK14; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Spliceosome; | 288.57 | 25.97 | 11.11 |
| Irbesartan | DB01029 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 262.69 | 27.45 | 9.57 |
| Acalabrutinib | DB11703 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 318.40 | 28.50 | 11.17 |
| Brexpiprazole | DB09128 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 312.37 | 28.29 | 11.04 |
| Parecoxib | DB08439 | JAK1;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 229.27 | 22.86 | 10.03 |
| Granisetron | DB00889 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway; | 292.59 | 26.24 | 11.15 |
| Pimozide | DB01100 | HDAC1;MAPK14;IGF1R; | Spliceosome;Necroptosis;Natural killer cell mediated cytotoxicity; | 288.32 | 29.54 | 9.76 |
| Azelastine | DB00972 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 272.14 | 23.87 | 11.4 |
| Idelalisib | DB09054 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;NF-kappa B signaling pathway;RNA transport; | 351.98 | 31.37 | 11.22 |
| Zolpidem | DB00425 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Natural killer cell mediated cytotoxicity; | 292.90 | 26.95 | 10.87 |
| Netarsudil | DB13931 | HDAC2;HDAC1;MAPK14; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;Transcriptional misregulation in cancer; | 257.61 | 27.82 | 9.26 |
| Estazolam | DB01215 | GSK3B;HDAC1;MAPK14; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway; | 298.84 | 29.36 | 10.18 |
| Phenprocoumon | DB00946 | GSK3B;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 229.32 | 25.06 | 9.15 |
| Rosoxacin | DB00817 | GSK3B;HDAC1;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 249.01 | 25.94 | 9.6 |
| Telmisartan | DB00966 | MAPK14;PIK3CB;PARP1; | Spliceosome;Phagosome;Transcriptional misregulation in cancer; | 197.82 | 25.26 | 7.83 |
| Eletriptan | DB00216 | JAK1;HDAC2;HDAC1; | RNA transport;NF-kappa B signaling pathway;Neutrophil extracellular trap formation; | 310.83 | 29.19 | 10.65 |
| Conivaptan | DB00872 | JAK1;HDAC2;HDAC1; | Spliceosome;Estrogen signaling pathway;Th1 and Th2 cell differentiation; | 299.51 | 29.39 | 10.19 |
| Encainide | DB01228 | GSK3B;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 229.45 | 22.76 | 10.08 |
| NADH | DB00157 | GSK3B;PIK3CB;PARP1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 125.24 | 25.30 | 4.95 |
| Domperidone | DB01184 | JAK1;GSK3B;MAPK14; | Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;Th1 and Th2 cell differentiation; | 303.76 | 30.10 | 10.09 |
| Ibrutinib | DB09053 | HDAC1;MAPK14;IGF1R; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 280.87 | 27.84 | 10.09 |
| Amsacrine | DB00276 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 266.53 | 26.44 | 10.08 |
| Dapiprazole | DB00298 | JAK1;GSK3B;HDAC1; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 244.07 | 24.73 | 9.87 |
| Glipizide | DB01067 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;NF-kappa B signaling pathway;T cell receptor signaling pathway; | 227.63 | 23.86 | 9.54 |
| Sertindole | DB06144 | JAK1;MAPK14;IGF1R; | Natural killer cell mediated cytotoxicity;Malaria;Starch and sucrose metabolism; | 291.67 | 29.55 | 9.87 |
| Midazolam | DB00683 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;NF-kappa B signaling pathway; | 287.05 | 28.56 | 10.05 |
| Warfarin | DB00682 | GSK3B;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;RNA transport; | 225.57 | 25.78 | 8.75 |
| Vidarabine | DB00194 | JAK1;GSK3B;HDAC1; | Th17 cell differentiation;Spliceosome;Th1 and Th2 cell differentiation; | 190.53 | 26.72 | 7.13 |
| Adenosine | DB00640 | JAK1;GSK3B;HDAC1; | Th17 cell differentiation;Spliceosome;Th1 and Th2 cell differentiation; | 178.76 | 25.11 | 7.12 |
| Promethazine | DB01069 | RAF1;PARP1;DRD2; | Necroptosis;Natural killer cell mediated cytotoxicity;Spliceosome; | 136.36 | 27.44 | 4.97 |
| Darifenacin | DB00496 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Leishmaniasis;T cell receptor signaling pathway; | 267.75 | 27.95 | 9.58 |
| Thiabendazole | DB00730 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;NF-kappa B signaling pathway; | 225.59 | 24.74 | 9.12 |
| Triazolam | DB00897 | JAK1;GSK3B;MAPK14; | Human cytomegalovirus infection;Spliceosome;Th1 and Th2 cell differentiation; | 256.29 | 27.50 | 9.32 |
| Trazodone | DB00656 | JAK1;GSK3B;MAPK14; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 249.72 | 25.69 | 9.72 |
| Dasabuvir | DB09183 | JAK1;HDAC2;HDAC1; | NF-kappa B signaling pathway;Transcriptional misregulation in cancer;RNA transport; | 223.52 | 22.69 | 9.85 |
| Cannabidiol | DB09061 | LCK;CYP19A1;DRD2; | Natural killer cell mediated cytotoxicity;Th17 cell differentiation;Spliceosome; | 120.88 | 26.57 | 4.55 |
| Cilostazol | DB01166 | JAK1;GSK3B;MAPK14; | Cytosolic DNA-sensing pathway;Th1 and Th2 cell differentiation;NF-kappa B signaling pathway; | 230.77 | 25.25 | 9.14 |
| Metergoline | DB13520 | GSK3B;HDAC1;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 218.09 | 24.10 | 9.05 |
| Sonidegib | DB09143 | GSK3B;HDAC1;MAPK14; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;NF-kappa B signaling pathway; | 275.99 | 28.48 | 9.69 |
| Glasdegib | DB11978 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway; | 265.48 | 24.86 | 10.68 |
| Benzatropine | DB00245 | HDAC1;MAPK14;IGF1R; | Complement and coagulation cascades;Natural killer cell mediated cytotoxicity;Cell cycle; | 241.25 | 24.67 | 9.78 |
| Etoricoxib | DB01628 | JAK1;HDAC2;HDAC1; | RNA transport;NF-kappa B signaling pathway;Natural killer cell mediated cytotoxicity; | 239.19 | 25.26 | 9.47 |
| Lorpiprazole | DB09195 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 232.28 | 26.70 | 8.7 |
| Dextromethorphan | DB00514 | HDAC1;MAPK14;IGF1R; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Hematopoietic cell lineage; | 175.60 | 25.64 | 6.85 |
| Rupatadine | DB11614 | MAPK14;IGF1R;RAF1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 271.54 | 28.86 | 9.41 |
| Olaparib | DB09074 | MAPK14;PIK3CB;RAF1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 246.31 | 27.58 | 8.93 |
| Mianserin | DB06148 | JAK1;HDAC1;IGF1R; | Complement and coagulation cascades;Human immunodeficiency virus 1 infection;Sphingolipid signaling pathway; | 241.81 | 28.51 | 8.48 |
| Papaverine | DB01113 | GSK3B;HDAC1;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 211.65 | 23.06 | 9.18 |
| Adenosine-phosphate | DB00131 | GSK3B;MAPK14;PIK3CB; | Transcriptional misregulation in cancer;Pyrimidine metabolism;Drug metabolism - other enzymes; | 146.87 | 25.50 | 5.76 |
| Rucaparib | DB12332 | JAK1;GSK3B;HDAC2; | NF-kappa B signaling pathway;RNA transport;Cytosolic DNA-sensing pathway; | 242.07 | 25.11 | 9.64 |
| Celecoxib | DB00482 | JAK1;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;NF-kappa B signaling pathway;Natural killer cell mediated cytotoxicity; | 197.74 | 24.59 | 8.04 |
| Indomethacin | DB00328 | IGF1R;PDGFRB;ALOX5; | Th1 and Th2 cell differentiation;Spliceosome;Transcriptional misregulation in cancer; | 192.30 | 26.90 | 7.15 |
| Flavone | DB07776 | GSK3B;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 187.33 | 24.98 | 7.5 |
| Pexidartinib | DB12978 | GSK3B;HDAC2;HDAC1; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;T cell receptor signaling pathway; | 272.16 | 28.56 | 9.53 |
| Zanubrutinib | DB15035 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 229.71 | 24.28 | 9.46 |
| Acetylsalicylic-acid | DB00945 | GSK3B;MAPK14;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 124.66 | 27.40 | 4.55 |
| Fluspirilene | DB04842 | HDAC1;MAPK14;IGF1R; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 273.90 | 29.51 | 9.28 |
| Aripiprazole | DB01238 | GSK3B;MAPK14;IGF1R; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Complement and coagulation cascades; | 208.03 | 24.53 | 8.48 |
| Valdecoxib | DB00580 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Inflammatory bowel disease; | 205.92 | 22.65 | 9.09 |
| Tamoxifen | DB00675 | JAK1;HDAC1;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Amoebiasis; | 201.74 | 27.41 | 7.36 |
| Nintedanib | DB09079 | HDAC1;MAPK14;IGF1R; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 199.90 | 22.95 | 8.71 |
| Piroxicam | DB00554 | JAK1;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;NF-kappa B signaling pathway;Inflammatory bowel disease; | 175.28 | 20.08 | 8.73 |
| Cyproheptadine | DB00434 | JAK1;GSK3B;HDAC2; | Complement and coagulation cascades;Natural killer cell mediated cytotoxicity;Necroptosis; | 266.52 | 27.45 | 9.71 |
| Prasterone | DB01708 | IGF1R;LCK;PARP1; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Spliceosome; | 253.18 | 28.77 | 8.8 |
| Alosetron | DB00969 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;NF-kappa B signaling pathway;T cell receptor signaling pathway; | 214.12 | 23.40 | 9.15 |
| Estradiol-valerate | DB13956 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 202.43 | 24.42 | 8.29 |
| Imipramine | DB00458 | IGF1R;RAF1;PARP1; | Neutrophil extracellular trap formation;Necroptosis;Ribosome; | 186.07 | 25.49 | 7.3 |
| Entrectinib | DB11986 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 184.23 | 20.11 | 9.16 |
| Fentanyl | DB00813 | HDAC2;HDAC1;MAPK14; | RNA transport;Natural killer cell mediated cytotoxicity;Spliceosome; | 171.71 | 23.33 | 7.36 |
| Ozenoxacin | DB12924 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;NF-kappa B signaling pathway;Th17 cell differentiation; | 233.33 | 26.88 | 8.68 |
| Carprofen | DB00821 | HDAC1;MAPK14;IGF1R; | RNA transport;Spliceosome;Th17 cell differentiation; | 222.76 | 25.90 | 8.6 |
| Ambrisentan | DB06403 | GSK3B;HDAC1;PDGFRB; | Th1 and Th2 cell differentiation;Spliceosome;Neutrophil extracellular trap formation; | 164.22 | 20.40 | 8.05 |
| Fludarabine | DB01073 | JAK1;GSK3B;HDAC1; | Spliceosome;Th17 cell differentiation;Th1 and Th2 cell differentiation; | 158.06 | 23.88 | 6.62 |
| Azatadine | DB00719 | HDAC1;MAPK14;IGF1R; | Natural killer cell mediated cytotoxicity;Complement and coagulation cascades;Leishmaniasis; | 245.90 | 25.86 | 9.51 |
| Pregnenolone | DB02789 | MAPK14;IGF1R;PARP1; | Spliceosome;Th17 cell differentiation;Human cytomegalovirus infection; | 241.01 | 28.45 | 8.47 |
| Brexanolone | DB11859 | IGF1R;PARP1;CDK1; | Spliceosome;Th17 cell differentiation;Th1 and Th2 cell differentiation; | 238.96 | 28.28 | 8.45 |
| Testosterone-propionate | DB01420 | JAK1;GSK3B;MAPK14; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Spliceosome; | 238.73 | 25.53 | 9.35 |
| Vismodegib | DB08828 | JAK1;HDAC1;MAPK14; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway; | 162.91 | 20.91 | 7.79 |
| Etomidate | DB00292 | GSK3B;HDAC2;HDAC1; | RNA transport;Transcriptional misregulation in cancer;Neutrophil extracellular trap formation; | 162.56 | 22.15 | 7.34 |
| Diphenoxylate | DB01081 | HDAC2;HDAC1;PARP1; | T cell receptor signaling pathway;RNA transport;Spliceosome; | 157.32 | 21.17 | 7.43 |
| Cabozantinib | DB08875 | JAK1;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 245.84 | 27.50 | 8.94 |
| Losartan | DB00678 | JAK1;HDAC2;HDAC1; | Natural killer cell mediated cytotoxicity;RNA transport;T cell receptor signaling pathway; | 164.51 | 24.05 | 6.84 |
| Nelarabine | DB01280 | JAK1;GSK3B;HDAC1; | Spliceosome;Th17 cell differentiation;Drug metabolism - other enzymes; | 162.09 | 24.05 | 6.74 |
| Progesterone | DB00396 | CYP19A1;DRD2;ALOX5; | Spliceosome;Neutrophil extracellular trap formation;Calcium signaling pathway; | 155.79 | 24.46 | 6.37 |
| Osilodrostat | DB11837 | GSK3B;HDAC2;HDAC1; | NF-kappa B signaling pathway;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 241.56 | 25.67 | 9.41 |
| Flibanserin | DB04908 | JAK1;GSK3B;MAPK14; | Natural killer cell mediated cytotoxicity;NF-kappa B signaling pathway;Human immunodeficiency virus 1 infection; | 230.08 | 26.85 | 8.57 |
| Ivacaftor | DB08820 | HDAC1;MAPK14;IGF1R; | Th17 cell differentiation;NF-kappa B signaling pathway;Th1 and Th2 cell differentiation; | 227.98 | 25.59 | 8.91 |
| Bazedoxifene | DB06401 | JAK1;HDAC2;HDAC1; | Natural killer cell mediated cytotoxicity;RNA transport;Complement and coagulation cascades; | 220.94 | 27.14 | 8.14 |
| Tacrine | DB00382 | JAK1;GSK3B;MAPK14; | Human cytomegalovirus infection;Cytosolic DNA-sensing pathway;Kaposi sarcoma-associated herpesvirus infection; | 196.10 | 24.00 | 8.17 |
| Lasofoxifene | DB06202 | GSK3B;HDAC1;IGF1R; | Transcriptional misregulation in cancer;Leishmaniasis;Th1 and Th2 cell differentiation; | 191.58 | 22.17 | 8.64 |
| Anthralin | DB11157 | GSK3B;MAPK14;IGF1R; | NF-kappa B signaling pathway;RNA transport;Transcriptional misregulation in cancer; | 179.09 | 23.02 | 7.78 |
| Mirtazapine | DB00370 | JAK1;GSK3B;MAPK14; | Human immunodeficiency virus 1 infection;Pathways in cancer;Kaposi sarcoma-associated herpesvirus infection; | 175.30 | 23.69 | 7.4 |
| Phenindione | DB00498 | MAPK14;IGF1R;LCK; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Human immunodeficiency virus 1 infection; | 172.17 | 23.58 | 7.3 |
| Repaglinide | DB00912 | HDAC2;HDAC1;LCK; | Th1 and Th2 cell differentiation;Spliceosome;RNA transport; | 163.59 | 23.14 | 7.07 |
| Bilastine | DB11591 | GSK3B;HDAC2;HDAC1; | RNA transport;Cushing syndrome;Inflammatory bowel disease; | 159.78 | 20.67 | 7.73 |
| Vilazodone | DB06684 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 155.50 | 19.63 | 7.92 |
| Valsartan | DB00177 | HDAC2;HDAC1;MAPK14; | RNA transport;Amoebiasis;Natural killer cell mediated cytotoxicity; | 137.87 | 20.95 | 6.58 |
| Tucatinib | DB11652 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 264.83 | 29.07 | 9.11 |
| Epinastine | DB00751 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 199.88 | 24.77 | 8.07 |
| Varenicline | DB01273 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Non-alcoholic fatty liver disease; | 192.59 | 22.71 | 8.48 |
| Esomeprazole | DB00736 | JAK1;GSK3B;HDAC1; | Spliceosome;NF-kappa B signaling pathway;Human cytomegalovirus infection; | 177.99 | 21.76 | 8.18 |
| Omeprazole | DB00338 | JAK1;GSK3B;HDAC1; | Spliceosome;NF-kappa B signaling pathway;Human cytomegalovirus infection; | 177.99 | 21.76 | 8.18 |
| Melatonin | DB01065 | HDAC1;PIK3CB;PARP1; | NF-kappa B signaling pathway;Spliceosome;Th1 and Th2 cell differentiation; | 156.12 | 24.94 | 6.26 |
| Sacubitril | DB09292 | HDAC2;HDAC1;DRD2; | Transcriptional misregulation in cancer;Inflammatory bowel disease;Sphingolipid signaling pathway; | 145.57 | 23.18 | 6.28 |
| Loperamide | DB00836 | HDAC1;DRD2;CA2; | Pathways in cancer;Necroptosis;Spliceosome; | 106.31 | 21.65 | 4.91 |
| Calcium-citrate | DB11093 | CALM1;MYL9;CANX; | Necroptosis;Calcium signaling pathway;Spliceosome; | 32.32 | 27.87 | 1.16 |
| Calcium-Phosphate | DB11348 | CALM1;MYL9;CANX; | Necroptosis;Calcium signaling pathway;Spliceosome; | 32.32 | 27.87 | 1.16 |
| Calcium-phosphate-dihydrate | DB14481 | CALM1;MYL9;CANX; | Necroptosis;Calcium signaling pathway;Spliceosome; | 32.32 | 27.87 | 1.16 |
| Testosterone | DB00624 | IGF1R;LCK;PARP1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Spliceosome; | 225.14 | 26.12 | 8.62 |
| Dydrogesterone | DB00378 | IGF1R;PARP1;CYP19A1; | Spliceosome;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 187.68 | 24.31 | 7.72 |
| Phenylbutazone | DB00812 | GSK3B;HDAC2;HDAC1; | Spliceosome;Human immunodeficiency virus 1 infection;Kaposi sarcoma-associated herpesvirus infection; | 169.50 | 21.21 | 7.99 |
| Rizatriptan | DB00953 | JAK1;GSK3B;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Glyoxylate and dicarboxylate metabolism; | 168.91 | 19.66 | 8.59 |
| Masoprocol | DB00179 | IGF1R;LCK;PARP1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Spliceosome; | 167.10 | 23.67 | 7.06 |
| Olmesartan | DB00275 | HDAC1;MAPK14;CYP19A1; | Natural killer cell mediated cytotoxicity;Amoebiasis;Starch and sucrose metabolism; | 123.44 | 22.08 | 5.59 |
| Zafirlukast | DB00549 | CYP19A1;DRD2;MMP9; | Neutrophil extracellular trap formation;Phagosome;Human immunodeficiency virus 1 infection; | 113.43 | 19.29 | 5.88 |
| Amitriptyline | DB00321 | HDAC2;HDAC1;DRD2; | Natural killer cell mediated cytotoxicity;RNA transport;RNA polymerase; | 107.26 | 20.47 | 5.24 |
| Amrinone | DB01427 | GSK3B;PIK3CB;PARP1; | Human immunodeficiency virus 1 infection;Kaposi sarcoma-associated herpesvirus infection;Phagosome; | 210.31 | 26.29 | 8 |
| Levorphanol | DB00854 | HDAC2;HDAC1;IGF1R; | Natural killer cell mediated cytotoxicity;RNA transport;Systemic lupus erythematosus; | 203.15 | 26.04 | 7.8 |
| Trimipramine | DB00726 | RAF1;PARP1;DRD2; | Neutrophil extracellular trap formation;Non-alcoholic fatty liver disease;Necroptosis; | 185.55 | 24.91 | 7.45 |
| Diphenidol | DB01231 | MAPK14;PIK3CB;DRD2; | Systemic lupus erythematosus;Leishmaniasis;Necroptosis; | 169.41 | 21.47 | 7.89 |
| Doxapram | DB00561 | MAPK14;PARP1;PDGFRB; | Complement and coagulation cascades;Natural killer cell mediated cytotoxicity;Necroptosis; | 165.90 | 21.30 | 7.79 |
| Nefazodone | DB01149 | GSK3B;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 148.16 | 16.82 | 8.81 |
| Donepezil | DB00843 | HDAC2;HDAC1;CYP19A1; | Necroptosis;Natural killer cell mediated cytotoxicity;Amoebiasis; | 144.26 | 20.91 | 6.9 |
| Nateglinide | DB00731 | HDAC2;HDAC1;MMP9; | Spliceosome;Neutrophil extracellular trap formation;RNA polymerase; | 134.12 | 21.29 | 6.3 |
| Methyltestosterone | DB06710 | HDAC2;HDAC1;IGF1R; | Th17 cell differentiation;Spliceosome;Cytosolic DNA-sensing pathway; | 224.68 | 25.83 | 8.7 |
| Eslicarbazepine-acetate | DB09119 | JAK1;GSK3B;HDAC2; | NF-kappa B signaling pathway;RNA transport;Transcriptional misregulation in cancer; | 201.43 | 23.31 | 8.64 |
| Ziprasidone | DB00246 | JAK1;GSK3B;HDAC2; | Natural killer cell mediated cytotoxicity;RNA transport;Human immunodeficiency virus 1 infection; | 191.78 | 24.52 | 7.82 |
| Sulfaphenazole | DB06729 | JAK1;GSK3B;MAPK14; | Herpes simplex virus 1 infection;Th1 and Th2 cell differentiation;Human cytomegalovirus infection; | 178.45 | 24.99 | 7.14 |
| Lumacaftor | DB09280 | HDAC2;HDAC1;MAPK14; | Neutrophil extracellular trap formation;Transcriptional misregulation in cancer;NF-kappa B signaling pathway; | 162.15 | 21.11 | 7.68 |
| Chlorpromazine | DB00477 | RAF1;DRD2;INSR; | Necroptosis;Neutrophil extracellular trap formation;Pathways in cancer; | 154.67 | 27.67 | 5.59 |
| Bepridil | DB01244 | DRD2;ABCB1;ADRB2; | Pathways in cancer;Spliceosome;Necroptosis; | 125.73 | 24.37 | 5.16 |
| Ketoprofen | DB01009 | HDAC2;MMP9;ALOX5; | RNA transport;T cell receptor signaling pathway;Transcriptional misregulation in cancer; | 116.66 | 19.57 | 5.96 |
| Abarelix | DB00106 | BIRC4;TLR2;BIRC3; | RNA polymerase;Neutrophil extracellular trap formation;Human immunodeficiency virus 1 infection; | 8.65 | 4.80 | 1.8 |
| Betrixaban | DB12364 | GSK3B;HDAC1;MAPK14; | T cell receptor signaling pathway;Th1 and Th2 cell differentiation;NF-kappa B signaling pathway; | 187.77 | 26.33 | 7.13 |
| Levallorphan | DB00504 | HDAC2;HDAC1;IGF1R; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;RNA transport; | 176.58 | 22.41 | 7.88 |
| Ketoconazole | DB01026 | IGF1R;LCK;PARP1; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Spliceosome; | 161.34 | 23.08 | 6.99 |
| Curcumin | DB11672 | GSK3B;HDAC1;CYP19A1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Sphingolipid signaling pathway; | 144.85 | 21.02 | 6.89 |
| Cinnarizine | DB00568 | IGF1R;LCK;DRD2; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 143.23 | 19.65 | 7.29 |
| Glyburide | DB01016 | HDAC2;HDAC1;RAF1; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Neutrophil extracellular trap formation; | 131.04 | 22.48 | 5.83 |
| Somatostatin | DB09099 | PARP1;ELA2;CA2; | Transcriptional misregulation in cancer;Neutrophil extracellular trap formation;Inflammatory bowel disease; | 64.11 | 17.86 | 3.59 |
| Palbociclib | DB09073 | JAK1;MAPK14;IGF1R; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 183.33 | 26.38 | 6.95 |
| Naratriptan | DB00952 | JAK1;GSK3B;HDAC1; | Necroptosis;Cytosolic DNA-sensing pathway;Non-alcoholic fatty liver disease; | 180.77 | 23.23 | 7.78 |
| Medrysone | DB00253 | MAPK14;PARP1;CYP19A1; | Spliceosome;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 162.76 | 22.33 | 7.29 |
| Adapalene | DB00210 | GSK3B;PIK3CB;DRD2; | Fc epsilon RI signaling pathway;Neutrophil extracellular trap formation;Spliceosome; | 142.19 | 22.29 | 6.38 |
| Maraviroc | DB04835 | JAK1;GSK3B;MAPK14; | NF-kappa B signaling pathway;Neutrophil extracellular trap formation;Transcriptional misregulation in cancer; | 132.05 | 21.44 | 6.16 |
| Trifluoperazine | DB00831 | DRD2;ADRB2;CYP2C9; | Necroptosis;Pathways in cancer;Spliceosome; | 76.31 | 24.00 | 3.18 |
| Angiotensin-II | DB11842 | GSK3B;DRD2;CA2; | Transcriptional misregulation in cancer;Sphingolipid signaling pathway;Natural killer cell mediated cytotoxicity; | 69.18 | 20.11 | 3.44 |
| Diphenylpyraline | DB01146 | HDAC1;IGF1R;PDGFRB; | Complement and coagulation cascades;Systemic lupus erythematosus;RNA polymerase; | 172.77 | 22.61 | 7.64 |
| Nevirapine | DB00238 | JAK1;GSK3B;PIK3CB; | Th1 and Th2 cell differentiation;NF-kappa B signaling pathway;Cytosolic DNA-sensing pathway; | 156.82 | 20.88 | 7.51 |
| Methdilazine | DB00902 | HDAC1;PARP1;DRD2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 147.25 | 20.57 | 7.16 |
| Dexmedetomidine | DB00633 | GSK3B;LCK;PARP1; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Neutrophil extracellular trap formation; | 141.58 | 19.72 | 7.18 |
| Talazoparib | DB11760 | JAK1;GSK3B;MAPK14; | Cell cycle;RNA transport;Alcoholism; | 138.09 | 18.44 | 7.49 |
| Flunarizine | DB04841 | HDAC1;MAPK14;IGF1R; | Necroptosis;Pathways in cancer;Spliceosome; | 117.94 | 22.09 | 5.34 |
| Lanreotide | DB06791 | GSK3B;LCK;PARP1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 87.90 | 20.07 | 4.38 |
| Tropisetron | DB11699 | GSK3B;HDAC2;HDAC1; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 195.54 | 22.02 | 8.88 |
| Erdafitinib | DB12147 | GSK3B;MAPK14;LCK; | Human cytomegalovirus infection;Th17 cell differentiation;Spliceosome; | 192.67 | 24.83 | 7.76 |
| Proflavine | DB01123 | GSK3B;IGF1R;LCK; | Th1 and Th2 cell differentiation;Human cytomegalovirus infection;Th17 cell differentiation; | 177.63 | 23.28 | 7.63 |
| Iloperidone | DB04946 | GSK3B;HDAC2;HDAC1; | Necroptosis;Spliceosome;Natural killer cell mediated cytotoxicity; | 152.82 | 20.54 | 7.44 |
| Diazepam | DB00829 | GSK3B;HDAC1;MAPK14; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;PD-L1 expression and PD-1 checkpoint pathway in cancer; | 150.57 | 20.40 | 7.38 |
| Dexlansoprazole | DB05351 | GSK3B;MAPK14;CDK1; | Th1 and Th2 cell differentiation;Starch and sucrose metabolism;Human cytomegalovirus infection; | 146.48 | 22.47 | 6.52 |
| Lansoprazole | DB00448 | GSK3B;MAPK14;CDK1; | Th1 and Th2 cell differentiation;Starch and sucrose metabolism;Human cytomegalovirus infection; | 146.48 | 22.47 | 6.52 |
| Abemaciclib | DB12001 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Amoebiasis; | 136.58 | 17.83 | 7.66 |
| Meloxicam | DB00814 | JAK1;HDAC2;HDAC1; | Neutrophil extracellular trap formation;Th1 and Th2 cell differentiation;NF-kappa B signaling pathway; | 132.87 | 17.83 | 7.45 |
| Eprosartan | DB00876 | HDAC1;PDGFRB;CA2; | Natural killer cell mediated cytotoxicity;Sphingolipid signaling pathway;Amoebiasis; | 103.73 | 22.80 | 4.55 |
| Naphazoline | DB06711 | MAPK14;PDGFRB;CYP19A1; | Complement and coagulation cascades;Natural killer cell mediated cytotoxicity;NF-kappa B signaling pathway; | 100.78 | 15.63 | 6.45 |
| Paliperidone | DB01267 | GSK3B;PARP1;PDGFRB; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus; | 98.52 | 15.13 | 6.51 |
| Estradiol-acetate | DB13952 | HDAC2;HDAC1;CYP19A1; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;T cell receptor signaling pathway; | 93.20 | 15.41 | 6.05 |
| Voxelotor | DB14975 | MAPK14;CDK1;CYP19A1; | Spliceosome;Arrhythmogenic right ventricular cardiomyopathy;Systemic lupus erythematosus; | 80.85 | 17.20 | 4.7 |
| Nedocromil | DB00716 | PDGFRB;ELA2;HSP90AA1; | Transcriptional misregulation in cancer;Aldosterone synthesis and secretion;Natural killer cell mediated cytotoxicity; | 57.74 | 19.18 | 3.01 |
| Citric-acid | DB04272 | LCK;AKR1C3;AKR1B1; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;Th17 cell differentiation; | 37.13 | 15.80 | 2.35 |
| Alectinib | DB11363 | JAK1;IGF1R;PIK3CB; | Neutrophil extracellular trap formation;Cell cycle;Transcriptional misregulation in cancer; | 205.98 | 28.10 | 7.33 |
| Alcaftadine | DB06766 | MAPK14;RAF1;LCK; | Natural killer cell mediated cytotoxicity;NF-kappa B signaling pathway;T cell receptor signaling pathway; | 204.91 | 24.87 | 8.24 |
| Econazole | DB01127 | GSK3B;MAPK14;IGF1R; | Th17 cell differentiation;Kaposi sarcoma-associated herpesvirus infection;Th1 and Th2 cell differentiation; | 195.26 | 25.62 | 7.62 |
| Metixene | DB00340 | HDAC1;MAPK14;PARP1; | Phagosome;Necroptosis;Leishmaniasis; | 181.93 | 21.68 | 8.39 |
| Sildenafil | DB00203 | GSK3B;HDAC2;HDAC1; | RNA transport;NF-kappa B signaling pathway;Th1 and Th2 cell differentiation; | 170.63 | 21.85 | 7.81 |
| Meclizine | DB00737 | MAPK14;IGF1R;CDK1; | Starch and sucrose metabolism;Spliceosome;Thiamine metabolism; | 168.86 | 22.48 | 7.51 |
| Panobinostat | DB06603 | GSK3B;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;RNA transport; | 164.65 | 19.67 | 8.37 |
| Oxcarbazepine | DB00776 | HDAC1;MAPK14;LCK; | Th1 and Th2 cell differentiation;NF-kappa B signaling pathway;Natural killer cell mediated cytotoxicity; | 164.65 | 22.28 | 7.39 |
| Levonorgestrel | DB00367 | IGF1R;PARP1;CYP19A1; | Spliceosome;Th17 cell differentiation;Tight junction; | 145.43 | 19.71 | 7.38 |
| Norgestrel | DB09389 | IGF1R;PARP1;CYP19A1; | Spliceosome;Th17 cell differentiation;Tight junction; | 145.43 | 19.71 | 7.38 |
| Tibolone | DB09070 | IGF1R;PARP1;CYP19A1; | Spliceosome;Th17 cell differentiation;Tight junction; | 145.43 | 19.71 | 7.38 |
| Rabeprazole | DB01129 | JAK1;GSK3B;CDK1; | Human cytomegalovirus infection;Spliceosome;Glyoxylate and dicarboxylate metabolism; | 143.54 | 20.59 | 6.97 |
| Clomipramine | DB01242 | RAF1;DRD2;INSR; | Necroptosis;Non-alcoholic fatty liver disease;Neutrophil extracellular trap formation; | 141.00 | 22.07 | 6.39 |
| Methadone | DB00333 | HDAC2;HDAC1;MAPK14; | Natural killer cell mediated cytotoxicity;Spliceosome;RNA transport; | 140.34 | 23.71 | 5.92 |
| Diethylstilbestrol | DB00255 | IGF1R;LCK;PARP1; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Spliceosome; | 133.00 | 20.65 | 6.44 |
| Oxyphenbutazone | DB03585 | GSK3B;MAPK14;PARP1; | Spliceosome;NF-kappa B signaling pathway;Transcriptional misregulation in cancer; | 131.21 | 19.44 | 6.75 |
| Medrogestone | DB09124 | CYP19A1;ALOX5;ABCB1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Spliceosome; | 122.92 | 19.89 | 6.18 |
| Theophylline | DB00277 | GSK3B;HDAC2;HDAC1; | RNA transport;Natural killer cell mediated cytotoxicity;Salivary secretion; | 111.95 | 18.94 | 5.91 |
| Sufentanil | DB00708 | HDAC2;HDAC1;PARP1; | T cell receptor signaling pathway;RNA transport;Inflammatory bowel disease; | 107.73 | 17.05 | 6.32 |
| Pirfenidone | DB04951 | MAPK14;IGF1R;PARP1; | Transcriptional misregulation in cancer;Neutrophil extracellular trap formation;Long-term potentiation; | 104.11 | 16.04 | 6.49 |
| Cyclobenzaprine | DB00924 | JAK1;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 100.97 | 14.57 | 6.93 |
| Estradiol | DB00783 | HDAC2;HDAC1;CYP19A1; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;T cell receptor signaling pathway; | 90.11 | 14.06 | 6.41 |
| Bupivacaine | DB00297 | HDAC2;HDAC1;RAF1; | Spliceosome;Natural killer cell mediated cytotoxicity;RNA transport; | 174.75 | 23.11 | 7.56 |
| Levobupivacaine | DB01002 | HDAC2;HDAC1;RAF1; | Spliceosome;Natural killer cell mediated cytotoxicity;RNA transport; | 174.75 | 23.11 | 7.56 |
| Prazepam | DB01588 | GSK3B;HDAC1;PIK3CB; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 158.17 | 21.46 | 7.37 |
| Dicoumarol | DB00266 | GSK3B;PARP1;CDK1; | Spliceosome;Th17 cell differentiation;Human immunodeficiency virus 1 infection; | 145.89 | 23.23 | 6.28 |
| Flavoxate | DB01148 | HDAC1;PARP1;PDGFRB; | Spliceosome;Necroptosis;RNA polymerase; | 145.54 | 20.41 | 7.13 |
| Vardenafil | DB00862 | JAK1;GSK3B;HDAC2; | Th1 and Th2 cell differentiation;RNA transport;Natural killer cell mediated cytotoxicity; | 135.65 | 18.02 | 7.53 |
| Tolvaptan | DB06212 | HDAC2;HDAC1;MAPK14; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 131.17 | 17.89 | 7.33 |
| Trihexyphenidyl | DB00376 | MAPK14;PIK3CB;DRD2; | Necroptosis;Leishmaniasis;Oxidative phosphorylation; | 130.91 | 18.01 | 7.27 |
| Nomifensine | DB04821 | JAK1;MAPK14;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Transcriptional misregulation in cancer; | 129.16 | 18.32 | 7.05 |
| Ifenprodil | DB08954 | MAPK14;PIK3CB;CYP19A1; | RNA polymerase;Necroptosis;Huntington disease; | 114.44 | 15.66 | 7.31 |
| Anisindione | DB01125 | LCK;PARP1;CYP19A1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Pathways in cancer; | 110.11 | 18.63 | 5.91 |
| Atomoxetine | DB00289 | HDAC1;CYP19A1;DRD2; | Calcium signaling pathway;Natural killer cell mediated cytotoxicity;Long-term potentiation; | 102.68 | 21.04 | 4.88 |
| Dimetindene | DB08801 | HDAC2;HDAC1;PDGFRB; | RNA polymerase;Necroptosis;Natural killer cell mediated cytotoxicity; | 94.56 | 15.15 | 6.24 |
| Eluxadoline | DB09272 | HDAC2;HDAC1;CDK1; | T cell receptor signaling pathway;Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation; | 73.89 | 15.30 | 4.83 |
| Rimexolone | DB00896 | PARP1;CYP19A1;DRD2; | Viral carcinogenesis;Calcium signaling pathway;Th1 and Th2 cell differentiation; | 143.03 | 22.24 | 6.43 |
| Norethisterone | DB00717 | HDAC2;HDAC1;IGF1R; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 138.74 | 17.63 | 7.87 |
| Norethynodrel | DB09371 | HDAC2;HDAC1;IGF1R; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 138.74 | 17.63 | 7.87 |
| Fenoprofen | DB00573 | HDAC2;PARP1;MMP9; | RNA transport;Spliceosome;Inflammatory bowel disease; | 131.05 | 20.07 | 6.53 |
| Bezafibrate | DB01393 | HDAC1;CA2;LTA4H; | Th1 and Th2 cell differentiation;Platelet activation;Tight junction; | 115.86 | 22.63 | 5.12 |
| Desipramine | DB01151 | IGF1R;PDGFRB;DRD2; | Necroptosis;Complement and coagulation cascades;Graft-versus-host disease; | 108.71 | 16.25 | 6.69 |
| Droperidol | DB00450 | HDAC2;HDAC1;MAPK14; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Amoebiasis; | 107.32 | 14.93 | 7.19 |
| Alvimopan | DB06274 | HDAC1;DRD2;ALOX5; | Spliceosome;Aldosterone synthesis and secretion;Natural killer cell mediated cytotoxicity; | 103.39 | 20.47 | 5.05 |
| Acemetacin | DB13783 | ALOX5;CA2;PDE4B; | Transcriptional misregulation in cancer;Spliceosome;Th1 and Th2 cell differentiation; | 101.22 | 17.42 | 5.81 |
| Prenylamine | DB04825 | HDAC1;CYP19A1;DRD2; | Necroptosis;Pathways in cancer;Spliceosome; | 96.37 | 22.15 | 4.35 |
| Cinchocaine | DB00527 | HDAC1;DRD2;ALOX5; | Spliceosome;Pathways in cancer;Necroptosis; | 92.45 | 23.46 | 3.94 |
| Sulfasalazine | DB00795 | GSK3B;HDAC1;CDK1; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 82.64 | 16.46 | 5.02 |
| Meperidine | DB00454 | HDAC1;CYP19A1;DRD2; | Natural killer cell mediated cytotoxicity;Long-term potentiation;Calcium signaling pathway; | 81.08 | 18.60 | 4.36 |
| Azilsartan-medoxomil | DB08822 | MAPK14;CA2;TNF; | Natural killer cell mediated cytotoxicity;Neutrophil extracellular trap formation;Systemic lupus erythematosus; | 63.91 | 17.65 | 3.62 |
| Phenindamine | DB01619 | HDAC1;PARP1;CYP19A1; | Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus;Necroptosis; | 157.66 | 20.53 | 7.68 |
| Vorinostat | DB02546 | HDAC2;HDAC1;IGF1R; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 156.74 | 22.08 | 7.1 |
| Arzoxifene | DB06249 | JAK1;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 150.70 | 20.31 | 7.42 |
| Dioxybenzone | DB11221 | RAF1;LCK;CDK1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 139.88 | 24.04 | 5.82 |
| Phenolphthalein | DB04824 | GSK3B;IGF1R;PDGFRB; | Spliceosome;Th1 and Th2 cell differentiation;Inflammatory bowel disease; | 138.31 | 21.15 | 6.54 |
| Ketorolac | DB00465 | GSK3B;IGF1R;PARP1; | RNA transport;Th1 and Th2 cell differentiation;Aldosterone synthesis and secretion; | 137.12 | 19.39 | 7.07 |
| Carbamazepine | DB00564 | HDAC1;PARP1;CYP19A1; | NF-kappa B signaling pathway;Cytosolic DNA-sensing pathway;Natural killer cell mediated cytotoxicity; | 133.01 | 20.21 | 6.58 |
| Estrone | DB00655 | HDAC2;HDAC1;RAF1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 129.25 | 19.35 | 6.68 |
| Antipyrine | DB01435 | GSK3B;PARP1;CYP19A1; | Human immunodeficiency virus 1 infection;Neutrophil extracellular trap formation;RNA polymerase; | 118.63 | 19.74 | 6.01 |
| Cycrimine | DB00942 | PIK3CB;DRD2;MMP9; | Necroptosis;RNA polymerase;Oxidative phosphorylation; | 116.64 | 17.13 | 6.81 |
| Procyclidine | DB00387 | PIK3CB;DRD2;MMP9; | Necroptosis;RNA polymerase;Oxidative phosphorylation; | 116.64 | 17.13 | 6.81 |
| Exemestane | DB00990 | IGF1R;PARP1;CYP19A1; | Spliceosome;Tight junction;Systemic lupus erythematosus; | 115.18 | 16.27 | 7.08 |
| Caffeine | DB00201 | GSK3B;PIK3CB;CA2; | "Cortisol synthesis and secretion;Parathyroid hormone synthesis, secretion and action;Inflammatory bowel disease;" | 107.67 | 18.25 | 5.9 |
| Berberine | DB04115 | GSK3B;PDGFRB;CDK1; | Natural killer cell mediated cytotoxicity;RNA polymerase;Spliceosome; | 106.36 | 16.57 | 6.42 |
| Rimonabant | DB06155 | MAPK14;IGF1R;PDGFRB; | Natural killer cell mediated cytotoxicity;Oocyte meiosis;Glutamatergic synapse; | 105.35 | 18.35 | 5.74 |
| Agomelatine | DB06594 | HDAC1;PARP1;MMP9; | Spliceosome;Th1 and Th2 cell differentiation;RNA polymerase; | 103.77 | 17.92 | 5.79 |
| Propiverine | DB12278 | HDAC2;HDAC1;PIK3CB; | RNA polymerase;Sphingolipid signaling pathway;RNA transport; | 100.64 | 14.95 | 6.73 |
| Levocabastine | DB01106 | HDAC2;HDAC1;DRD2; | RNA polymerase;T cell receptor signaling pathway;Th1 and Th2 cell differentiation; | 84.90 | 14.22 | 5.97 |
| Trifarotene | DB12808 | HDAC2;HDAC1;ALOX5; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 78.16 | 14.06 | 5.56 |
| Olopatadine | DB00768 | HDAC2;HDAC1;DRD2; | Natural killer cell mediated cytotoxicity;Spliceosome;RNA transport; | 77.07 | 17.20 | 4.48 |
| Dexibuprofen | DB09213 | HDAC1;ALOX5;CYP2C9; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Amoebiasis; | 73.21 | 15.38 | 4.76 |
| Phenytoin | DB00252 | GSK3B;PARP1;MMP9; | Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;Th1 and Th2 cell differentiation; | 73.18 | 13.35 | 5.48 |
| Oxybenzone | DB01428 | HDAC2;HDAC1;RAF1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Spliceosome; | 191.19 | 24.99 | 7.65 |
| Pizotifen | DB06153 | HDAC1;MAPK14;PARP1; | Amoebiasis;Systemic lupus erythematosus;Natural killer cell mediated cytotoxicity; | 148.23 | 19.45 | 7.62 |
| Medroxyprogesterone-acetate | DB00603 | CYP19A1;ABCB1;CYP2C9; | Human cytomegalovirus infection;Calcium signaling pathway;Cushing syndrome; | 143.76 | 23.41 | 6.14 |
| Tafamidis | DB11644 | MAPK14;IGF1R;PARP1; | RNA polymerase;NF-kappa B signaling pathway;Human cytomegalovirus infection; | 137.89 | 21.12 | 6.53 |
| Dobutamine | DB00841 | IGF1R;PARP1;CYP19A1; | Spliceosome;Transcriptional misregulation in cancer;Neutrophil extracellular trap formation; | 131.26 | 20.07 | 6.54 |
| Mebendazole | DB00643 | GSK3B;HDAC1;IGF1R; | Spliceosome;Human immunodeficiency virus 1 infection;Pathways in cancer; | 129.93 | 18.51 | 7.02 |
| Cyclizine | DB01176 | IGF1R;DRD2;MMP9; | Phagosome;Transcriptional misregulation in cancer;Tuberculosis; | 124.84 | 19.15 | 6.52 |
| Pheniramine | DB01620 | MAPK14;RAF1;DRD2; | Complement and coagulation cascades;Graft-versus-host disease;Natural killer cell mediated cytotoxicity; | 122.60 | 20.67 | 5.93 |
| Butenafine | DB01091 | JAK1;HDAC1;LCK; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;NF-kappa B signaling pathway; | 120.00 | 16.67 | 7.2 |
| Minaprine | DB00805 | GSK3B;PIK3CB;PARP1; | Graft-versus-host disease;Natural killer cell mediated cytotoxicity;Renin secretion; | 119.13 | 20.65 | 5.77 |
| Buclizine | DB00354 | IGF1R;LCK;DRD2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 116.16 | 17.84 | 6.51 |
| Ergometrine | DB01253 | JAK1;HDAC1;PARP1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Amoebiasis; | 110.34 | 17.03 | 6.48 |
| Naftifine | DB00735 | JAK1;LCK;CYP19A1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;RNA polymerase; | 107.97 | 15.63 | 6.91 |
| Dexketoprofen | DB09214 | HDAC2;MMP9;ALOX5; | T cell receptor signaling pathway;Transcriptional misregulation in cancer;Inflammatory bowel disease; | 105.99 | 16.36 | 6.48 |
| Folic-acid | DB00158 | HDAC1;ABCB1;TNF; | T cell receptor signaling pathway;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 101.49 | 21.06 | 4.82 |
| Minocycline | DB01017 | GSK3B;MAPK14;CDK1; | Human cytomegalovirus infection;Th1 and Th2 cell differentiation;Inflammatory bowel disease; | 101.21 | 21.86 | 4.63 |
| Temazepam | DB00231 | HDAC1;MAPK14;CDK1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;PD-L1 expression and PD-1 checkpoint pathway in cancer; | 99.19 | 15.57 | 6.37 |
| Bexarotene | DB00307 | HDAC1;MAPK14;CYP19A1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 98.72 | 18.59 | 5.31 |
| Lesinurad | DB11560 | GSK3B;CYP19A1;PDE4B; | Human cytomegalovirus infection;Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus; | 97.64 | 18.78 | 5.2 |
| Testosterone-undecanoate | DB13946 | IGF1R;CYP19A1;PTK2; | Th1 and Th2 cell differentiation;VEGF signaling pathway;PD-L1 expression and PD-1 checkpoint pathway in cancer; | 97.60 | 15.42 | 6.33 |
| Phenoxybenzamine | DB00925 | DRD2;ADRB2;LTA4H; | Necroptosis;Pathways in cancer;Spliceosome; | 87.40 | 20.09 | 4.35 |
| Bortezomib | DB00188 | GSK3B;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;NF-kappa B signaling pathway;T cell receptor signaling pathway; | 76.67 | 11.56 | 6.63 |
| alpha-Tocopherol-succinate | DB14001 | ALOX5;PRKCA;PRKACA; | Spliceosome;Platelet activation;Pathways in cancer; | 75.89 | 23.00 | 3.3 |
| Tramadol | DB00193 | DRD2;ADRB2;LTA4H; | Calcium signaling pathway;Natural killer cell mediated cytotoxicity;Spliceosome; | 73.46 | 19.08 | 3.85 |
| Testosterone-cypionate | DB13943 | CYP19A1;ALOX5;CA2; | RNA transport;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 72.33 | 13.80 | 5.24 |
| Fluphenazine | DB00623 | DRD2;ADRB2;CYP2C9; | Necroptosis;Pathways in cancer;Spliceosome; | 72.12 | 20.60 | 3.5 |
| Deoxycholic-acid | DB03619 | JAK1;G6PD;PSEN1; | Human cytomegalovirus infection;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 69.27 | 18.77 | 3.69 |
| Miconazole | DB01110 | CYP19A1;ABCB1;CYP2C9; | RNA polymerase;Thiamine metabolism;Starch and sucrose metabolism; | 64.96 | 17.90 | 3.63 |
| Sulindac | DB00605 | GSK3B;MAPK14;CDK1; | Th1 and Th2 cell differentiation;Human cytomegalovirus infection;NF-kappa B signaling pathway; | 60.95 | 19.60 | 3.11 |
| Afamelanotide | DB04931 | MMP9;INSR;CA2; | Inflammatory bowel disease;Leishmaniasis;Antigen processing and presentation; | 51.59 | 11.51 | 4.48 |
| Nifedipine | DB01115 | ABCB1;NR3C2;NR1I2; | Necroptosis;Pathways in cancer;Spliceosome; | 42.24 | 17.97 | 2.35 |
| Paroxetine | DB00715 | MAPK14;RAF1;LCK; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Graft-versus-host disease; | 177.41 | 24.07 | 7.37 |
| Almotriptan | DB00918 | JAK1;HDAC1;PIK3CB; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Amoebiasis; | 127.89 | 17.66 | 7.24 |
| Terconazole | DB00251 | MAPK14;LCK;CDK1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Neutrophil extracellular trap formation; | 127.18 | 18.73 | 6.79 |
| Ketotifen | DB00920 | HDAC1;PARP1;CYP19A1; | Natural killer cell mediated cytotoxicity;Leishmaniasis;Sphingolipid signaling pathway; | 122.30 | 19.54 | 6.26 |
| Clonazepam | DB01068 | GSK3B;HDAC1;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 110.38 | 18.25 | 6.05 |
| Pemetrexed | DB00642 | HDAC2;HDAC1;ABCB1; | T cell receptor signaling pathway;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 109.99 | 21.23 | 5.18 |
| Flufenamic-acid | DB02266 | GSK3B;CA2;MAP2K1; | Human cytomegalovirus infection;Chemokine signaling pathway;Spliceosome; | 109.75 | 20.32 | 5.4 |
| Dienogest | DB09123 | IGF1R;LCK;PARP1; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 108.59 | 15.76 | 6.89 |
| Yohimbine | DB01392 | JAK1;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Amoebiasis; | 104.40 | 15.02 | 6.95 |
| Phenyltoloxamine | DB11160 | HDAC2;HDAC1;MAPK14; | Natural killer cell mediated cytotoxicity;RNA transport;Amoebiasis; | 101.66 | 13.57 | 7.49 |
| Pimavanserin | DB05316 | HDAC1;MAPK14;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 98.79 | 14.86 | 6.65 |
| Clotiazepam | DB01559 | GSK3B;CDK1;CYP19A1; | Inflammatory bowel disease;Graft-versus-host disease;Th1 and Th2 cell differentiation; | 97.20 | 15.09 | 6.44 |
| Sulfinpyrazone | DB01138 | GSK3B;PARP1;ALOX5; | Fc epsilon RI signaling pathway;Spliceosome;Th17 cell differentiation; | 92.12 | 17.35 | 5.31 |
| Cladribine | DB00242 | GSK3B;PIK3CB;DRD2; | Pyrimidine metabolism;NF-kappa B signaling pathway;Drug metabolism - other enzymes; | 85.85 | 17.14 | 5.01 |
| Anileridine | DB00913 | HDAC2;HDAC1;DRD2; | RNA transport;Natural killer cell mediated cytotoxicity;RNA polymerase; | 85.20 | 15.90 | 5.36 |
| Gliquidone | DB01251 | HDAC1;PARP1;MMP9; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Inflammatory bowel disease; | 80.32 | 13.97 | 5.75 |
| Benzphetamine | DB00865 | HDAC2;HDAC1;DRD2; | RNA transport;Systemic lupus erythematosus;Oxidative phosphorylation; | 80.22 | 13.67 | 5.87 |
| Dextropropoxyphene | DB00647 | HDAC2;HDAC1;DRD2; | RNA transport;Natural killer cell mediated cytotoxicity;Necroptosis; | 78.02 | 16.46 | 4.74 |
| Vitamin-E | DB00163 | ALOX5;PRKCA;PRKACA; | Spliceosome;Pathways in cancer;Phagosome; | 75.95 | 22.47 | 3.38 |
| Clozapine | DB00363 | MAPK14;LCK;CDK1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 75.73 | 14.16 | 5.35 |
| Estradiol-cypionate | DB13954 | HDAC2;HDAC1;CYP19A1; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 75.31 | 18.32 | 4.11 |
| Acrivastine | DB09488 | HDAC2;HDAC1;CYP19A1; | Natural killer cell mediated cytotoxicity;Neutrophil extracellular trap formation;Amoebiasis; | 71.65 | 13.22 | 5.42 |
| Mepivacaine | DB00961 | PARP1;DRD2;ALOX5; | Spliceosome;Complement and coagulation cascades;Necroptosis; | 71.12 | 12.52 | 5.68 |
| Isoflurane | DB00753 | CALM1;GABRA4;GABRB3; | Necroptosis;Pathways in cancer;Spliceosome; | 33.22 | 18.05 | 1.84 |
| Glutamic-acid | DB00142 | CA2;KIF11;GRIN2D; | Complement and coagulation cascades;Spliceosome;Primary immunodeficiency; | 26.55 | 12.46 | 2.13 |
| Loratadine | DB00455 | HDAC1;MAPK14;RAF1; | Th17 cell differentiation;Spliceosome;Natural killer cell mediated cytotoxicity; | 159.13 | 22.04 | 7.22 |
| Tolmetin | DB00500 | HDAC1;RAF1;CYP19A1; | Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;NF-kappa B signaling pathway; | 134.84 | 21.68 | 6.22 |
| Ropivacaine | DB00296 | RAF1;PARP1;DRD2; | Spliceosome;Complement and coagulation cascades;Tight junction; | 129.20 | 20.71 | 6.24 |
| Prazosin | DB00457 | JAK1;PIK3CB;PDGFRB; | Systemic lupus erythematosus;Natural killer cell mediated cytotoxicity;Kaposi sarcoma-associated herpesvirus infection; | 127.53 | 21.54 | 5.92 |
| Tolfenamic-acid | DB09216 | GSK3B;HDAC1;ALOX5; | Spliceosome;Chemokine signaling pathway;Th1 and Th2 cell differentiation; | 118.96 | 19.47 | 6.11 |
| Alverine | DB01616 | HDAC2;HDAC1;RAF1; | RNA transport;Neutrophil extracellular trap formation;Alcoholism; | 116.55 | 18.10 | 6.44 |
| Chlorpheniramine | DB01114 | RAF1;DRD2;PTK2; | Neutrophil extracellular trap formation;Alcoholism;Systemic lupus erythematosus; | 114.93 | 19.95 | 5.76 |
| Biperiden | DB00810 | HDAC1;PIK3CB;PARP1; | Necroptosis;RNA polymerase;Systemic lupus erythematosus; | 111.13 | 16.37 | 6.79 |
| Desoxycorticosterone-acetate | DB06780 | CYP19A1;ABCB1;CYP2C9; | Th1 and Th2 cell differentiation;Systemic lupus erythematosus;Glyoxylate and dicarboxylate metabolism; | 107.25 | 19.15 | 5.6 |
| Phenylbutyric-acid | DB06819 | GSK3B;HDAC2;HDAC1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;RNA transport; | 107.19 | 15.65 | 6.85 |
| Bromazepam | DB01558 | GSK3B;HDAC1;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 107.06 | 16.83 | 6.36 |
| Dabrafenib | DB08912 | GSK3B;MAPK14;PIK3CB; | Fc epsilon RI signaling pathway;Natural killer cell mediated cytotoxicity;Starch and sucrose metabolism; | 105.70 | 19.18 | 5.51 |
| Meclofenamic-acid | DB00939 | GSK3B;HDAC1;ALOX5; | Spliceosome;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 104.21 | 17.51 | 5.95 |
| Frovatriptan | DB00998 | JAK1;PARP1;DRD2; | Spliceosome;Pathways in cancer;RNA transport; | 102.58 | 16.84 | 6.09 |
| Hydrocortisone-acetate | DB14539 | MAPK14;CA2;ABCB1; | Th1 and Th2 cell differentiation;Human cytomegalovirus infection;NF-kappa B signaling pathway; | 101.91 | 18.56 | 5.49 |
| Chlordiazepoxide | DB00475 | MAPK14;PARP1;CDK1; | Cell cycle;Graft-versus-host disease;Morphine addiction; | 101.27 | 16.31 | 6.21 |
| Lurasidone | DB08815 | CDK1;DRD2;PRKCA; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 96.32 | 17.84 | 5.4 |
| Raloxifene | DB00481 | HDAC2;HDAC1;DRD2; | Th17 cell differentiation;Amoebiasis;Th1 and Th2 cell differentiation; | 92.21 | 17.50 | 5.27 |
| Cytarabine | DB00987 | GSK3B;PIK3CB;MAP3K7; | Glyoxylate and dicarboxylate metabolism;Spliceosome;Pathways in cancer; | 83.04 | 21.46 | 3.87 |
| Cholecalciferol | DB00169 | IGF1R;CYP19A1;PTK2; | Th1 and Th2 cell differentiation;VEGF signaling pathway;Oocyte meiosis; | 82.56 | 15.58 | 5.3 |
| Duloxetine | DB00476 | HDAC1;CDK1;DRD2; | Amoebiasis;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 81.55 | 13.87 | 5.88 |
| Chenodeoxycholic-acid | DB06777 | JAK1;AKR1C3;NR1I2; | Human cytomegalovirus infection;Glutathione metabolism;Calcium signaling pathway; | 81.48 | 19.59 | 4.16 |
| Mesoridazine | DB00933 | HDAC1;PARP1;DRD2; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 75.49 | 14.03 | 5.38 |
| Alimemazine | DB01246 | PARP1;DRD2;INSR; | Neutrophil extracellular trap formation;Systemic lupus erythematosus;Alcoholism; | 74.35 | 11.55 | 6.44 |
| Perphenazine | DB00850 | DRD2;ADRB2;CYP2C9; | Necroptosis;Pathways in cancer;Spliceosome; | 61.28 | 19.71 | 3.11 |
| Nicardipine | DB00622 | ABCB1;ADRB2;PDE4B; | Pathways in cancer;Spliceosome;Necroptosis; | 58.78 | 20.99 | 2.8 |
| Menadione | DB00170 | ALOX5;MAP2K1;F2; | Th1 and Th2 cell differentiation;Spliceosome;Th17 cell differentiation; | 55.60 | 17.43 | 3.19 |
| Candesartan-cilexetil | DB00796 | CYP19A1;PDE4B;CYP2C9; | Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus;Long-term potentiation; | 38.27 | 15.07 | 2.54 |
| Lisuride | DB00589 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 155.14 | 20.20 | 7.68 |
| Mefenamic-acid | DB00784 | GSK3B;HDAC2;HDAC1; | RNA transport;Th1 and Th2 cell differentiation;Spliceosome; | 140.88 | 22.40 | 6.29 |
| Sertaconazole | DB01153 | MAPK14;PIK3CB;CDK1; | Human immunodeficiency virus 1 infection;Kaposi sarcoma-associated herpesvirus infection;Systemic lupus erythematosus; | 132.77 | 20.43 | 6.5 |
| Dienestrol | DB00890 | IGF1R;LCK;PARP1; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Pathways in cancer; | 115.73 | 19.29 | 6 |
| Phenyl-salicylate | DB11071 | HDAC2;ALOX5;CA2; | Spliceosome;RNA transport;Viral carcinogenesis; | 113.17 | 19.85 | 5.7 |
| Megestrol-acetate | DB00351 | LCK;CYP19A1;ABCB1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 112.94 | 18.95 | 5.96 |
| Promazine | DB00420 | RAF1;PARP1;DRD2; | Neutrophil extracellular trap formation;Alcoholism;Systemic lupus erythematosus; | 112.85 | 17.97 | 6.28 |
| Lumiracoxib | DB01283 | GSK3B;HDAC1;ALOX5; | Spliceosome;Chemokine signaling pathway;Th1 and Th2 cell differentiation; | 111.27 | 18.67 | 5.96 |
| Oxazepam | DB00842 | GSK3B;HDAC1;PARP1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Human cytomegalovirus infection; | 108.63 | 17.44 | 6.23 |
| Nitrazepam | DB01595 | GSK3B;HDAC1;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Hematopoietic cell lineage; | 103.38 | 16.18 | 6.39 |
| Lorazepam | DB00186 | GSK3B;HDAC1;CDK1; | Th1 and Th2 cell differentiation;Human cytomegalovirus infection;Th17 cell differentiation; | 101.27 | 17.11 | 5.92 |
| Quinidine | DB00908 | MAPK14;IGF1R;DRD2; | Necroptosis;Systemic lupus erythematosus;Alcoholism; | 95.07 | 13.88 | 6.85 |
| Ticlopidine | DB00208 | CDK1;CYP19A1;DRD2; | Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;Th1 and Th2 cell differentiation; | 94.34 | 16.49 | 5.72 |
| Indapamide | DB00808 | IGF1R;CDK1;DRD2; | Inflammatory bowel disease;Th1 and Th2 cell differentiation;Graft-versus-host disease; | 93.26 | 16.11 | 5.79 |
| Colchicine | DB01394 | HDAC2;HDAC1;DRD2; | Salmonella infection;Necroptosis;Th17 cell differentiation; | 91.68 | 16.31 | 5.62 |
| Hydrocortisone-cypionate | DB14541 | ALOX5;PRKCA;G6PD; | Human cytomegalovirus infection;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 85.97 | 20.52 | 4.19 |
| Lorlatinib | DB12130 | PTK2;PDE4B;HSP90AA1; | Cushing syndrome;Insulin secretion;Salmonella infection; | 83.54 | 16.71 | 5 |
| Dihydrotachysterol | DB01070 | IGF1R;CYP19A1;PTK2; | Th1 and Th2 cell differentiation;VEGF signaling pathway;Oocyte meiosis; | 81.93 | 15.58 | 5.26 |
| Ibuprofen | DB01050 | HDAC1;ALOX5;CYP2C9; | Th1 and Th2 cell differentiation;Phagosome;RNA transport; | 81.58 | 15.60 | 5.23 |
| Profenamine | DB00392 | PARP1;DRD2;INSR; | Neutrophil extracellular trap formation;Systemic lupus erythematosus;Alcoholism; | 80.91 | 12.62 | 6.41 |
| Pralatrexate | DB06813 | HDAC1;ABCB1;TNF; | T cell receptor signaling pathway;Th1 and Th2 cell differentiation;Epithelial cell signaling in Helicobacter pylori infection; | 80.49 | 19.03 | 4.23 |
| Apalutamide | DB11901 | HDAC2;HDAC1;MAPK14; | NF-kappa B signaling pathway;Transcriptional misregulation in cancer;Th1 and Th2 cell differentiation; | 79.17 | 13.13 | 6.03 |
| Rutin | DB01698 | GSK3B;MAPK14;CYP19A1; | Complement and coagulation cascades;Glutathione metabolism;Sphingolipid signaling pathway; | 74.91 | 12.55 | 5.97 |
| Enprofylline | DB00824 | GSK3B;CA2;ADRB2; | "Cortisol synthesis and secretion;Parathyroid hormone synthesis, secretion and action;Staphylococcus aureus infection;" | 68.91 | 13.25 | 5.2 |
| Ursodeoxycholic-acid | DB01586 | JAK1;AKR1C3;G6PD; | Human cytomegalovirus infection;Glutathione metabolism;Calcium signaling pathway; | 68.63 | 18.06 | 3.8 |
| Verapamil | DB00661 | PARP1;ABCB1;ADRB2; | Systemic lupus erythematosus;IL-17 signaling pathway;Aminoacyl-tRNA biosynthesis; | 67.90 | 15.65 | 4.34 |
| Fenofibrate | DB01039 | HDAC1;CYP19A1;ELA2; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Neutrophil extracellular trap formation; | 67.83 | 14.28 | 4.75 |
| Alfacalcidol | DB01436 | HDAC2;IGF1R;PTK2; | Th1 and Th2 cell differentiation;VEGF signaling pathway;Progesterone-mediated oocyte maturation; | 65.06 | 14.85 | 4.38 |
| Bepotastine | DB04890 | MAPK14;PIK3CB;DRD2; | RNA polymerase;Systemic lupus erythematosus;Alcoholism; | 63.74 | 10.09 | 6.32 |
| Montelukast | DB00471 | ALOX5;PDE4B;CYP2C9; | RNA transport;Spliceosome;Human immunodeficiency virus 1 infection; | 51.80 | 15.10 | 3.43 |
| Nicotine | DB00184 | CYP19A1;DRD2;CA2; | Natural killer cell mediated cytotoxicity;RNA polymerase;Malaria; | 49.50 | 10.71 | 4.62 |
| Clemastine | DB00283 | DRD2;LTA4H;CYP2C9; | RNA polymerase;Neutrophil extracellular trap formation;Systemic lupus erythematosus; | 44.84 | 9.13 | 4.91 |
| Isavuconazole | DB11633 | MAPK14;ALOX5;CYP2C9; | Aminoacyl-tRNA biosynthesis;Thiamine metabolism;RNA polymerase; | 42.81 | 11.67 | 3.67 |
| Aminocaproic-acid | DB00513 | GSK3B;HDAC1;ELA2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Amoebiasis; | 41.51 | 13.61 | 3.05 |
| Lacosamide | DB06218 | HDAC2;HDAC1;IGF1R; | Transcriptional misregulation in cancer;Th1 and Th2 cell differentiation;Neutrophil extracellular trap formation; | 114.80 | 17.61 | 6.52 |
| Gilteritinib | DB12141 | JAK1;MAPK14;IGF1R; | GABAergic synapse;Glyoxylate and dicarboxylate metabolism;Glutamatergic synapse; | 110.99 | 18.72 | 5.93 |
| Flurbiprofen | DB00712 | HDAC2;CA2;BCL2; | Phagosome;RNA transport;Ether lipid metabolism; | 102.32 | 18.30 | 5.59 |
| Segesterone-acetate | DB14583 | CYP19A1;ABCB1;CYP2C9; | Systemic lupus erythematosus;Glyoxylate and dicarboxylate metabolism;Alcoholism; | 101.59 | 18.21 | 5.58 |
| Diclofenac | DB00586 | GSK3B;HDAC1;ALOX5; | Spliceosome;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 97.42 | 15.94 | 6.11 |
| Udenafil | DB06267 | GSK3B;HDAC2;HDAC1; | RNA transport;Calcium signaling pathway;Amoebiasis; | 96.42 | 13.52 | 7.13 |
| Milrinone | DB00235 | GSK3B;PIK3CB;LCK; | Th1 and Th2 cell differentiation;Pyrimidine metabolism;Th17 cell differentiation; | 92.72 | 15.74 | 5.89 |
| Tolazoline | DB00797 | CYP19A1;DRD2;ALOX5; | Natural killer cell mediated cytotoxicity;Human immunodeficiency virus 1 infection;NF-kappa B signaling pathway; | 90.17 | 18.94 | 4.76 |
| Apomorphine | DB00714 | MAPK14;CYP19A1;DRD2; | Natural killer cell mediated cytotoxicity;Graft-versus-host disease;Neutrophil extracellular trap formation; | 85.36 | 13.79 | 6.19 |
| Etonogestrel | DB00294 | IGF1R;PARP1;CYP19A1; | Adherens junction;Rap1 signaling pathway;Salmonella infection; | 85.25 | 13.86 | 6.15 |
| Gestrinone | DB11619 | IGF1R;PARP1;CYP19A1; | Adherens junction;Rap1 signaling pathway;Salmonella infection; | 83.54 | 13.32 | 6.27 |
| Menthyl-salicylate | DB11201 | HDAC2;CYP19A1;MMP9; | Transcriptional misregulation in cancer;Neutrophil extracellular trap formation;Inflammatory bowel disease; | 76.98 | 12.85 | 5.99 |
| Pergolide | DB01186 | JAK1;LCK;PARP1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 76.09 | 11.76 | 6.47 |
| Calcitriol | DB00136 | HDAC2;IGF1R;PTK2; | Th1 and Th2 cell differentiation;RNA transport;Th17 cell differentiation; | 74.19 | 13.95 | 5.32 |
| Paricalcitol | DB00910 | HDAC2;IGF1R;PTK2; | Th1 and Th2 cell differentiation;RNA transport;Th17 cell differentiation; | 74.19 | 13.95 | 5.32 |
| Azacitidine | DB00928 | GSK3B;PIK3CB;MAP3K7; | Pathways in cancer;Glyoxylate and dicarboxylate metabolism;Spliceosome; | 72.63 | 19.01 | 3.82 |
| Atropine | DB00572 | PIK3CB;PARP1;DRD2; | Pyrimidine metabolism;Transcriptional misregulation in cancer;Oxidative phosphorylation; | 70.09 | 12.32 | 5.69 |
| Tolbutamide | DB01124 | HDAC1;IGF1R;CA2; | Aminoacyl-tRNA biosynthesis;Starch and sucrose metabolism;Natural killer cell mediated cytotoxicity; | 69.67 | 14.54 | 4.79 |
| Lidocaine | DB00281 | GSK3B;HDAC1;PIK3CB; | Neutrophil extracellular trap formation;Glyoxylate and dicarboxylate metabolism;Pathways of neurodegeneration - multiple diseases; | 68.84 | 14.02 | 4.91 |
| Phentolamine | DB00692 | HDAC1;CDK1;DRD2; | Natural killer cell mediated cytotoxicity;Cell cycle;Amoebiasis; | 67.05 | 12.39 | 5.41 |
| Cholesterol | DB04540 | CYP19A1;ABCB1;F2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Calcium signaling pathway; | 66.19 | 15.01 | 4.41 |
| Ritonavir | DB00503 | MAPK14;ABCB1;PDE4B; | Alcoholism;Systemic lupus erythematosus;Pathways in cancer; | 65.17 | 12.63 | 5.16 |
| Hesperidin | DB04703 | GSK3B;MAPK14;CYP19A1; | Arginine biosynthesis;IL-17 signaling pathway;Graft-versus-host disease; | 64.84 | 13.05 | 4.97 |
| Ranolazine | DB00243 | GSK3B;DRD2;ABCB1; | Thiamine metabolism;Starch and sucrose metabolism;IL-17 signaling pathway; | 64.58 | 14.85 | 4.35 |
| Doxylamine | DB00366 | MAPK14;PDGFRB;DRD2; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 63.67 | 10.74 | 5.93 |
| Reboxetine | DB00234 | PIK3CB;PDGFRB;DRD2; | Spliceosome;Complement and coagulation cascades;Non-alcoholic fatty liver disease; | 63.43 | 11.77 | 5.39 |
| Cocaine | DB00907 | DRD2;PRKCA;CA2; | Necroptosis;Pyrimidine metabolism;Leishmaniasis; | 63.07 | 13.45 | 4.69 |
| Lamotrigine | DB00555 | PDGFRB;DRD2;ADRB2; | Morphine addiction;Salmonella infection;Salivary secretion; | 60.01 | 17.24 | 3.48 |
| Estradiol-benzoate | DB13953 | HDAC2;HDAC1;CYP19A1; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;T cell receptor signaling pathway; | 59.67 | 13.84 | 4.31 |
| Oxacillin | DB00713 | HDAC2;PIK3CB;PARP1; | Th1 and Th2 cell differentiation;Platelet activation;RNA transport; | 58.48 | 12.34 | 4.74 |
| Methotrimeprazine | DB01403 | PARP1;DRD2;CA2; | Neutrophil extracellular trap formation;Systemic lupus erythematosus;Alcoholism; | 57.90 | 9.83 | 5.89 |
| Clopidogrel | DB00758 | HDAC1;CYP19A1;DRD2; | Pyrimidine metabolism;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 57.13 | 11.38 | 5.02 |
| Testosterone-enanthate | DB13944 | CYP19A1;CA2;NR3C2; | Th1 and Th2 cell differentiation;RNA transport;NF-kappa B signaling pathway; | 56.65 | 10.79 | 5.25 |
| Siponimod | DB12371 | DRD2;ALOX5;CYP2C9; | Neutrophil extracellular trap formation;Spliceosome;Systemic lupus erythematosus; | 55.94 | 12.32 | 4.54 |
| Cyclosporine | DB00091 | HDAC1;ABCB1;CYP2C9; | Pathways in cancer;Calcium signaling pathway;Spliceosome; | 53.43 | 18.88 | 2.83 |
| Dosulepin | DB09167 | DRD2;INSR;ADRB2; | Necroptosis;Ribosome;Pentose phosphate pathway; | 48.77 | 10.16 | 4.8 |
| Haloperidol | DB00502 | DRD2;ABCB1;ADRB2; | RNA polymerase;Systemic lupus erythematosus;Alcoholism; | 48.56 | 9.39 | 5.17 |
| Glutathione | DB00143 | MMP9;AKR1C3;AKR1B1; | Inflammatory bowel disease;Glutathione metabolism;Metabolism of xenobiotics by cytochrome P450; | 40.13 | 13.16 | 3.05 |
| Phosphatidyl-serine | DB00144 | PRKCA;PRKACA;PRKACB; | Phagosome;Necroptosis;Gap junction; | 35.81 | 17.14 | 2.09 |
| Ferrous-ascorbate | DB14490 | HDAC1;EGLN1;POLB; | Arrhythmogenic right ventricular cardiomyopathy;Dilated cardiomyopathy;Hypertrophic cardiomyopathy; | 24.54 | 15.05 | 1.63 |
| Ferrous-fumarate | DB14491 | HDAC1;EGLN1;POLB; | Arrhythmogenic right ventricular cardiomyopathy;Dilated cardiomyopathy;Hypertrophic cardiomyopathy; | 24.54 | 15.05 | 1.63 |
| Ferrous-gluconate | DB14488 | HDAC1;EGLN1;POLB; | Arrhythmogenic right ventricular cardiomyopathy;Dilated cardiomyopathy;Hypertrophic cardiomyopathy; | 24.54 | 15.05 | 1.63 |
| Ferrous-glycine-sulfate | DB14501 | HDAC1;EGLN1;POLB; | Arrhythmogenic right ventricular cardiomyopathy;Dilated cardiomyopathy;Hypertrophic cardiomyopathy; | 24.54 | 15.05 | 1.63 |
| Ferrous-succinate | DB14489 | HDAC1;EGLN1;POLB; | Arrhythmogenic right ventricular cardiomyopathy;Dilated cardiomyopathy;Hypertrophic cardiomyopathy; | 24.54 | 15.05 | 1.63 |
| Pasireotide | DB06663 | CXCR4;CXCR2;CXCR1; | Transcriptional misregulation in cancer;Natural killer cell mediated cytotoxicity;Neutrophil extracellular trap formation; | 19.30 | 15.08 | 1.28 |
| Alitretinoin | DB00523 | ALOX5;NR1I2;NR1H3; | Th17 cell differentiation;Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation; | 18.24 | 11.33 | 1.61 |
| Lutetium-Lu-177-dotatate | DB13985 | CXCR4;CXCR2;CXCR1; | Transcriptional misregulation in cancer;Natural killer cell mediated cytotoxicity;Neutrophil extracellular trap formation; | 14.78 | 15.39 | 0.96 |
| Hydrocortisone-probutate | DB14543 | RAF1;PRKCA;TNF; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 106.53 | 24.49 | 4.35 |
| Buspirone | DB00490 | JAK1;GSK3B;IGF1R; | Platelet activation;Non-alcoholic fatty liver disease;Tight junction; | 105.84 | 15.63 | 6.77 |
| Methysergide | DB00247 | HDAC1;PARP1;DRD2; | Natural killer cell mediated cytotoxicity;Amoebiasis;Th1 and Th2 cell differentiation; | 94.49 | 14.95 | 6.32 |
| Darolutamide | DB12941 | JAK1;GSK3B;ALOX5; | Inflammatory bowel disease;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 82.98 | 15.17 | 5.47 |
| Homosalate | DB11064 | HDAC2;HDAC1;ALOX5; | Neutrophil extracellular trap formation;RNA transport;Transcriptional misregulation in cancer; | 81.23 | 14.18 | 5.73 |
| Quinine | DB00468 | MAPK14;IGF1R;DRD2; | Necroptosis;Systemic lupus erythematosus;Alcoholism; | 80.51 | 11.50 | 7 |
| Quinapril | DB00881 | HDAC1;DRD2;MMP9; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Platelet activation; | 80.29 | 15.18 | 5.29 |
| Colchiceine | DB15534 | HDAC2;HDAC1;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 79.91 | 14.29 | 5.59 |
| Leflunomide | DB01097 | JAK1;GSK3B;HDAC1; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 79.64 | 12.97 | 6.14 |
| Suprofen | DB00870 | HDAC1;CYP19A1;ELA2; | NF-kappa B signaling pathway;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 77.36 | 14.07 | 5.5 |
| Tiaprofenic-acid | DB01600 | HDAC1;CYP19A1;ELA2; | NF-kappa B signaling pathway;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 77.36 | 14.07 | 5.5 |
| Trimethaphan | DB01116 | MAPK14;PIK3CB;PDGFRB; | Spliceosome;Complement and coagulation cascades;B cell receptor signaling pathway; | 77.28 | 12.55 | 6.16 |
| Hydrocortisone-butyrate | DB14540 | ABCB1;CYP2C9;NR3C2; | Th1 and Th2 cell differentiation;Human cytomegalovirus infection;T cell receptor signaling pathway; | 76.83 | 17.62 | 4.36 |
| Ingenol-mebutate | DB05013 | PRKCA;PRKACA;PRKACB; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Natural killer cell mediated cytotoxicity; | 76.32 | 20.63 | 3.7 |
| Tazarotene | DB00799 | HDAC1;MAPK14;CYP19A1; | Spliceosome;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 74.27 | 15.03 | 4.94 |
| Terazosin | DB01162 | PIK3CB;PDGFRB;ADRB2; | Th1 and Th2 cell differentiation;C-type lectin receptor signaling pathway;Inflammatory bowel disease; | 73.87 | 17.93 | 4.12 |
| Diphenhydramine | DB01075 | HDAC2;HDAC1;DRD2; | RNA transport;Systemic lupus erythematosus;Natural killer cell mediated cytotoxicity; | 73.27 | 11.78 | 6.22 |
| Istradefylline | DB11757 | JAK1;HDAC2;HDAC1; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Amoebiasis; | 73.11 | 12.78 | 5.72 |
| Nortriptyline | DB00540 | HDAC2;HDAC1;DRD2; | Systemic lupus erythematosus;Natural killer cell mediated cytotoxicity;Pentose phosphate pathway; | 72.11 | 12.02 | 6 |
| Salicylic-acid | DB00936 | GSK3B;ALOX5;CA2; | Inflammatory bowel disease;Graft-versus-host disease;Sphingolipid signaling pathway; | 71.82 | 14.96 | 4.8 |
| Benazepril | DB00542 | HDAC1;DRD2;ALOX5; | Platelet activation;Spliceosome;Th1 and Th2 cell differentiation; | 70.89 | 14.86 | 4.77 |
| Fenofibric-acid | DB13873 | HDAC1;MMP9;ELA2; | Neutrophil extracellular trap formation;Transcriptional misregulation in cancer;NF-kappa B signaling pathway; | 69.81 | 15.76 | 4.43 |
| Fluoroestradiol-F-18 | DB15690 | HDAC2;HDAC1;CYP19A1; | Th1 and Th2 cell differentiation;Systemic lupus erythematosus;NF-kappa B signaling pathway; | 69.35 | 11.31 | 6.13 |
| Acenocoumarol | DB01418 | LCK;CYP19A1;ALOX5; | Th1 and Th2 cell differentiation;Th17 cell differentiation;PD-L1 expression and PD-1 checkpoint pathway in cancer; | 69.27 | 13.80 | 5.02 |
| Belinostat | DB05015 | HDAC2;HDAC1;CYP19A1; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;Neutrophil extracellular trap formation; | 67.21 | 11.28 | 5.96 |
| Vernakalant | DB06217 | DRD2;ABCB1;ADRB2; | RNA polymerase;Ribosome;Pathways of neurodegeneration - multiple diseases; | 66.06 | 14.65 | 4.51 |
| Orphenadrine | DB01173 | DRD2;ADRB2;LTA4H; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 65.10 | 12.45 | 5.23 |
| Mesalazine | DB00244 | CDK1;ALOX5;CA2; | Spliceosome;Graft-versus-host disease;Platelet activation; | 64.22 | 15.11 | 4.25 |
| Methotrexate | DB00563 | ABCB1;HSP90AA1;HSP90AB1; | Ribosome;T cell receptor signaling pathway;Protein processing in endoplasmic reticulum; | 61.12 | 18.36 | 3.33 |
| Ergocalciferol | DB00153 | IGF1R;PTK2;MAP2K1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;VEGF signaling pathway; | 60.03 | 14.50 | 4.14 |
| Levacetylmethadol | DB01227 | HDAC2;HDAC1;DRD2; | RNA transport;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway; | 54.97 | 11.95 | 4.6 |
| Butorphanol | DB00611 | HDAC1;DRD2;CA2; | Natural killer cell mediated cytotoxicity;Complement and coagulation cascades;T cell receptor signaling pathway; | 54.07 | 12.97 | 4.17 |
| Carvedilol | DB01136 | GSK3B;DRD2;PTK2; | Thiamine metabolism;Starch and sucrose metabolism;IL-17 signaling pathway; | 53.68 | 11.14 | 4.82 |
| Doxepin | DB01142 | PDGFRB;DRD2;ADRB2; | Natural killer cell mediated cytotoxicity;Complement and coagulation cascades;Necroptosis; | 49.71 | 10.23 | 4.86 |
| alpha-Linolenic-acid | DB00132 | CYP19A1;ALOX5;NR1I2; | Spliceosome;VEGF signaling pathway;Platelet activation; | 49.52 | 14.87 | 3.33 |
| Benzylpenicillin | DB01053 | PARP1;ELA2;CA2; | Platelet activation;Transcriptional misregulation in cancer;Neutrophil extracellular trap formation; | 49.51 | 11.41 | 4.34 |
| Trimebutine | DB09089 | DRD2;MMP9;ALOX5; | Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis;Spliceosome; | 48.68 | 11.40 | 4.27 |
| Telaprevir | DB05521 | ELA2;NR3C2;F2; | T cell receptor signaling pathway;NF-kappa B signaling pathway;Th1 and Th2 cell differentiation; | 48.53 | 12.67 | 3.83 |
| Nafcillin | DB00607 | HDAC1;PIK3CB;MMP9; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Inflammatory bowel disease; | 47.57 | 10.14 | 4.69 |
| Mifepristone | DB00834 | CYP19A1;ELA2;CYP2C9; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;NF-kappa B signaling pathway; | 38.36 | 12.58 | 3.05 |
| Disopyramide | DB00280 | PARP1;DRD2;LTA4H; | Necroptosis;Neutrophil extracellular trap formation;Ribosome; | 38.32 | 10.25 | 3.74 |
| Felodipine | DB01023 | ABCB1;NR3C2;CALM1; | Necroptosis;Pathways in cancer;Spliceosome; | 37.07 | 16.26 | 2.28 |
| Butamben | DB11148 | LTA4H;ITK;PLCG1; | Th17 cell differentiation;Phototransduction;Th1 and Th2 cell differentiation; | 35.25 | 15.07 | 2.34 |
| Hyaluronic-acid | DB08818 | DRD2;ELA2;CA2; | NF-kappa B signaling pathway;Amoebiasis;Th1 and Th2 cell differentiation; | 32.42 | 13.57 | 2.39 |
| Tranexamic-acid | DB00302 | ELA2;HSP90AA1;F2; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;Th17 cell differentiation; | 32.07 | 14.51 | 2.21 |
| Estradiol-dienanthate | DB13955 | NR1I2;FNTA;PTGES; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway; | 27.64 | 10.47 | 2.64 |
| Cholic-Acid | DB02659 | JAK1;AKR1B1;NR1H3; | Endocytosis;Oocyte meiosis;Ribosome; | 23.10 | 9.54 | 2.42 |
| Vitamin-A | DB00162 | NR1H3;S1PR1;RARB; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Measles; | 15.87 | 12.80 | 1.24 |
| Azathioprine | DB00993 | RHOA;PADI4;RALA; | Th1 and Th2 cell differentiation;Hematopoietic cell lineage;Natural killer cell mediated cytotoxicity; | 14.62 | 13.30 | 1.1 |
| Diltiazem | DB00343 | GSK3B;HDAC2;HDAC1; | RNA transport;Spliceosome;Systemic lupus erythematosus; | 109.40 | 15.70 | 6.97 |
| Isoprenaline | DB01064 | MAPK14;RAF1;CDK1; | Adrenergic signaling in cardiomyocytes;Cortisol synthesis and secretion;Ribosome; | 101.46 | 23.49 | 4.32 |
| Hexylcaine | DB00473 | GSK3B;HDAC1;DRD2; | Th1 and Th2 cell differentiation;Graft-versus-host disease;Natural killer cell mediated cytotoxicity; | 95.81 | 18.04 | 5.31 |
| Sirolimus | DB00877 | RAF1;CYP19A1;DRD2; | Phospholipase D signaling pathway;Thiamine metabolism;Rap1 signaling pathway; | 94.06 | 19.89 | 4.73 |
| Fluorometholone | DB00324 | MAPK14;CYP19A1;CA2; | Alcoholism;Viral carcinogenesis;Kaposi sarcoma-associated herpesvirus infection; | 90.85 | 16.31 | 5.57 |
| Desoximetasone | DB00547 | CYP19A1;CA2;ABCB1; | Calcium signaling pathway;Alcoholism;Viral carcinogenesis; | 89.12 | 16.78 | 5.31 |
| Nimesulide | DB04743 | HDAC2;HDAC1;CYP19A1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Necroptosis; | 86.88 | 14.50 | 5.99 |
| Oxiconazole | DB00239 | HDAC1;MAPK14;CYP19A1; | Kaposi sarcoma-associated herpesvirus infection;Th17 cell differentiation;Chemokine signaling pathway; | 83.46 | 15.26 | 5.47 |
| Pirenzepine | DB00670 | JAK1;GSK3B;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Pathways in cancer; | 81.28 | 15.05 | 5.4 |
| Lovastatin | DB00227 | HDAC2;HDAC1;PRKCA; | Th1 and Th2 cell differentiation;RNA transport;Th17 cell differentiation; | 81.08 | 14.93 | 5.43 |
| Simvastatin | DB00641 | HDAC2;HDAC1;PRKCA; | Th1 and Th2 cell differentiation;RNA transport;Th17 cell differentiation; | 81.08 | 14.93 | 5.43 |
| Oxymetholone | DB06412 | IGF1R;CYP19A1;DRD2; | Adherens junction;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 79.95 | 14.20 | 5.63 |
| Chlorcyclizine | DB08936 | IGF1R;DRD2;MMP9; | Transcriptional misregulation in cancer;Oxidative phosphorylation;Graft-versus-host disease; | 77.84 | 13.85 | 5.62 |
| Clorazepic-acid | DB00628 | GSK3B;HDAC1;CDK1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 73.64 | 14.03 | 5.25 |
| Calcifediol | DB00146 | HDAC2;IGF1R;PTK2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Choline metabolism in cancer; | 70.03 | 14.74 | 4.75 |
| Protriptyline | DB00344 | HDAC2;HDAC1;DRD2; | Systemic lupus erythematosus;Natural killer cell mediated cytotoxicity;Pentose phosphate pathway; | 69.71 | 12.02 | 5.8 |
| Apixaban | DB06605 | HDAC2;HDAC1;PIK3CB; | Natural killer cell mediated cytotoxicity;RNA transport;Th1 and Th2 cell differentiation; | 67.81 | 11.36 | 5.97 |
| Hyoscyamine | DB00424 | PIK3CB;PARP1;DRD2; | Pyrimidine metabolism;Transcriptional misregulation in cancer;Oxidative phosphorylation; | 66.90 | 11.26 | 5.94 |
| Hydrocortisone-valerate | DB14544 | TNF;CYP2C9;NR3C2; | Human cytomegalovirus infection;Cushing syndrome;Systemic lupus erythematosus; | 65.88 | 15.65 | 4.21 |
| Pentagastrin | DB00183 | DRD2;ALOX5;ELA2; | Spliceosome;Platelet activation;Tight junction; | 63.77 | 15.15 | 4.21 |
| Nylidrin | DB06152 | CDK1;DRD2;CA2; | Pentose phosphate pathway;Graft-versus-host disease;Necroptosis; | 63.52 | 11.30 | 5.62 |
| Tazemetostat | DB12887 | MAPK14;LCK;DRD2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 63.10 | 11.86 | 5.32 |
| Prochlorperazine | DB00433 | DRD2;ADRB2;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 61.44 | 13.84 | 4.44 |
| Obeticholic-acid | DB05990 | JAK1;HDAC2;AKR1B1; | Human cytomegalovirus infection;RNA transport;Calcium signaling pathway; | 61.37 | 16.07 | 3.82 |
| Thioridazine | DB00679 | DRD2;ADRB2;CYP2C9; | Th1 and Th2 cell differentiation;Graft-versus-host disease;T cell receptor signaling pathway; | 61.17 | 13.90 | 4.4 |
| Rotigotine | DB05271 | DRD2;CA2;ADRB2; | Systemic lupus erythematosus;Non-alcoholic fatty liver disease;Alcoholism; | 60.09 | 10.24 | 5.87 |
| Olanzapine | DB00334 | MAPK14;DRD2;ADRB2; | Natural killer cell mediated cytotoxicity;Graft-versus-host disease;Pentose phosphate pathway; | 57.35 | 11.25 | 5.1 |
| Lormetazepam | DB13872 | CDK1;DRD2;ALB; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;Cell cycle; | 56.94 | 11.84 | 4.81 |
| Lopinavir | DB01601 | HDAC2;HDAC1;CA2; | RNA transport;Phagosome;Systemic lupus erythematosus; | 56.69 | 10.90 | 5.2 |
| Finasteride | DB01216 | HDAC2;HDAC1;MAPK14; | Th1 and Th2 cell differentiation;Th17 cell differentiation;RNA transport; | 55.46 | 10.33 | 5.37 |
| Triflupromazine | DB00508 | DRD2;CA2;ABCB1; | Neutrophil extracellular trap formation;Systemic lupus erythematosus;Alcoholism; | 54.07 | 9.83 | 5.5 |
| Metyrapone | DB01011 | GSK3B;LCK;CYP19A1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 51.75 | 10.69 | 4.84 |
| Tadalafil | DB00820 | PARP1;DRD2;PDE4B; | Necroptosis;Systemic lupus erythematosus;Salmonella infection; | 51.48 | 10.19 | 5.05 |
| Nandrolone-decanoate | DB08804 | LCK;CYP19A1;NR3C2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 51.33 | 10.27 | 5 |
| Mephenytoin | DB00532 | CYP19A1;MMP9;ELA2; | Transcriptional misregulation in cancer;Inflammatory bowel disease;NF-kappa B signaling pathway; | 50.38 | 11.12 | 4.53 |
| Sulpiride | DB00391 | CYP19A1;DRD2;MMP9; | Graft-versus-host disease;Sphingolipid signaling pathway;Inflammatory bowel disease; | 49.93 | 10.21 | 4.89 |
| Ramelteon | DB00980 | GSK3B;MAPK14;DRD2; | Spliceosome;Fluid shear stress and atherosclerosis;Systemic lupus erythematosus; | 47.55 | 8.76 | 5.43 |
| Naldemedine | DB11691 | HDAC1;DRD2;ALOX5; | RNA transport;Spliceosome;Natural killer cell mediated cytotoxicity; | 46.36 | 14.72 | 3.15 |
| Vortioxetine | DB09068 | DRD2;ADRB2;LTA4H; | Systemic lupus erythematosus;Necroptosis;Ribosome; | 41.78 | 9.61 | 4.35 |
| Icosapent | DB00159 | CYP19A1;ALOX5;NR1I2; | Spliceosome;Glyoxylate and dicarboxylate metabolism;Platelet activation; | 41.61 | 14.45 | 2.88 |
| Ketamine | DB01221 | DRD2;ADRB2;SLC6A4; | Natural killer cell mediated cytotoxicity;Salivary secretion;Antigen processing and presentation; | 34.94 | 12.66 | 2.76 |
| Saquinavir | DB01232 | DRD2;CA2;ABCB1; | Complement and coagulation cascades;African trypanosomiasis;Sphingolipid signaling pathway; | 32.02 | 7.08 | 4.52 |
| Aspartic-acid | DB00128 | CA2;KIF11;GRIA4; | Complement and coagulation cascades;Malaria;Th1 and Th2 cell differentiation; | 16.78 | 11.11 | 1.51 |
| Edotreotide-gallium-Ga-68 | DB15494 | CXCR4;CXCR2;CXCR1; | Transcriptional misregulation in cancer;Natural killer cell mediated cytotoxicity;Neutrophil extracellular trap formation; | 14.61 | 14.91 | 0.98 |
| Dronedarone | DB04855 | DRD2;ADRB2;HTR1F; | RNA polymerase;Ribosome;Huntington disease; | 13.13 | 10.50 | 1.25 |
| Goserelin | DB00014 | GSK3B;EGLN1;TLR2; | Fluid shear stress and atherosclerosis;Starch and sucrose metabolism;Notch signaling pathway; | 8.50 | 3.15 | 2.7 |
| Prednisolone-acetate | DB15566 | PRKCA;CA2;ABCB1; | Systemic lupus erythematosus;Cushing syndrome;Aldosterone synthesis and secretion; | 91.08 | 16.09 | 5.66 |
| Brimonidine | DB00484 | GSK3B;CDK1;DRD2; | Adrenergic signaling in cardiomyocytes;Human cytomegalovirus infection;Dopaminergic synapse; | 84.72 | 18.30 | 4.63 |
| Monobenzone | DB00600 | HDAC2;HDAC1;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 83.75 | 14.01 | 5.98 |
| Everolimus | DB01590 | RAF1;DRD2;MMP9; | Phospholipase D signaling pathway;Thiamine metabolism;Rap1 signaling pathway; | 82.72 | 19.42 | 4.26 |
| Fluoxymesterone | DB01185 | MAPK14;IGF1R;CYP19A1; | Starch and sucrose metabolism;Thiamine metabolism;Human cytomegalovirus infection; | 80.81 | 13.54 | 5.97 |
| Antazoline | DB08799 | JAK1;HDAC2;HDAC1; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Spliceosome; | 80.27 | 14.01 | 5.73 |
| Antrafenine | DB01419 | MAPK14;LCK;DRD2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 76.89 | 14.51 | 5.3 |
| Probenecid | DB01032 | HDAC1;IGF1R;MMP9; | T cell receptor signaling pathway;Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation; | 71.65 | 15.75 | 4.55 |
| Flurazepam | DB00690 | DRD2;ADRB2;CYP2C9; | Salivary secretion;Graft-versus-host disease;Morphine addiction; | 70.88 | 15.15 | 4.68 |
| Raltitrexed | DB00293 | HDAC2;HDAC1;HSP90AA1; | RNA transport;Th17 cell differentiation;Th1 and Th2 cell differentiation; | 70.40 | 15.47 | 4.55 |
| Selexipag | DB11362 | HDAC2;HDAC1;MMP9; | RNA transport;Calcium signaling pathway;Th1 and Th2 cell differentiation; | 69.54 | 12.53 | 5.55 |
| Triamterene | DB00384 | GSK3B;IGF1R;INSR; | Human cytomegalovirus infection;RNA polymerase;Cytosolic DNA-sensing pathway; | 68.76 | 13.78 | 4.99 |
| Tolterodine | DB01036 | HDAC2;HDAC1;DRD2; | RNA transport;Oxidative phosphorylation;Spliceosome; | 68.54 | 11.90 | 5.76 |
| Hydrocortisone | DB00741 | CYP19A1;CA2;ABCB1; | Systemic lupus erythematosus;Natural killer cell mediated cytotoxicity;Alcoholism; | 65.86 | 13.09 | 5.03 |
| Mazindol | DB00579 | GSK3B;PARP1;CDK1; | Human cytomegalovirus infection;Systemic lupus erythematosus;Cytosolic DNA-sensing pathway; | 65.23 | 12.17 | 5.36 |
| Memantine | DB01043 | LCK;DRD2;LTA4H; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Necroptosis; | 62.75 | 12.14 | 5.17 |
| Revefenacin | DB11855 | IGF1R;LCK;PDGFRB; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 59.91 | 11.07 | 5.41 |
| Regadenoson | DB06213 | JAK1;PIK3CB;CA2; | Systemic lupus erythematosus;Alcoholism;Pentose phosphate pathway; | 59.22 | 12.82 | 4.62 |
| Nicergoline | DB00699 | GSK3B;MAPK14;DRD2; | Starch and sucrose metabolism;Fluid shear stress and atherosclerosis;IL-17 signaling pathway; | 58.90 | 11.85 | 4.97 |
| Macimorelin | DB13074 | HDAC2;HDAC1;MAPK14; | Th1 and Th2 cell differentiation;Amoebiasis;T cell receptor signaling pathway; | 57.61 | 10.91 | 5.28 |
| Triclabendazole | DB12245 | CYP19A1;HSP90AB1;FNTA; | Kaposi sarcoma-associated herpesvirus infection;RNA transport;Th17 cell differentiation; | 57.07 | 16.99 | 3.36 |
| Aminosalicylic-acid | DB00233 | CDK1;ALOX5;CA2; | Spliceosome;Platelet activation;Tight junction; | 55.62 | 13.87 | 4.01 |
| Homatropine | DB11181 | PIK3CB;DRD2;CA2; | Pyrimidine metabolism;Glyoxylate and dicarboxylate metabolism;Oxidative phosphorylation; | 55.39 | 10.32 | 5.37 |
| Tripelennamine | DB00792 | PARP1;DRD2;CA2; | Non-alcoholic fatty liver disease;Neutrophil extracellular trap formation;Natural killer cell mediated cytotoxicity; | 55.15 | 10.12 | 5.45 |
| Ethinylestradiol | DB00977 | HDAC2;HDAC1;CYP19A1; | Systemic lupus erythematosus;Alcoholism;Th17 cell differentiation; | 54.08 | 9.83 | 5.5 |
| Dexamethasone | DB01234 | CA2;ABCB1;TNF; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 52.80 | 11.55 | 4.57 |
| Valine | DB00161 | GSK3B;HDAC1;DRD2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;PD-L1 expression and PD-1 checkpoint pathway in cancer; | 52.48 | 12.23 | 4.29 |
| Gemfibrozil | DB01241 | HDAC1;MMP9;ELA2; | Neutrophil extracellular trap formation;Transcriptional misregulation in cancer;NF-kappa B signaling pathway; | 52.40 | 13.30 | 3.94 |
| Chlorprothixene | DB01239 | DRD2;INSR;ABCB1; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 52.12 | 9.37 | 5.56 |
| Netupitant | DB09048 | GSK3B;PIK3CB;DRD2; | Spliceosome;Starch and sucrose metabolism;B cell receptor signaling pathway; | 51.30 | 8.40 | 6.11 |
| Ozanimod | DB12612 | GSK3B;MAPK14;CDK1; | Natural killer cell mediated cytotoxicity;Neutrophil extracellular trap formation;Amoebiasis; | 49.51 | 9.71 | 5.1 |
| Doxercalciferol | DB06410 | HDAC2;IGF1R;PTK2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;PD-L1 expression and PD-1 checkpoint pathway in cancer; | 49.33 | 10.52 | 4.69 |
| Apremilast | DB05676 | HDAC1;MMP9;PDE4B; | T cell receptor signaling pathway;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 49.28 | 9.63 | 5.12 |
| Methylphenidate | DB00422 | GSK3B;HDAC1;CYP19A1; | Natural killer cell mediated cytotoxicity;Fluid shear stress and atherosclerosis;Th17 cell differentiation; | 48.53 | 10.39 | 4.67 |
| Ritodrine | DB00867 | CDK1;DRD2;CA2; | Pentose phosphate pathway;Graft-versus-host disease;Neutrophil extracellular trap formation; | 48.01 | 9.16 | 5.24 |
| Trametinib | DB08911 | GSK3B;MAPK14;CDK1; | Fluid shear stress and atherosclerosis;Systemic lupus erythematosus;Starch and sucrose metabolism; | 45.84 | 9.04 | 5.07 |
| Larotrectinib | DB14723 | DRD2;ADRB2;LTA4H; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Inflammatory bowel disease; | 45.27 | 10.08 | 4.49 |
| Maprotiline | DB00934 | HDAC1;DRD2;ADRB2; | Natural killer cell mediated cytotoxicity;Amoebiasis;Systemic lupus erythematosus; | 43.36 | 10.20 | 4.25 |
| Pseudoephedrine | DB00852 | DRD2;ADRB2;TNF; | Natural killer cell mediated cytotoxicity;Pathways of neurodegeneration - multiple diseases;Malaria; | 42.84 | 11.74 | 3.65 |
| Docetaxel | DB01248 | ABCB1;BCL2;NR1I2; | Salmonella infection;Human immunodeficiency virus 1 infection;Phototransduction; | 41.66 | 12.15 | 3.43 |
| Paclitaxel | DB01229 | ABCB1;BCL2;NR1I2; | Salmonella infection;Human immunodeficiency virus 1 infection;Phototransduction; | 41.66 | 12.15 | 3.43 |
| Tetryzoline | DB06764 | PDGFRB;CYP19A1;DRD2; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Graft-versus-host disease; | 41.53 | 8.86 | 4.69 |
| Loxapine | DB00408 | DRD2;ADRB2;LTA4H; | Systemic lupus erythematosus;Necroptosis;Pentose phosphate pathway; | 39.05 | 9.50 | 4.11 |
| Migalastat | DB05018 | HDAC2;HDAC1;MMP9; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 37.37 | 10.29 | 3.63 |
| Bremelanotide | DB11653 | GSK3B;CA2;CA4; | Natural killer cell mediated cytotoxicity;Malaria;Starch and sucrose metabolism; | 37.12 | 8.99 | 4.13 |
| Amphetamine | DB00182 | CYP19A1;DRD2;ADRB2; | Natural killer cell mediated cytotoxicity;Graft-versus-host disease;Pentose phosphate pathway; | 36.97 | 9.81 | 3.77 |
| Fingolimod | DB08868 | HDAC2;HDAC1;DYRK1A; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;RNA transport; | 36.86 | 10.35 | 3.56 |
| Nandrolone-phenpropionate | DB00984 | HDAC2;PDGFRB;CYP19A1; | Th1 and Th2 cell differentiation;RNA transport;T cell receptor signaling pathway; | 36.26 | 9.27 | 3.91 |
| Pyrimethamine | DB00205 | CYP2C9;SLC22A1;HSP90AB1; | Alcoholism;Systemic lupus erythematosus;Pyrimidine metabolism; | 35.14 | 11.05 | 3.18 |
| Dextroamphetamine | DB01576 | CYP19A1;DRD2;ADRB2; | Natural killer cell mediated cytotoxicity;Graft-versus-host disease;Pentose phosphate pathway; | 33.24 | 9.81 | 3.39 |
| Podofilox | DB01179 | CYP19A1;ALOX5;TOP2A; | Spliceosome;Human immunodeficiency virus 1 infection;Pathways in cancer; | 32.77 | 10.60 | 3.09 |
| Chloroquine | DB00608 | CDK1;DRD2;TNF; | Kaposi sarcoma-associated herpesvirus infection;Th17 cell differentiation;Phagosome; | 32.70 | 10.58 | 3.09 |
| Palmitic-Acid | DB03796 | CYP19A1;CYP2C9;NR1I2; | VEGF signaling pathway;Systemic lupus erythematosus;Oocyte meiosis; | 30.44 | 10.68 | 2.85 |
| Phenylalanine | DB00120 | HSP90AA1;KIF11;BIRC4; | RNA polymerase;Epithelial cell signaling in Helicobacter pylori infection;PD-L1 expression and PD-1 checkpoint pathway in cancer; | 28.50 | 11.09 | 2.57 |
| Clofazimine | DB00845 | LCK;ABCB1;FNTA; | Th1 and Th2 cell differentiation;RNA polymerase;Ribosome; | 27.93 | 9.47 | 2.95 |
| Tapentadol | DB06204 | CDK1;CA2;SLC6A4; | Complement and coagulation cascades;Natural killer cell mediated cytotoxicity;Collecting duct acid secretion; | 27.83 | 10.46 | 2.66 |
| Avapritinib | DB15233 | PIK3CB;LCK;PDGFRB; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Hematopoietic cell lineage; | 24.86 | 6.04 | 4.12 |
| Phenformin | DB00914 | MAPK14;CDK1;PRKACA; | Starch and sucrose metabolism;Thiamine metabolism;Fluid shear stress and atherosclerosis; | 24.86 | 9.90 | 2.51 |
| Enflurane | DB00228 | GABRA4;GABRB3;KCNA3; | Ribosome;Coronavirus disease - COVID-19;RNA polymerase; | 21.44 | 9.49 | 2.26 |
| Tretinoin | DB00755 | ALOX5;NR1I2;NR1H3; | Natural killer cell mediated cytotoxicity;Spliceosome;Th17 cell differentiation; | 20.36 | 9.98 | 2.04 |
| Flavin-mononucleotide | DB03247 | PRKACA;PRKACB;RPS6KA1; | Necroptosis;Arginine biosynthesis;Graft-versus-host disease; | 19.75 | 11.97 | 1.65 |
| Lauric-acid | DB03017 | CA2;TLR2;RARB; | Complement and coagulation cascades;Neutrophil extracellular trap formation;Endocytosis; | 14.41 | 8.19 | 1.76 |
| Sulfamerazine | DB01581 | JAK1;PIK3CB;PRKCA; | Systemic lupus erythematosus;C-type lectin receptor signaling pathway;Estrogen signaling pathway; | 106.61 | 19.97 | 5.34 |
| Ripretinib | DB14840 | MAPK14;RAF1;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 102.60 | 16.66 | 6.16 |
| Hydroxyprogesterone-caproate | DB06789 | LCK;CYP19A1;NR3C2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 88.84 | 17.80 | 4.99 |
| Bufexamac | DB13346 | HDAC2;HDAC1;MMP9; | Neutrophil extracellular trap formation;NF-kappa B signaling pathway;Spliceosome; | 84.74 | 15.49 | 5.47 |
| Norepinephrine | DB00368 | RAF1;DRD2;CA2; | Ribosome;Coronavirus disease - COVID-19;Natural killer cell mediated cytotoxicity; | 84.56 | 18.46 | 4.58 |
| Enoximone | DB04880 | GSK3B;HDAC2;HDAC1; | Amoebiasis;Th1 and Th2 cell differentiation;Starch and sucrose metabolism; | 77.91 | 16.47 | 4.73 |
| Tacrolimus | DB00864 | RAF1;CYP19A1;MMP9; | Phospholipase D signaling pathway;Thiamine metabolism;Rap1 signaling pathway; | 72.94 | 18.37 | 3.97 |
| Methylprednisolone | DB00959 | PRKCA;CA2;ABCB1; | Systemic lupus erythematosus;Neutrophil extracellular trap formation;Alcoholism; | 69.49 | 14.72 | 4.72 |
| Pantoprazole | DB00213 | GSK3B;HDAC1;ABCB1; | Alcoholism;Systemic lupus erythematosus;Starch and sucrose metabolism; | 64.29 | 13.39 | 4.8 |
| Flutemetamol-(18F) | DB09151 | GSK3B;MAPK14;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 61.48 | 12.08 | 5.09 |
| Gliclazide | DB01120 | PARP1;ALOX5;CA2; | RNA polymerase;Spliceosome;IL-17 signaling pathway; | 61.23 | 11.71 | 5.23 |
| Dexamethasone-acetate | DB14649 | CA2;ABCB1;NR3C2; | Cushing syndrome;Aldosterone synthesis and secretion;Calcium signaling pathway; | 60.22 | 15.28 | 3.94 |
| Tixocortol | DB09091 | HDAC2;HDAC1;CYP19A1; | Systemic lupus erythematosus;Natural killer cell mediated cytotoxicity;Alcoholism; | 58.52 | 9.69 | 6.04 |
| Methylergometrine | DB00353 | JAK1;MAPK14;PARP1; | Pentose phosphate pathway;IL-17 signaling pathway;Natural killer cell mediated cytotoxicity; | 54.17 | 8.98 | 6.03 |
| Loxoprofen | DB09212 | ELA2;CA2;CYP2C9; | NF-kappa B signaling pathway;Neutrophil extracellular trap formation;Transcriptional misregulation in cancer; | 54.15 | 11.45 | 4.73 |
| Dexmethylphenidate | DB06701 | GSK3B;HDAC1;CYP19A1; | Natural killer cell mediated cytotoxicity;Fluid shear stress and atherosclerosis;Th17 cell differentiation; | 50.09 | 10.39 | 4.82 |
| Perhexiline | DB01074 | DRD2;PRKCA;LTA4H; | Systemic lupus erythematosus;Neutrophil extracellular trap formation;Necroptosis; | 49.67 | 11.06 | 4.49 |
| Tenoxicam | DB00469 | CYP19A1;MMP9;PRKACA; | Neutrophil extracellular trap formation;Glutathione metabolism;Transcriptional misregulation in cancer; | 48.31 | 9.33 | 5.18 |
| Xylometazoline | DB06694 | HDAC2;HDAC1;CYP19A1; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Amoebiasis; | 48.17 | 10.75 | 4.48 |
| Estriol | DB04573 | CYP19A1;CYP2C9;AKR1C3; | Systemic lupus erythematosus;Alcoholism;Inflammatory bowel disease; | 47.75 | 9.89 | 4.83 |
| Alogliptin | DB06203 | JAK1;GSK3B;PARP1; | Non-alcoholic fatty liver disease;Systemic lupus erythematosus;Alcoholism; | 46.74 | 8.50 | 5.5 |
| Diacerein | DB11994 | ALOX5;ELA2;HSP90AA1; | Spliceosome;Neutrophil extracellular trap formation;Tight junction; | 46.22 | 13.24 | 3.49 |
| Balsalazide | DB01014 | MMP9;ALOX5;CA2; | Platelet activation;Tight junction;Inflammatory bowel disease; | 43.69 | 11.41 | 3.83 |
| Gabapentin | DB00996 | ADRB2;HSP90AA1;BIRC4; | Cortisol synthesis and secretion;Aldosterone synthesis and secretion;Adrenergic signaling in cardiomyocytes; | 43.54 | 17.07 | 2.55 |
| Zolmitriptan | DB00315 | PARP1;CYP19A1;DRD2; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Graft-versus-host disease; | 42.95 | 8.47 | 5.07 |
| Clomifene | DB00882 | CYP19A1;DRD2;ABCB1; | RNA polymerase;Huntington disease;Primary immunodeficiency; | 40.67 | 9.02 | 4.51 |
| Oxitriptan | DB02959 | PARP1;DRD2;CA2; | Pathways in cancer;Circadian entrainment;African trypanosomiasis; | 40.45 | 10.11 | 4 |
| Thiethylperazine | DB00372 | DRD2;CYP2C9;SLC6A4; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 38.80 | 8.00 | 4.85 |
| Oleic-Acid | DB04224 | CYP19A1;ALOX5;NR1I2; | Spliceosome;VEGF signaling pathway;Platelet activation; | 37.62 | 10.84 | 3.47 |
| Bethanidine | DB00217 | DRD2;CA2;ADRB2; | Systemic lupus erythematosus;Alcoholism;Calcium signaling pathway; | 35.52 | 10.36 | 3.43 |
| Periciazine | DB01608 | DRD2;ADRB2;HTR1F; | RNA polymerase;Th1 and Th2 cell differentiation;Graft-versus-host disease; | 34.94 | 11.42 | 3.06 |
| Pentoxyverine | DB11186 | DRD2;LTA4H;SLC6A4; | Neutrophil extracellular trap formation;Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis; | 34.17 | 11.58 | 2.95 |
| Pentazocine | DB00652 | DRD2;CA2;CYP2C9; | Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus;Neutrophil extracellular trap formation; | 33.90 | 11.38 | 2.98 |
| Lumateperone | DB06077 | DRD2;ADRB2;TNF; | Natural killer cell mediated cytotoxicity;Malaria;Pentose phosphate pathway; | 32.84 | 9.23 | 3.56 |
| Dezocine | DB01209 | DRD2;LTA4H;NR3C2; | Salmonella infection;Necroptosis;Natural killer cell mediated cytotoxicity; | 32.18 | 11.06 | 2.91 |
| Naltrexone | DB00704 | ALOX5;ABCB1;SLC22A1; | Spliceosome;Aminoacyl-tRNA biosynthesis;Starch and sucrose metabolism; | 32.08 | 11.88 | 2.7 |
| Amoxapine | DB00543 | DRD2;ADRB2;SLC6A4; | Graft-versus-host disease;Morphine addiction;Adherens junction; | 31.25 | 8.56 | 3.65 |
| Modafinil | DB00745 | DRD2;ADRB2;CYP2C9; | RNA transport;Systemic lupus erythematosus;Pentose phosphate pathway; | 31.17 | 9.74 | 3.2 |
| Abacavir | DB01048 | GSK3B;PRKACA;ABCB1; | Antigen processing and presentation;Ascorbate and aldarate metabolism;RNA transport; | 30.52 | 8.23 | 3.71 |
| Nalmefene | DB06230 | ALOX5;ABCB1;SLC22A1; | Spliceosome;Starch and sucrose metabolism;Aminoacyl-tRNA biosynthesis; | 30.36 | 11.63 | 2.61 |
| Cyproterone-acetate | DB04839 | CYP19A1;ELA2;NR3C2; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;NF-kappa B signaling pathway; | 29.53 | 11.10 | 2.66 |
| Codeine | DB00318 | PRKACA;ABCB1;SLC22A1; | Starch and sucrose metabolism;Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis; | 28.89 | 10.70 | 2.7 |
| Dopamine | DB00988 | DRD2;CA2;ADRB2; | Complement and coagulation cascades;ABC transporters;Pentose phosphate pathway; | 27.92 | 7.45 | 3.75 |
| Naloxone | DB01183 | ABCB1;SLC22A1;CXCR2; | Starch and sucrose metabolism;Salivary secretion;Natural killer cell mediated cytotoxicity; | 25.18 | 11.88 | 2.12 |
| Ganirelix | DB06785 | INSR;HSP90AA1;KIF11; | Ribosome;Coronavirus disease - COVID-19;PI3K-Akt signaling pathway; | 24.83 | 8.12 | 3.06 |
| Amiodarone | DB01118 | ABCB1;ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Sphingolipid signaling pathway; | 22.24 | 7.54 | 2.95 |
| Valproic-acid | DB00313 | HDAC2;HDAC1;AKR1B1; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 21.10 | 7.70 | 2.74 |
| Halothane | DB01159 | GABRA4;GABRB3;GABRE; | Glyoxylate and dicarboxylate metabolism;Amoebiasis;Morphine addiction; | 18.49 | 9.78 | 1.89 |
| Ubrogepant | DB15328 | PARP1;PDE4B;TNF; | Systemic lupus erythematosus;B cell receptor signaling pathway;Staphylococcus aureus infection; | 17.64 | 3.99 | 4.42 |
| Iloprost | DB01088 | PDE4B;CTSG;FPR1; | Th1 and Th2 cell differentiation;Amoebiasis;Inflammatory bowel disease; | 14.50 | 11.69 | 1.24 |
| Calcium-levulinate | DB13800 | CALM1;MYL9;MYLPF; | Pathways in cancer;Necroptosis;Spliceosome; | 13.95 | 14.53 | 0.96 |
| Desflurane | DB01189 | GABRA4;GABRB3;KCNA3; | Coronavirus disease - COVID-19;RNA polymerase;Ribosome; | 12.59 | 7.27 | 1.73 |
| Buprenorphine | DB00921 | CXCR4;CXCR2;CXCR1; | Sphingolipid signaling pathway;Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis; | 12.17 | 13.09 | 0.93 |
| Sulfamethazine | DB01582 | JAK1;PIK3CB;PRKCA; | Systemic lupus erythematosus;C-type lectin receptor signaling pathway;Estrogen signaling pathway; | 101.95 | 19.68 | 5.18 |
| Lenvatinib | DB09078 | RAF1;LCK;PDGFRB; | Th17 cell differentiation;Th1 and Th2 cell differentiation;T cell receptor signaling pathway; | 90.59 | 18.68 | 4.85 |
| Epinephrine | DB00668 | RAF1;DRD2;CA2; | Natural killer cell mediated cytotoxicity;Ribosome;Coronavirus disease - COVID-19; | 85.98 | 17.62 | 4.88 |
| Fenoldopam | DB00800 | PDGFRB;DRD2;MMP9; | Complement and coagulation cascades;Sphingolipid signaling pathway;Collecting duct acid secretion; | 63.77 | 13.10 | 4.87 |
| Prednisolone | DB00860 | CYP19A1;PRKCA;CA2; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 63.64 | 11.36 | 5.6 |
| Naproxen | DB00788 | HDAC2;HDAC1;ALOX5; | Spliceosome;Amoebiasis;Th1 and Th2 cell differentiation; | 63.17 | 12.66 | 4.99 |
| Tioconazole | DB01007 | CYP19A1;ABCB1;PDE4B; | Kaposi sarcoma-associated herpesvirus infection;Spliceosome;Chemokine signaling pathway; | 62.89 | 13.55 | 4.64 |
| Benzoic-acid | DB03793 | HDAC2;HDAC1;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 62.25 | 11.59 | 5.37 |
| Carbidopa | DB00190 | HDAC1;MMP9;ALOX5; | Th1 and Th2 cell differentiation;Spliceosome;Th17 cell differentiation; | 61.52 | 11.70 | 5.26 |
| Propranolol | DB00571 | CDK1;DRD2;ABCB1; | Graft-versus-host disease;Necroptosis;Non-alcoholic fatty liver disease; | 59.08 | 10.42 | 5.67 |
| Nabumetone | DB00461 | HDAC1;CYP19A1;CA2; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 58.27 | 10.81 | 5.39 |
| Sumatriptan | DB00669 | HDAC1;CYP19A1;DRD2; | Natural killer cell mediated cytotoxicity;Graft-versus-host disease;Amoebiasis; | 57.91 | 10.74 | 5.39 |
| Amylocaine | DB09088 | HDAC1;CDK1;DRD2; | Ribosome;Coronavirus disease - COVID-19;Natural killer cell mediated cytotoxicity; | 57.61 | 12.66 | 4.55 |
| Indinavir | DB00224 | LCK;INSR;CA2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Systemic lupus erythematosus; | 56.92 | 10.58 | 5.38 |
| Flunitrazepam | DB01544 | HDAC1;CDK1;CA2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Morphine addiction; | 56.15 | 11.30 | 4.97 |
| Flumazenil | DB01205 | ALOX5;ELA2;PDE4B; | Spliceosome;Human immunodeficiency virus 1 infection;Transcriptional misregulation in cancer; | 55.33 | 11.80 | 4.69 |
| Arformoterol | DB01274 | GSK3B;CDK1;DRD2; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 54.14 | 9.95 | 5.44 |
| Formoterol | DB00983 | GSK3B;CDK1;DRD2; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 54.14 | 9.95 | 5.44 |
| Prasugrel | DB06209 | HDAC1;PDGFRB;DRD2; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;Amoebiasis; | 53.25 | 9.88 | 5.39 |
| Baricitinib | DB11817 | JAK1;PIK3CB;CA2; | Glyoxylate and dicarboxylate metabolism;Systemic lupus erythematosus;Renin secretion; | 53.08 | 10.64 | 4.99 |
| Indecainide | DB00192 | HDAC2;HDAC1;PARP1; | RNA transport;Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus; | 52.50 | 9.31 | 5.64 |
| Propafenone | DB01182 | CDK1;DRD2;ABCB1; | Necroptosis;Diabetic cardiomyopathy;Non-alcoholic fatty liver disease; | 50.55 | 9.45 | 5.35 |
| Abiraterone | DB05812 | HDAC2;HDAC1;CYP19A1; | RNA transport;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 48.89 | 10.47 | 4.67 |
| Prednisone | DB00635 | CYP19A1;CA2;ABCB1; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 48.21 | 8.81 | 5.47 |
| Ximelagatran | DB04898 | DRD2;MMP9;F2; | Platelet activation;RNA polymerase;T cell receptor signaling pathway; | 45.58 | 11.12 | 4.1 |
| Salsalate | DB01399 | ALOX5;CA2;ALB; | Spliceosome;Th17 cell differentiation;Th1 and Th2 cell differentiation; | 44.21 | 11.16 | 3.96 |
| Difluocortolone | DB09095 | CA2;ABCB1;TNF; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 43.96 | 10.04 | 4.38 |
| Dyclonine | DB00645 | MAPK14;DRD2;ADRB2; | Spliceosome;Necroptosis;Pentose phosphate pathway; | 43.71 | 9.38 | 4.66 |
| Pefloxacin | DB00487 | DRD2;MMP9;CYP2C9; | Necroptosis;Graft-versus-host disease;Systemic lupus erythematosus; | 43.69 | 9.73 | 4.49 |
| Hydrocortisone-phosphate | DB14542 | CA2;ABCB1;TNF; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Starch and sucrose metabolism; | 42.91 | 11.54 | 3.72 |
| Venlafaxine | DB00285 | DRD2;ADRB2;LTA4H; | Oxidative phosphorylation;Necroptosis;Pentose phosphate pathway; | 42.72 | 9.39 | 4.55 |
| Amantadine | DB00915 | LCK;DRD2;LTA4H; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Necroptosis; | 39.80 | 9.03 | 4.41 |
| Riociguat | DB08931 | MAPK14;PIK3CB;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Transcriptional misregulation in cancer; | 38.84 | 9.10 | 4.27 |
| Clarithromycin | DB01211 | HDAC1;ABCB1;CYP2C9; | Th1 and Th2 cell differentiation;Amoebiasis;T cell receptor signaling pathway; | 38.28 | 11.96 | 3.2 |
| Tranylcypromine | DB00752 | LCK;DRD2;CA2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Necroptosis; | 38.15 | 8.91 | 4.28 |
| Ketazolam | DB01587 | PARP1;NR3C2;FNTA; | Morphine addiction;Adherens junction;Th1 and Th2 cell differentiation; | 37.45 | 9.78 | 3.83 |
| Acetohexamide | DB00414 | HDAC2;HDAC1;MMP9; | Amoebiasis;Th1 and Th2 cell differentiation;T cell receptor signaling pathway; | 37.40 | 8.82 | 4.24 |
| Propiomazine | DB00777 | DRD2;CA2;ABCB1; | Sphingolipid signaling pathway;Neutrophil extracellular trap formation;Ribosome; | 36.77 | 7.96 | 4.62 |
| Stearic-acid | DB03193 | CYP19A1;ALOX5;NR1I2; | Spliceosome;Platelet activation;B cell receptor signaling pathway; | 36.62 | 10.11 | 3.62 |
| Vinorelbine | DB00361 | DRD2;ABCB1;MAP2K1; | Pathways in cancer;Necroptosis;Salmonella infection; | 36.30 | 9.73 | 3.73 |
| Pimecrolimus | DB00337 | CYP19A1;ABCB1;TNF; | Thiamine metabolism;Phospholipase D signaling pathway;Staphylococcus aureus infection; | 36.26 | 10.86 | 3.34 |
| Arbutamine | DB01102 | CDK1;DRD2;CA2; | Pentose phosphate pathway;Neutrophil extracellular trap formation;Natural killer cell mediated cytotoxicity; | 35.60 | 7.45 | 4.78 |
| Fenoterol | DB01288 | CDK1;DRD2;CA2; | Pentose phosphate pathway;Neutrophil extracellular trap formation;Natural killer cell mediated cytotoxicity; | 35.60 | 7.45 | 4.78 |
| Thalidomide | DB01041 | PDE4B;TNF;AKR1B1; | Neutrophil extracellular trap formation;Staphylococcus aureus infection;Malaria; | 35.34 | 12.49 | 2.83 |
| Phenobarbital | DB01174 | CYP19A1;MMP9;NR1I2; | Calcium signaling pathway;Inflammatory bowel disease;Thiamine metabolism; | 34.63 | 11.51 | 3.01 |
| Fluoxetine | DB00472 | DRD2;ABCB1;ADRB2; | Graft-versus-host disease;Sphingolipid signaling pathway;Antigen processing and presentation; | 34.48 | 8.77 | 3.93 |
| Noscapine | DB06174 | CYP19A1;DRD2;ADRB2; | Sphingolipid signaling pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 32.93 | 8.92 | 3.69 |
| Molindone | DB01618 | PIK3CB;PARP1;DRD2; | Necroptosis;Pentose phosphate pathway;Relaxin signaling pathway; | 32.16 | 7.26 | 4.43 |
| Methylphenobarbital | DB00849 | CYP19A1;MMP9;NR1I2; | Morphine addiction;Adherens junction;Thiamine metabolism; | 31.63 | 10.17 | 3.11 |
| Nalbuphine | DB00844 | ALOX5;ABCB1;SLC22A1; | Spliceosome;Aminoacyl-tRNA biosynthesis;Starch and sucrose metabolism; | 30.03 | 11.51 | 2.61 |
| Lithium-citrate | DB14507 | GSK3B;MAPK14;CDK1; | Thiamine metabolism;Human cytomegalovirus infection;Starch and sucrose metabolism; | 29.06 | 12.58 | 2.31 |
| Ademetionine | DB00118 | CA2;NR3C2;CA4; | RNA transport;Staphylococcus aureus infection;NF-kappa B signaling pathway; | 28.14 | 9.38 | 3 |
| Diamorphine | DB01452 | HDAC1;SLC6A4;CXCR2; | Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway;Salivary secretion; | 26.20 | 12.30 | 2.13 |
| Diazoxide | DB01119 | ELA2;CA2;PBEF1; | Transcriptional misregulation in cancer;Neutrophil extracellular trap formation;NF-kappa B signaling pathway; | 25.52 | 9.05 | 2.82 |
| Acitretin | DB00459 | AKR1C3;NR1I2;AKR1B1; | Renin secretion;Circadian rhythm;Neuroactive ligand-receptor interaction; | 24.57 | 8.19 | 3 |
| Hydromorphone | DB00327 | ABCB1;SLC22A1;CXCR2; | Starch and sucrose metabolism;Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis; | 22.96 | 10.53 | 2.18 |
| Morphine | DB00295 | ABCB1;SLC22A1;CXCR2; | Starch and sucrose metabolism;Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis; | 22.96 | 10.53 | 2.18 |
| Oxymorphone | DB01192 | ABCB1;SLC22A1;CXCR2; | Starch and sucrose metabolism;Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis; | 22.96 | 10.53 | 2.18 |
| Metamfetamine | DB01577 | DRD2;ADRB2;SLC6A4; | Pentose phosphate pathway;Melanoma;Natural killer cell mediated cytotoxicity; | 21.76 | 7.97 | 2.73 |
| Metyrosine | DB00765 | DRD2;EGLN1;KIF11; | RNA polymerase;Primary immunodeficiency;Starch and sucrose metabolism; | 21.08 | 6.48 | 3.25 |
| Topiramate | DB00273 | JAK1;CA2;CA4; | Complement and coagulation cascades;Thiamine metabolism;African trypanosomiasis; | 20.86 | 6.91 | 3.02 |
| Lifitegrast | DB11611 | CYP2C9;F2;CTSS; | Alcoholism;Systemic lupus erythematosus;Th1 and Th2 cell differentiation; | 19.68 | 6.31 | 3.12 |
| Carbocisteine | DB04339 | DRD2;CA2;SLC6A4; | Complement and coagulation cascades;African trypanosomiasis;Malaria; | 18.36 | 5.62 | 3.27 |
| Griseofulvin | DB00400 | SLC22A1;TUBA1A;TUBB2C; | Salmonella infection;Human immunodeficiency virus 1 infection;Pathways in cancer; | 16.78 | 8.74 | 1.92 |
| Remifentanil | DB00899 | SIRT1;CXCR2;CXCR1; | RNA transport;Platelet activation;Natural killer cell mediated cytotoxicity; | 16.38 | 10.36 | 1.58 |
| Tasimelteon | DB09071 | ALOX5;CYP2C9;PSEN1; | RNA polymerase;Spliceosome;Huntington disease; | 16.15 | 4.60 | 3.51 |
| Icatibant | DB06196 | EGLN1;PTPN11;CXCR2; | Malaria;Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis; | 11.43 | 5.66 | 2.02 |
| Levosimendan | DB00922 | CALM1;PDE3B;KCNJ1; | Pathways in cancer;Necroptosis;Spliceosome; | 11.36 | 15.36 | 0.74 |
| Ferric-pyrophosphate-citrate | DB13995 | HBA2;HBB;FTL; | Arrhythmogenic right ventricular cardiomyopathy;Dilated cardiomyopathy;Hypertrophic cardiomyopathy; | 2.86 | 4.54 | 0.63 |
| Hydroxyzine | DB00557 | IGF1R;RAF1;DRD2; | Hepatocellular carcinoma;Kaposi sarcoma-associated herpesvirus infection;Neutrophil extracellular trap formation; | 103.40 | 20.52 | 5.04 |
| Levonordefrin | DB06707 | RAF1;DRD2;CA2; | Ribosome;Natural killer cell mediated cytotoxicity;Coronavirus disease - COVID-19; | 74.36 | 17.46 | 4.26 |
| Zidovudine | DB00495 | GSK3B;ADRB2;ALB; | Necroptosis;Non-alcoholic fatty liver disease;PI3K-Akt signaling pathway; | 63.00 | 15.55 | 4.05 |
| Stavudine | DB00649 | GSK3B;ALB;G6PD; | Necroptosis;Non-alcoholic fatty liver disease;PI3K-Akt signaling pathway; | 54.17 | 13.82 | 3.92 |
| Pindolol | DB00960 | PDGFRB;DRD2;ABCB1; | Necroptosis;Non-alcoholic fatty liver disease;IL-17 signaling pathway; | 51.88 | 9.37 | 5.54 |
| Penbutolol | DB01359 | CDK1;DRD2;ABCB1; | Necroptosis;Non-alcoholic fatty liver disease;IL-17 signaling pathway; | 51.45 | 9.30 | 5.53 |
| Sulfapyridine | DB00891 | PIK3CB;PRKCA;CA2; | Inflammatory bowel disease;Sphingolipid signaling pathway;Graft-versus-host disease; | 50.90 | 12.45 | 4.09 |
| Albendazole | DB00518 | ALOX5;CYP2C9;CDK5; | Spliceosome;Cytosolic DNA-sensing pathway;Pathways in cancer; | 50.74 | 14.71 | 3.45 |
| Copanlisib | DB12483 | GSK3B;PIK3CB;AKT2; | Fluid shear stress and atherosclerosis;B cell receptor signaling pathway;Ribosome; | 49.36 | 11.37 | 4.34 |
| Lypressin | DB14642 | GSK3B;HDAC1;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Amoebiasis; | 49.08 | 9.42 | 5.21 |
| Dihydroergocornine | DB11273 | DRD2;CA2;ABCB1; | Inflammatory bowel disease;Natural killer cell mediated cytotoxicity;Sphingolipid signaling pathway; | 48.50 | 9.24 | 5.25 |
| Apraclonidine | DB00964 | DRD2;ADRB2;HSP90AA1; | Kaposi sarcoma-associated herpesvirus infection;Protein processing in endoplasmic reticulum;Adrenergic signaling in cardiomyocytes; | 47.70 | 13.75 | 3.47 |
| Adenine | DB00173 | GSK3B;CDK1;HSP90AA1; | Protein processing in endoplasmic reticulum;Kaposi sarcoma-associated herpesvirus infection;Human cytomegalovirus infection; | 47.14 | 11.25 | 4.19 |
| Emedastine | DB01084 | JAK1;GSK3B;PARP1; | Non-alcoholic fatty liver disease;Bile secretion;Starch and sucrose metabolism; | 46.26 | 7.83 | 5.91 |
| Moexipril | DB00691 | HDAC2;HDAC1;DRD2; | Spliceosome;RNA transport;Th17 cell differentiation; | 45.71 | 10.16 | 4.5 |
| Tamsulosin | DB00706 | HDAC1;DRD2;MMP9; | Natural killer cell mediated cytotoxicity;Amoebiasis;Inflammatory bowel disease; | 45.61 | 10.46 | 4.36 |
| Febuxostat | DB04854 | HDAC1;CYP19A1;LTA4H; | Th1 and Th2 cell differentiation;Necroptosis;Hematopoietic cell lineage; | 45.57 | 11.99 | 3.8 |
| Aceclofenac | DB06736 | CA2;CYP2C9;ALB; | Metabolic pathways;Graft-versus-host disease;Inflammatory bowel disease; | 43.99 | 10.35 | 4.25 |
| Cyclandelate | DB04838 | MMP9;ELA2;CA2; | Neutrophil extracellular trap formation;Transcriptional misregulation in cancer;Leishmaniasis; | 43.97 | 10.06 | 4.37 |
| Zileuton | DB00744 | ALOX5;LTA4H;CDK5; | Spliceosome;Cytosolic DNA-sensing pathway;Tight junction; | 42.49 | 13.62 | 3.12 |
| Eslicarbazepine | DB14575 | HDAC1;CYP19A1;DRD2; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;PD-L1 expression and PD-1 checkpoint pathway in cancer; | 41.65 | 9.60 | 4.34 |
| Roflumilast | DB01656 | GSK3B;HDAC1;ALOX5; | Spliceosome;Th17 cell differentiation;Amoebiasis; | 41.58 | 9.74 | 4.27 |
| Dutasteride | DB01126 | MAPK14;LCK;ABCB1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;NF-kappa B signaling pathway; | 40.71 | 8.31 | 4.9 |
| Dolasetron | DB00757 | HDAC2;HDAC1;DRD2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;RNA transport; | 40.43 | 7.66 | 5.28 |
| Nabilone | DB00486 | IGF1R;ALOX5;PTK2; | Spliceosome;VEGF signaling pathway;Oocyte meiosis; | 40.15 | 9.70 | 4.14 |
| Cariprazine | DB06016 | MAPK14;DRD2;PTK2; | Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus;Renin secretion; | 38.84 | 8.67 | 4.48 |
| Rifabutin | DB00615 | HSP90AA1;ALB;NR1I2; | Protein processing in endoplasmic reticulum;Insulin secretion;Spliceosome; | 38.34 | 11.58 | 3.31 |
| Alpelisib | DB12015 | MAPK14;PIK3CB;CYP2C9; | Systemic lupus erythematosus;Transcriptional misregulation in cancer;NF-kappa B signaling pathway; | 38.06 | 8.98 | 4.24 |
| Elvitegravir | DB09101 | HDAC1;MAPK14;CYP2C9; | Th1 and Th2 cell differentiation;NF-kappa B signaling pathway;Amoebiasis; | 37.77 | 8.51 | 4.44 |
| Ethotoin | DB00754 | CYP19A1;ELA2;CA2; | Transcriptional misregulation in cancer;Salmonella infection;Human immunodeficiency virus 1 infection; | 37.65 | 9.46 | 3.98 |
| Glutethimide | DB01437 | PARP1;CYP19A1;ELA2; | Human immunodeficiency virus 1 infection;Morphine addiction;Adherens junction; | 37.50 | 8.99 | 4.17 |
| Bosentan | DB00559 | JAK1;PDGFRB;DRD2; | Complement and coagulation cascades;Non-alcoholic fatty liver disease;Necroptosis; | 37.13 | 8.70 | 4.27 |
| Enalaprilat | DB09477 | LTA4H;NR1I2;SIRT1; | Oxidative phosphorylation;Platelet activation;Natural killer cell mediated cytotoxicity; | 36.34 | 11.46 | 3.17 |
| Solifenacin | DB01591 | PARP1;DRD2;LTA4H; | Systemic lupus erythematosus;Necroptosis;Th17 cell differentiation; | 36.03 | 7.06 | 5.1 |
| Lofexidine | DB04948 | DRD2;ELA2;CA2; | Complement and coagulation cascades;Graft-versus-host disease;Malaria; | 34.94 | 10.22 | 3.42 |
| Clocortolone | DB00838 | CYP19A1;CA2;ABCB1; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 33.54 | 6.41 | 5.23 |
| Cisapride | DB00604 | PARP1;DRD2;CA2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 32.46 | 6.96 | 4.66 |
| Palonosetron | DB00377 | PARP1;CYP19A1;DRD2; | Systemic lupus erythematosus;African trypanosomiasis;Complement and coagulation cascades; | 31.62 | 6.57 | 4.81 |
| Tetracycline | DB00759 | MMP9;CYP2C9;ALB; | Inflammatory bowel disease;Graft-versus-host disease;Neutrophil extracellular trap formation; | 31.30 | 9.54 | 3.28 |
| Terfenadine | DB00342 | DRD2;CA2;ABCB1; | Neutrophil extracellular trap formation;Systemic lupus erythematosus;Amyotrophic lateral sclerosis; | 31.11 | 6.88 | 4.52 |
| Grepafloxacin | DB00365 | CYP2C9;ALB;PIM2; | Systemic lupus erythematosus;Necroptosis;Metabolic pathways; | 30.34 | 8.01 | 3.79 |
| Zuclopenthixol | DB01624 | DRD2;ADRB2;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 30.34 | 7.74 | 3.92 |
| Decitabine | DB01262 | ALB;CXCR4;DNMT1; | Necroptosis;Tuberculosis;Spliceosome; | 30.12 | 13.63 | 2.21 |
| Selpercatinib | DB15685 | JAK1;PIK3CB;PDGFRB; | Staphylococcus aureus infection;B cell receptor signaling pathway;Complement and coagulation cascades; | 30.00 | 6.06 | 4.95 |
| Flupentixol | DB00875 | DRD2;ADRB2;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 29.20 | 7.85 | 3.72 |
| Fexofenadine | DB00950 | CA2;ABCB1;CYP2C9; | Complement and coagulation cascades;Systemic lupus erythematosus;Amyotrophic lateral sclerosis; | 29.00 | 6.89 | 4.21 |
| Galantamine | DB00674 | PRKACA;ABCB1;LTA4H; | Necroptosis;Alcoholism;Systemic lupus erythematosus; | 28.44 | 6.63 | 4.29 |
| Phenelzine | DB00780 | ALOX5;CYP2C9;SLC6A4; | Neutrophil extracellular trap formation;Systemic lupus erythematosus;Spliceosome; | 28.36 | 8.08 | 3.51 |
| Chlorthalidone | DB00310 | CDK1;MMP9;CA2; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;Sphingolipid signaling pathway; | 27.94 | 6.59 | 4.24 |
| Brompheniramine | DB00835 | DRD2;PTK2;SLC6A4; | Graft-versus-host disease;Progesterone-mediated oocyte maturation;Non-alcoholic fatty liver disease; | 27.84 | 7.16 | 3.89 |
| Dexbrompheniramine | DB00405 | DRD2;PTK2;SLC6A4; | Graft-versus-host disease;Progesterone-mediated oocyte maturation;Non-alcoholic fatty liver disease; | 27.84 | 7.16 | 3.89 |
| Vinblastine | DB00570 | DRD2;ABCB1;TEK; | Necroptosis;Salmonella infection;Pathways in cancer; | 27.61 | 8.82 | 3.13 |
| Doconexent | DB03756 | CYP19A1;ALOX5;FNTA; | Spliceosome;VEGF signaling pathway;Platelet activation; | 26.43 | 9.86 | 2.68 |
| Phenoxymethylpenicillin | DB00417 | PARP1;ELA2;CA2; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Human immunodeficiency virus 1 infection; | 25.47 | 6.37 | 4 |
| Droxidopa | DB06262 | DRD2;CA2;ADRB2; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Graft-versus-host disease; | 24.29 | 7.86 | 3.09 |
| Armodafinil | DB06413 | DRD2;CYP2C9;SLC6A4; | RNA transport;Systemic lupus erythematosus;Phagosome; | 22.17 | 7.13 | 3.11 |
| Dronabinol | DB00470 | ALOX5;PSEN1;FNTA; | Spliceosome;RNA transport;Cushing syndrome; | 20.83 | 6.33 | 3.29 |
| Levomenthol | DB00825 | CA2;CA4;AGTR2; | Complement and coagulation cascades;Glioma;Pertussis; | 20.27 | 11.32 | 1.79 |
| Alfentanil | DB00802 | GSK3B;ABCB1;CXCR2; | Natural killer cell mediated cytotoxicity;Starch and sucrose metabolism;T cell receptor signaling pathway; | 19.67 | 7.84 | 2.51 |
| Plerixafor | DB06809 | CYP2C9;CXCR4;CXCR2; | Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus;Aminoacyl-tRNA biosynthesis; | 18.11 | 9.69 | 1.87 |
| Spironolactone | DB00421 | ABCB1;CYP2C9;NR3C2; | Salmonella infection;Systemic lupus erythematosus;Cytosolic DNA-sensing pathway; | 17.87 | 6.18 | 2.89 |
| Hydrocodone | DB00956 | CYP2C9;CXCR2;CXCR1; | Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus;Aminoacyl-tRNA biosynthesis; | 15.09 | 9.43 | 1.6 |
| Methoxyflurane | DB01028 | GABRA4;GABRB3;KCNA3; | Coronavirus disease - COVID-19;RNA polymerase;Ribosome; | 10.62 | 6.60 | 1.61 |
| Troglitazone | DB00197 | GSTP1;NR1H3;RARB; | Th17 cell differentiation;Ribosome;Pentose and glucuronate interconversions; | 7.04 | 6.07 | 1.16 |
| Pentaerythritol-tetranitrate | DB06154 | HBA2;HBB;HBZ; | Arrhythmogenic right ventricular cardiomyopathy;Dilated cardiomyopathy;Hypertrophic cardiomyopathy; | 2.33 | 4.39 | 0.53 |
| Ferric-derisomaltose | DB15617 | HBA2;HBB;HBZ; | Arrhythmogenic right ventricular cardiomyopathy;Dilated cardiomyopathy;Hypertrophic cardiomyopathy; | 1.93 | 4.39 | 0.44 |
| Isoetharine | DB00221 | RAF1;DRD2;ADRB2; | Ribosome;Natural killer cell mediated cytotoxicity;Coronavirus disease - COVID-19; | 75.84 | 17.16 | 4.42 |
| Orciprenaline | DB00816 | RAF1;DRD2;ADRB2; | Ribosome;Natural killer cell mediated cytotoxicity;Coronavirus disease - COVID-19; | 75.84 | 17.16 | 4.42 |
| Terbutaline | DB00871 | RAF1;DRD2;ADRB2; | Ribosome;Natural killer cell mediated cytotoxicity;Coronavirus disease - COVID-19; | 75.84 | 17.16 | 4.42 |
| Clobetasol-propionate | DB01013 | RAF1;NR3C2;G6PD; | Cushing syndrome;Aldosterone synthesis and secretion;Calcium signaling pathway; | 68.35 | 20.10 | 3.4 |
| Remoxipride | DB00409 | RAF1;DRD2;ADRB2; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Antigen processing and presentation; | 54.59 | 14.83 | 3.68 |
| Clofarabine | DB00631 | GSK3B;PIK3CB;DRD2; | Drug metabolism - other enzymes;Parkinson disease;African trypanosomiasis; | 50.07 | 11.03 | 4.54 |
| Ivabradine | DB09083 | IGF1R;DRD2;ALOX5; | Spliceosome;Calcium signaling pathway;Fc epsilon RI signaling pathway; | 45.28 | 10.46 | 4.33 |
| Dicyclomine | DB00804 | HDAC2;HDAC1;DRD2; | RNA transport;Amoebiasis;Th1 and Th2 cell differentiation; | 44.24 | 8.10 | 5.46 |
| Dihydroergocristine | DB13345 | PARP1;DRD2;ABCB1; | Systemic lupus erythematosus;Pentose phosphate pathway;Natural killer cell mediated cytotoxicity; | 44.02 | 7.85 | 5.61 |
| Levobunolol | DB01210 | CDK1;DRD2;ABCB1; | Necroptosis;IL-17 signaling pathway;Pentose phosphate pathway; | 42.89 | 9.03 | 4.75 |
| Bendroflumethiazide | DB00436 | HDAC1;ALOX5;CA2; | Th1 and Th2 cell differentiation;Amoebiasis;Spliceosome; | 41.36 | 9.60 | 4.31 |
| Nelfinavir | DB00220 | MAPK14;MMP9;CA2; | Insulin secretion;Thiamine metabolism;Starch and sucrose metabolism; | 41.16 | 9.07 | 4.54 |
| Moricizine | DB00680 | PARP1;DRD2;ABCB1; | Inflammatory bowel disease;NF-kappa B signaling pathway;Systemic lupus erythematosus; | 40.43 | 8.51 | 4.75 |
| Halazepam | DB00801 | CDK1;CA2;ALB; | Morphine addiction;Adherens junction;Coronavirus disease - COVID-19; | 39.73 | 9.55 | 4.16 |
| Estrone-sulfate | DB04574 | HDAC2;HDAC1;CYP19A1; | Natural killer cell mediated cytotoxicity;RNA transport;Amoebiasis; | 39.58 | 7.58 | 5.22 |
| Clobazam | DB00349 | PARP1;CDK1;ALB; | Morphine addiction;Adherens junction;Coronavirus disease - COVID-19; | 39.29 | 9.01 | 4.36 |
| Amodiaquine | DB00613 | CDK1;DRD2;ALOX5; | Spliceosome;Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus; | 38.31 | 8.49 | 4.51 |
| Bumetanide | DB00887 | CYP19A1;MMP9;CA2; | Sphingolipid signaling pathway;Inflammatory bowel disease;Neutrophil extracellular trap formation; | 37.65 | 10.09 | 3.73 |
| Daunorubicin | DB00694 | MAPK14;ABCB1;HSP90AA1; | Thyroid hormone synthesis;Spliceosome;Glyoxylate and dicarboxylate metabolism; | 37.13 | 9.06 | 4.1 |
| Doxorubicin | DB00997 | MAPK14;ABCB1;HSP90AA1; | Thyroid hormone synthesis;Spliceosome;Glyoxylate and dicarboxylate metabolism; | 37.13 | 9.06 | 4.1 |
| Epirubicin | DB00445 | MAPK14;ABCB1;HSP90AA1; | Thyroid hormone synthesis;Spliceosome;Glyoxylate and dicarboxylate metabolism; | 37.13 | 9.06 | 4.1 |
| Idarubicin | DB01177 | MAPK14;ABCB1;HSP90AA1; | Thyroid hormone synthesis;Spliceosome;Glyoxylate and dicarboxylate metabolism; | 37.13 | 9.06 | 4.1 |
| Atorvastatin | DB01076 | HDAC2;HDAC1;ABCB1; | RNA transport;Th17 cell differentiation;Amoebiasis; | 36.88 | 8.56 | 4.31 |
| Atosiban | DB09059 | HDAC1;LCK;PARP1; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Amoebiasis; | 36.83 | 8.02 | 4.59 |
| Norelgestromin | DB06713 | CYP19A1;DRD2;CA2; | Necroptosis;Non-alcoholic fatty liver disease;African trypanosomiasis; | 36.50 | 7.72 | 4.73 |
| Piretanide | DB02925 | HDAC1;MMP9;CA2; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;T cell receptor signaling pathway; | 35.37 | 8.42 | 4.2 |
| Trilostane | DB01108 | HDAC2;HDAC1;CYP19A1; | RNA transport;Natural killer cell mediated cytotoxicity;Thermogenesis; | 35.06 | 7.13 | 4.92 |
| Bedaquiline | DB08903 | IGF1R;CA2;FNTA; | Complement and coagulation cascades;Transcriptional misregulation in cancer;Calcium signaling pathway; | 34.95 | 10.02 | 3.49 |
| Clonidine | DB00575 | HDAC1;DRD2;ADRB2; | Natural killer cell mediated cytotoxicity;Amoebiasis;Alcoholism; | 33.44 | 9.64 | 3.47 |
| Ramipril | DB00178 | DRD2;MMP9;SIRT1; | Platelet activation;RNA polymerase;RNA transport; | 33.07 | 9.61 | 3.44 |
| Indacaterol | DB05039 | DRD2;ABCB1;ADRB2; | Pentose phosphate pathway;Neutrophil extracellular trap formation;Natural killer cell mediated cytotoxicity; | 32.50 | 7.27 | 4.47 |
| Prednisolone-phosphate | DB14631 | CA2;ABCB1;TNF; | Malaria;Natural killer cell mediated cytotoxicity;NOD-like receptor signaling pathway; | 31.17 | 8.98 | 3.47 |
| Enalapril | DB00584 | DRD2;NR1I2;SIRT1; | Platelet activation;RNA transport;Oxidative phosphorylation; | 30.98 | 8.93 | 3.47 |
| Bromodiphenhydramine | DB01237 | DRD2;ADRB2;LTA4H; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 30.92 | 6.83 | 4.53 |
| Chlortetracycline | DB09093 | MMP9;CYP2C9;ALB; | Inflammatory bowel disease;Graft-versus-host disease;Neutrophil extracellular trap formation; | 30.53 | 9.54 | 3.2 |
| Demeclocycline | DB00618 | MMP9;CYP2C9;ALB; | Inflammatory bowel disease;Graft-versus-host disease;Neutrophil extracellular trap formation; | 30.53 | 9.54 | 3.2 |
| Oxytetracycline | DB00595 | MMP9;CYP2C9;ALB; | Inflammatory bowel disease;Graft-versus-host disease;Neutrophil extracellular trap formation; | 30.53 | 9.54 | 3.2 |
| Quetiapine | DB01224 | PARP1;DRD2;ADRB2; | Necroptosis;Pentose phosphate pathway;Diabetic cardiomyopathy; | 30.12 | 6.42 | 4.69 |
| Mafenide | DB06795 | MMP9;CA2;F2; | Inflammatory bowel disease;Transcriptional misregulation in cancer;Complement and coagulation cascades; | 29.45 | 8.69 | 3.39 |
| Metolazone | DB00524 | CDK1;CA2;CYP2C9; | Th1 and Th2 cell differentiation;Neutrophil extracellular trap formation;Systemic lupus erythematosus; | 28.25 | 6.46 | 4.37 |
| Pipradrol | DB11584 | DRD2;ADRB2;LTA4H; | Systemic lupus erythematosus;Necroptosis;Pentose phosphate pathway; | 28.20 | 7.16 | 3.94 |
| Amisulpride | DB06288 | DRD2;CA2;ADRB2; | Ribosome;Coronavirus disease - COVID-19;Graft-versus-host disease; | 27.66 | 7.00 | 3.95 |
| Vincristine | DB00541 | DRD2;ABCB1;TEK; | Necroptosis;Salmonella infection;Pathways in cancer; | 26.64 | 8.82 | 3.02 |
| Vindesine | DB00309 | DRD2;ABCB1;TEK; | Necroptosis;Salmonella infection;Pathways in cancer; | 26.64 | 8.82 | 3.02 |
| Vinflunine | DB11641 | DRD2;ABCB1;TEK; | Necroptosis;Salmonella infection;Pathways in cancer; | 26.64 | 8.82 | 3.02 |
| Fludrocortisone | DB00687 | CA2;ABCB1;TNF; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 26.06 | 5.30 | 4.92 |
| Zotepine | DB09225 | DRD2;ADRB2;SLC6A4; | Pentose phosphate pathway;Neutrophil extracellular trap formation;Natural killer cell mediated cytotoxicity; | 25.41 | 6.96 | 3.65 |
| Alclometasone | DB00240 | CA2;ABCB1;TNF; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 25.37 | 5.30 | 4.79 |
| Betamethasone | DB00443 | CA2;ABCB1;TNF; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 25.37 | 5.30 | 4.79 |
| Diflorasone | DB00223 | CA2;ABCB1;TNF; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 25.37 | 5.30 | 4.79 |
| Flumethasone | DB00663 | CA2;ABCB1;TNF; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 25.37 | 5.30 | 4.79 |
| Metoclopramide | DB01233 | DRD2;ADRB2;SLC22A1; | Graft-versus-host disease;Pentose phosphate pathway;Antigen processing and presentation; | 24.48 | 7.65 | 3.2 |
| Tetrabenazine | DB04844 | DRD2;PDE4B;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Drug metabolism - cytochrome P450; | 23.90 | 6.77 | 3.53 |
| Gatifloxacin | DB01044 | PDE4B;CYP2C9;ALB; | Systemic lupus erythematosus;Necroptosis;PPAR signaling pathway; | 23.78 | 6.44 | 3.69 |
| Rivaroxaban | DB06228 | PARP1;CYP2C9;F2; | Th1 and Th2 cell differentiation;Systemic lupus erythematosus;Necroptosis; | 23.48 | 6.59 | 3.56 |
| Cetirizine | DB00341 | DRD2;LTA4H;SLC22A1; | Herpes simplex virus 1 infection;Necroptosis;Renin secretion; | 23.39 | 6.53 | 3.58 |
| Levocetirizine | DB06282 | DRD2;LTA4H;SLC22A1; | Herpes simplex virus 1 infection;Necroptosis;Renin secretion; | 23.39 | 6.53 | 3.58 |
| Nialamide | DB04820 | HDAC2;HDAC1;CYP2C9; | RNA transport;Systemic lupus erythematosus;Amoebiasis; | 23.29 | 5.99 | 3.89 |
| Desvenlafaxine | DB06700 | DRD2;BCL2;SLC6A4; | Neutrophil extracellular trap formation;Phagosome;Alcoholism; | 23.12 | 6.10 | 3.79 |
| Sertraline | DB01104 | DRD2;ABCB1;CYP2C9; | Systemic lupus erythematosus;Bile secretion;Neutrophil extracellular trap formation; | 22.65 | 5.79 | 3.91 |
| Carbenicillin | DB00578 | ELA2;CA2;TEK; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Human immunodeficiency virus 1 infection; | 22.64 | 6.62 | 3.42 |
| Escitalopram | DB01175 | DRD2;ADRB2;SLC6A4; | Pentose phosphate pathway;Neutrophil extracellular trap formation;Natural killer cell mediated cytotoxicity; | 22.41 | 6.96 | 3.22 |
| Erythromycin | DB00199 | ABCB1;CYP2C9;ALB; | Sphingolipid signaling pathway;Systemic lupus erythematosus;Thiamine metabolism; | 22.40 | 8.24 | 2.72 |
| Phentermine | DB00191 | DRD2;ADRB2;SLC6A4; | Graft-versus-host disease;Pentose phosphate pathway;Melanoma; | 22.19 | 7.79 | 2.85 |
| Carfilzomib | DB08889 | HSP90AA1;PSMB5;CTSG; | Aldosterone synthesis and secretion;Insulin secretion;Transcriptional misregulation in cancer; | 21.82 | 8.90 | 2.45 |
| Pentobarbital | DB00312 | NR1I2;GABRA4;GABRB3; | Calcium signaling pathway;Morphine addiction;Adherens junction; | 21.58 | 7.96 | 2.71 |
| Hydroxychloroquine | DB01611 | CDK1;TNF;HSP90AB1; | Kaposi sarcoma-associated herpesvirus infection;Cell cycle;Apelin signaling pathway; | 21.41 | 7.93 | 2.7 |
| Dipyridamole | DB00975 | ABCB1;PDE4B;HSP90AA1; | Neutrophil extracellular trap formation;Sphingolipid signaling pathway;Drug metabolism - other enzymes; | 21.08 | 7.03 | 3 |
| Eltrombopag | DB06210 | CYP2C9;NR3C2;BCL2; | Neutrophil extracellular trap formation;Systemic lupus erythematosus;Alcoholism; | 21.05 | 5.10 | 4.13 |
| Zonisamide | DB00909 | CA2;ABCB1;CYP2C9; | Neutrophil extracellular trap formation;Systemic lupus erythematosus;Alcoholism; | 20.76 | 5.45 | 3.81 |
| Temsirolimus | DB06287 | ABCB1;NR1I2;DNMT1; | Thiamine metabolism;Phospholipase D signaling pathway;Galactose metabolism; | 20.15 | 8.96 | 2.25 |
| Umeclidinium | DB09076 | JAK1;CTSS;SIRT1; | RNA transport;Vibrio cholerae infection;Oxidative phosphorylation; | 19.92 | 5.36 | 3.72 |
| Dofetilide | DB00204 | MMP9;CA2;LTA4H; | Leishmaniasis;IL-17 signaling pathway;Aminoacyl-tRNA biosynthesis; | 18.44 | 6.25 | 2.95 |
| Furosemide | DB00695 | CA2;ALB;CA4; | Necroptosis;Pentose phosphate pathway;Complement and coagulation cascades; | 18.31 | 6.27 | 2.92 |
| Milnacipran | DB04896 | CYP19A1;SLC6A4;SLC6A1; | Calcium signaling pathway;Pathways of neurodegeneration - multiple diseases;Spliceosome; | 18.00 | 7.03 | 2.56 |
| Chloroprocaine | DB01161 | DRD2;SLC6A4;SLC22A1; | Neutrophil extracellular trap formation;Graft-versus-host disease;Transcriptional misregulation in cancer; | 17.66 | 6.26 | 2.82 |
| Aurothioglucose | DB09121 | CA2;ADCY7;ADCY1; | Cytosolic DNA-sensing pathway;NF-kappa B signaling pathway;Toll-like receptor signaling pathway; | 16.75 | 8.09 | 2.07 |
| Glymidine | DB01382 | CYP19A1;CA2;CTSS; | Starch and sucrose metabolism;Thiamine metabolism;Aminoacyl-tRNA biosynthesis; | 16.14 | 5.78 | 2.79 |
| Fusidic-acid | DB02703 | CA2;TNF;AKR1B1; | Natural killer cell mediated cytotoxicity;Malaria;Glutathione metabolism; | 15.54 | 4.26 | 3.65 |
| Phendimetrazine | DB01579 | DRD2;ADRB2;SLC6A4; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 15.52 | 6.44 | 2.41 |
| Tyrosine | DB00135 | DRD2;EGLN1;BIRC4; | RNA polymerase;Starch and sucrose metabolism;Natural killer cell mediated cytotoxicity; | 14.80 | 5.17 | 2.86 |
| Zimelidine | DB04832 | DRD2;PTK2;SLC6A4; | Non-alcoholic fatty liver disease;Complement and coagulation cascades;Glycosphingolipid biosynthesis - ganglio series; | 14.36 | 4.26 | 3.37 |
| Disulfiram | DB00822 | JARID1A;GSTO1;ALDH1A1; | Spliceosome;Natural killer cell mediated cytotoxicity;Herpes simplex virus 1 infection; | 13.85 | 10.49 | 1.32 |
| Nicotinamide | DB02701 | PARP1;SLC22A1;SIRT1; | RNA transport;Neutrophil extracellular trap formation;Alcoholism; | 13.78 | 4.80 | 2.87 |
| Nitazoxanide | DB00507 | PARP1;CA2;CYP2C9; | Metabolism of xenobiotics by cytochrome P450;Systemic lupus erythematosus;Chemical carcinogenesis; | 13.47 | 3.47 | 3.88 |
| Tryptophan | DB00150 | PARP1;DRD2;ALPL; | Malaria;Glycerolipid metabolism;African trypanosomiasis; | 11.74 | 4.30 | 2.73 |
| Levothyroxine | DB00451 | NR1I2;ITGA2B;NR1H3; | Platelet activation;cGMP-PKG signaling pathway;Calcium signaling pathway; | 11.59 | 7.48 | 1.55 |
| Framycetin | DB00452 | CXCR4;CXCR2;CXCR1; | Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis;RNA transport; | 11.38 | 8.82 | 1.29 |
| Leuprolide | DB00007 | GSK3B;EGLN1;BIRC4; | RNA polymerase;Fluid shear stress and atherosclerosis;Starch and sucrose metabolism; | 10.43 | 3.62 | 2.88 |
| Oxycodone | DB00497 | CXCR2;CXCR1;FPR1; | Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis;Salmonella infection; | 8.56 | 8.56 | 1 |
| Ampicillin | DB00415 | PARP1;CA2;TEK; | Renin-angiotensin system;Complement and coagulation cascades;Sulfur relay system; | 7.53 | 1.97 | 3.82 |
| Levocarnitine | DB00583 | SLC22A1;MPO;NLGN2; | Alcoholism;Neutrophil extracellular trap formation;Transcriptional misregulation in cancer; | 6.10 | 5.70 | 1.07 |
| Amlexanox | DB01025 | S100A10;S100A8;S100P; | Natural killer cell mediated cytotoxicity;Antigen processing and presentation;Epstein-Barr virus infection; | 3.70 | 9.49 | 0.39 |
| Cromoglicic-acid | DB01003 | S100A10;S100A8;S100P; | Antigen processing and presentation;Natural killer cell mediated cytotoxicity;RNA transport; | 2.53 | 8.42 | 0.3 |
| Flavin-adenine-dinucleotide | DB03147 | ALDH1A1;NQO2;CYB5R1; | "Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Alanine, aspartate and glutamate metabolism;" | 2.32 | 2.61 | 0.89 |
| Sulfacytine | DB01298 | JAK1;PIK3CB;PRKCA; | Intestinal immune network for IgA production;Cholinergic synapse;Insulin secretion; | 69.11 | 14.70 | 4.7 |
| Sulfisoxazole | DB00263 | PIK3CB;PRKCA;CA2; | Systemic lupus erythematosus;C-type lectin receptor signaling pathway;Intestinal immune network for IgA production; | 67.10 | 15.11 | 4.44 |
| Sulfamethoxazole | DB01015 | PIK3CB;PRKCA;CA2; | C-type lectin receptor signaling pathway;Intestinal immune network for IgA production;Sphingolipid signaling pathway; | 66.00 | 15.42 | 4.28 |
| Sulfathiazole | DB06147 | PIK3CB;PRKCA;CA2; | C-type lectin receptor signaling pathway;Intestinal immune network for IgA production;Sphingolipid signaling pathway; | 66.00 | 15.42 | 4.28 |
| Metipranolol | DB01214 | RAF1;ABCB1;ADRB2; | Alcoholism;Systemic lupus erythematosus;Neutrophil extracellular trap formation; | 60.24 | 13.54 | 4.45 |
| Esmolol | DB00187 | RAF1;ABCB1;ADRB2; | Alcoholism;Systemic lupus erythematosus;Neutrophil extracellular trap formation; | 58.08 | 13.54 | 4.29 |
| Sulfadiazine | DB00359 | PIK3CB;PRKCA;CA2; | Intestinal immune network for IgA production;Sphingolipid signaling pathway;Cholinergic synapse; | 57.31 | 13.42 | 4.27 |
| Bempedoic-acid | DB11936 | PRKCA;ABCB1;FNTA; | Th1 and Th2 cell differentiation;Sphingolipid signaling pathway;Inflammatory bowel disease; | 50.81 | 13.20 | 3.85 |
| Trimetrexate | DB01157 | HDAC1;LCK;PDGFRB; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Amoebiasis; | 49.54 | 11.31 | 4.38 |
| Linagliptin | DB08882 | HDAC2;HDAC1;IGF1R; | Th1 and Th2 cell differentiation;RNA transport;Transcriptional misregulation in cancer; | 47.79 | 10.13 | 4.72 |
| Hexylresorcinol | DB11254 | RAF1;ALOX5;CA2; | Spliceosome;Platelet activation;Tight junction; | 45.10 | 13.71 | 3.29 |
| Ofloxacin | DB01165 | PARP1;ELA2;CYP2C9; | Necroptosis;Alcoholism;Human immunodeficiency virus 1 infection; | 43.71 | 11.04 | 3.96 |
| Triamcinolone | DB00620 | PRKCA;CA2;ABCB1; | Systemic lupus erythematosus;Salmonella infection;Tuberculosis; | 43.48 | 9.41 | 4.62 |
| Levofloxacin | DB01137 | PARP1;ELA2;CYP2C9; | Necroptosis;Alcoholism;Human immunodeficiency virus 1 infection; | 42.72 | 11.04 | 3.87 |
| Dipivefrin | DB00449 | RAF1;DRD2;ADRB2; | Renin secretion;Natural killer cell mediated cytotoxicity;Salivary secretion; | 42.13 | 14.73 | 2.86 |
| Cortisone-acetate | DB01380 | NR3C2;AKR1C3;G6PD; | Th1 and Th2 cell differentiation;Cushing syndrome;Aldosterone synthesis and secretion; | 39.93 | 11.89 | 3.36 |
| Eplerenone | DB00700 | GSK3B;LCK;ELA2; | NF-kappa B signaling pathway;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 39.19 | 8.85 | 4.43 |
| Fluvastatin | DB01095 | HDAC2;HDAC1;ADRB2; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Amoebiasis; | 38.68 | 8.63 | 4.48 |
| Dimenhydrinate | DB00985 | MAPK14;CYP2C9;PBEF1; | Systemic lupus erythematosus;Transcriptional misregulation in cancer;NF-kappa B signaling pathway; | 36.82 | 8.89 | 4.14 |
| Rolitetracycline | DB01301 | MMP9;CYP2C9;NR1H3; | Inflammatory bowel disease;Graft-versus-host disease;Neutrophil extracellular trap formation; | 36.57 | 12.70 | 2.88 |
| Trandolapril | DB00519 | HDAC1;DRD2;SIRT1; | Platelet activation;RNA transport;Amoebiasis; | 35.97 | 9.75 | 3.69 |
| Crisaborole | DB05219 | PRKCA;PRKACA;CA2; | Ribosome;Coronavirus disease - COVID-19;Tuberculosis; | 35.85 | 8.38 | 4.28 |
| Diflunisal | DB00861 | CA2;BCL2;ALB; | Phagosome;Transcriptional misregulation in cancer;Necroptosis; | 34.24 | 9.30 | 3.68 |
| Tolnaftate | DB00525 | GSK3B;PDGFRB;DRD2; | Natural killer cell mediated cytotoxicity;Antigen processing and presentation;Pentose phosphate pathway; | 33.75 | 7.18 | 4.7 |
| Safinamide | DB06654 | HDAC2;HDAC1;DRD2; | RNA transport;Oxidative phosphorylation;Amoebiasis; | 33.26 | 6.80 | 4.89 |
| Rimantadine | DB00478 | LCK;DRD2;LTA4H; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Necroptosis; | 32.55 | 7.02 | 4.64 |
| Metoprolol | DB00264 | LCK;ABCB1;ADRB2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Systemic lupus erythematosus; | 31.89 | 7.23 | 4.41 |
| Tizanidine | DB00697 | CDK1;DRD2;ADRB2; | Adrenergic signaling in cardiomyocytes;Human cytomegalovirus infection;Cytosolic DNA-sensing pathway; | 31.20 | 11.82 | 2.64 |
| Pomalidomide | DB08910 | PDE4B;TNF;AKR1B1; | Cushing syndrome;Human cytomegalovirus infection;Glutathione metabolism; | 30.45 | 9.61 | 3.17 |
| Moxifloxacin | DB00218 | GSK3B;ELA2;PDE4B; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Sphingolipid signaling pathway; | 29.73 | 7.68 | 3.87 |
| Captopril | DB01197 | DRD2;MMP9;LTA4H; | Necroptosis;Pantothenate and CoA biosynthesis;T cell receptor signaling pathway; | 29.73 | 8.01 | 3.71 |
| Ropinirole | DB00268 | DRD2;ADRB2;ALB; | Necroptosis;Non-alcoholic fatty liver disease;Pentose phosphate pathway; | 29.12 | 6.92 | 4.21 |
| Pitavastatin | DB08860 | HDAC1;DRD2;CYP2C9; | Th1 and Th2 cell differentiation;Alcoholism;Systemic lupus erythematosus; | 28.34 | 8.03 | 3.53 |
| Prilocaine | DB00750 | HDAC2;HDAC1;PIK3CB; | Glyoxylate and dicarboxylate metabolism;RNA transport;Th17 cell differentiation; | 28.24 | 6.99 | 4.04 |
| Toremifene | DB00539 | CYP19A1;DRD2;ABCB1; | Systemic lupus erythematosus;Platelet activation;Neutrophil extracellular trap formation; | 27.05 | 6.58 | 4.11 |
| Propofol | DB00818 | ALOX5;CA2;GABRA4; | Spliceosome;Platelet activation;Morphine addiction; | 26.10 | 7.66 | 3.41 |
| Sotalol | DB00489 | CA2;ADRB2;ALB; | Pentose phosphate pathway;IL-17 signaling pathway;Necroptosis; | 25.87 | 7.29 | 3.55 |
| Betamethasone-phosphate | DB14669 | CA2;ABCB1;NR3C2; | Th1 and Th2 cell differentiation;Amoebiasis;T cell receptor signaling pathway; | 25.56 | 8.52 | 3 |
| Ergotamine | DB00696 | PARP1;DRD2;ABCB1; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Sphingolipid signaling pathway; | 25.11 | 5.30 | 4.74 |
| Chlorzoxazone | DB00356 | PARP1;ELA2;CA2; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Leishmaniasis; | 24.91 | 6.31 | 3.95 |
| Danazol | DB01406 | CYP2C9;NR3C2;PIM2; | Human cytomegalovirus infection;Cytosolic DNA-sensing pathway;Systemic lupus erythematosus; | 24.47 | 9.13 | 2.68 |
| Betaxolol | DB00195 | ABCB1;ADRB2;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 24.33 | 5.81 | 4.19 |
| Dihydroergotamine | DB00320 | PARP1;DRD2;ABCB1; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Sphingolipid signaling pathway; | 24.05 | 5.30 | 4.54 |
| Roxithromycin | DB00778 | ABCB1;CYP2C9;ALB; | Sphingolipid signaling pathway;Systemic lupus erythematosus;Thiamine metabolism; | 24.04 | 8.07 | 2.98 |
| Primaquine | DB01087 | HSP90AA1;HSP90AB1;MPO; | Ribosome;Coronavirus disease - COVID-19;Kaposi sarcoma-associated herpesvirus infection; | 23.92 | 9.57 | 2.5 |
| Levobetaxolol | DB09351 | ABCB1;ADRB2;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 23.40 | 5.81 | 4.03 |
| Deutetrabenazine | DB12161 | DRD2;PDE4B;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Drug metabolism - cytochrome P450; | 22.75 | 6.77 | 3.36 |
| Tocainide | DB01056 | HDAC1;CA2;LTA4H; | Epithelial cell signaling in Helicobacter pylori infection;Amoebiasis;Th1 and Th2 cell differentiation; | 22.66 | 5.75 | 3.94 |
| Benzthiazide | DB00562 | ALOX5;CA2;CYP2C9; | Spliceosome;Metabolism of xenobiotics by cytochrome P450;Systemic lupus erythematosus; | 22.64 | 5.87 | 3.86 |
| Stanozolol | DB06718 | CYP19A1;CYP2C9;NR3C2; | Systemic lupus erythematosus;Oocyte meiosis;Cytosolic DNA-sensing pathway; | 22.20 | 5.97 | 3.72 |
| Letermovir | DB12070 | PDGFRB;CYP2C9;PBEF1; | Systemic lupus erythematosus;Alcoholism;Th1 and Th2 cell differentiation; | 21.69 | 6.72 | 3.23 |
| Cabazitaxel | DB06772 | ABCB1;KIF11;TUBA1A; | Salmonella infection;Pathways in cancer;Necroptosis; | 21.60 | 8.89 | 2.43 |
| Sulfadoxine | DB01299 | CA2;HSP90AB1;CTSS; | Kaposi sarcoma-associated herpesvirus infection;Pathways in cancer;Th17 cell differentiation; | 20.61 | 7.75 | 2.66 |
| Sulfanilamide | DB00259 | MMP9;CA2;F2; | Pyrimidine metabolism;Transcriptional misregulation in cancer;Complement and coagulation cascades; | 20.34 | 6.22 | 3.27 |
| Esculin | DB13155 | HDAC1;CA2;TNF; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 19.94 | 5.51 | 3.62 |
| Labetalol | DB00598 | CDK1;DRD2;ADRB2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Cell cycle; | 19.56 | 5.30 | 3.69 |
| Lisinopril | DB00722 | F2;NR1I2;SIRT1; | Th1 and Th2 cell differentiation;RNA transport;Oxidative phosphorylation; | 19.34 | 6.96 | 2.78 |
| DL-Methylephedrine | DB11278 | DRD2;CA2;ADRB2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 19.27 | 6.02 | 3.2 |
| Trimethoprim | DB00440 | JAK1;SLC22A1;PADI4; | Alcoholism;Inflammatory bowel disease;Graft-versus-host disease; | 19.05 | 7.16 | 2.66 |
| Acetaminophen | DB00316 | PARP1;CA2;CA4; | Endocytosis;Th17 cell differentiation;Hematopoietic cell lineage; | 18.44 | 6.36 | 2.9 |
| Carbinoxamine | DB00748 | DRD2;PTK2;SLC6A4; | Neutrophil extracellular trap formation;Alcoholism;Non-alcoholic fatty liver disease; | 17.76 | 4.47 | 3.97 |
| Vigabatrin | DB01080 | HDAC1;GABRA4;SLC6A1; | Th1 and Th2 cell differentiation;Complement and coagulation cascades;Th17 cell differentiation; | 17.73 | 6.61 | 2.68 |
| Eribulin | DB08871 | BCL2;BCL2L1;TUBA1A; | Human immunodeficiency virus 1 infection;Phototransduction;Salmonella infection; | 17.48 | 7.70 | 2.27 |
| Etodolac | DB00749 | CA2;POLB;RARB; | EGFR tyrosine kinase inhibitor resistance;VEGF signaling pathway;Oocyte meiosis; | 17.08 | 8.76 | 1.95 |
| Oxymetazoline | DB00935 | DRD2;CA2;ADRB2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 17.06 | 6.72 | 2.54 |
| Lasmiditan | DB11732 | DRD2;ADRB2;HTR1F; | Natural killer cell mediated cytotoxicity;Antigen processing and presentation;Pentose phosphate pathway; | 16.65 | 5.44 | 3.06 |
| Methionine | DB00134 | DRD2;SLC6A4;KIF11; | Primary immunodeficiency;PD-L1 expression and PD-1 checkpoint pathway in cancer;Oxidative phosphorylation; | 16.46 | 6.01 | 2.74 |
| Vorapaxar | DB09030 | CYP2C9;AKR1C3;F2R; | Glyoxylate and dicarboxylate metabolism;Spliceosome;Th1 and Th2 cell differentiation; | 16.13 | 7.79 | 2.07 |
| Rifampicin | DB01045 | ALB;NR1I2;RARB; | Necroptosis;Pertussis;IL-17 signaling pathway; | 14.84 | 6.48 | 2.29 |
| Rifaximin | DB01220 | ALB;NR1I2;RARB; | Necroptosis;Pertussis;IL-17 signaling pathway; | 14.84 | 6.48 | 2.29 |
| Pentoxifylline | DB00806 | ADRB2;PDE4B;TNF; | Drug metabolism - other enzymes;Pyrimidine metabolism;Staphylococcus aureus infection; | 14.82 | 5.59 | 2.65 |
| Norfloxacin | DB01059 | PARP1;CYP2C9;PIM2; | Systemic lupus erythematosus;Alcoholism;Graft-versus-host disease; | 14.67 | 3.63 | 4.04 |
| Dorzolamide | DB00869 | DRD2;CA2;CA4; | Necroptosis;African trypanosomiasis;Complement and coagulation cascades; | 14.53 | 4.70 | 3.09 |
| Moclobemide | DB01171 | DRD2;SLC6A4;JARID1A; | Non-alcoholic fatty liver disease;Complement and coagulation cascades;Pyrimidine metabolism; | 14.25 | 4.98 | 2.86 |
| Levodopa | DB01235 | DRD2;ADRB2;HTR1F; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Graft-versus-host disease; | 12.87 | 5.17 | 2.49 |
| Isotretinoin | DB00982 | ALOX5;NR1I2;NR1H3; | Spliceosome;Chronic myeloid leukemia;Th17 cell differentiation; | 12.87 | 5.90 | 2.18 |
| Amlodipine | DB00381 | CA2;ABCB1;NR3C2; | Complement and coagulation cascades;Cytosolic DNA-sensing pathway;NF-kappa B signaling pathway; | 11.80 | 4.04 | 2.92 |
| Enzacamene | DB11219 | CYP19A1;CYP2C9;SLC6A4; | Systemic lupus erythematosus;Oxidative phosphorylation;Neutrophil extracellular trap formation; | 11.70 | 3.68 | 3.18 |
| Primidone | DB00794 | SIRT1;GABRA4;EP300; | Morphine addiction;Adherens junction;RNA transport; | 11.62 | 4.49 | 2.59 |
| Tiludronic-acid | DB01133 | CA2;PTPN11;PTPN6; | Vibrio cholerae infection;Collecting duct acid secretion;Epithelial cell signaling in Helicobacter pylori infection; | 11.50 | 4.96 | 2.32 |
| Sucrose | DB02772 | CA2;ACTB;ACTG1; | Natural killer cell mediated cytotoxicity;Amoebiasis;Th1 and Th2 cell differentiation; | 10.82 | 5.58 | 1.94 |
| Levomilnacipran | DB08918 | CYP19A1;SLC6A4;SLC6A1; | Pathways of neurodegeneration - multiple diseases;Prion disease;VEGF signaling pathway; | 10.39 | 4.42 | 2.35 |
| Glutathione-disulfide | DB03310 | PTGES;GSTP1;EHMT2; | Ribosome;Pentose and glucuronate interconversions;Apelin signaling pathway; | 10.24 | 6.28 | 1.63 |
| Calcipotriol | DB02300 | CA2;NR1I2;EGLN1; | Complement and coagulation cascades;Salivary secretion;Pancreatic secretion; | 10.23 | 3.94 | 2.6 |
| Kappadione | DB09332 | F2;CTSG;PROZ; | Th1 and Th2 cell differentiation;Amoebiasis;Inflammatory bowel disease; | 9.67 | 9.21 | 1.05 |
| Loracarbef | DB00447 | CA2;F2;TEK; | Complement and coagulation cascades;Inflammatory bowel disease;Transcriptional misregulation in cancer; | 9.51 | 3.30 | 2.88 |
| Triclosan | DB08604 | PARP1;NR1I2;MPO; | Graft-versus-host disease;Hepatitis B;Cortisol synthesis and secretion; | 8.94 | 3.74 | 2.39 |
| Procaine | DB00721 | SLC6A4;SLC22A1;SLC6A1; | Amyotrophic lateral sclerosis;Neutrophil extracellular trap formation;Spinocerebellar ataxia; | 8.90 | 4.20 | 2.12 |
| Debrisoquine | DB04840 | CYP19A1;PDE4B;SLC6A4; | VEGF signaling pathway;Complement and coagulation cascades;Glycosphingolipid biosynthesis - ganglio series; | 8.57 | 3.36 | 2.55 |
| Histrelin | DB06788 | DRD2;CTSS;TLR2; | Biosynthesis of amino acids;Notch signaling pathway;Neutrophil extracellular trap formation; | 8.49 | 3.58 | 2.37 |
| Ascorbic-acid | DB00126 | TEK;EGLN1;JARID1A; | Graft-versus-host disease;Antigen processing and presentation;Spliceosome; | 7.88 | 4.10 | 1.92 |
| Probucol | DB01599 | CA2;EP300;NRP1; | Complement and coagulation cascades;Arrhythmogenic right ventricular cardiomyopathy;Collecting duct acid secretion; | 6.88 | 3.70 | 1.86 |
| Methylnaltrexone | DB06800 | CXCR2;CXCR1;FPR1; | Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis;Salmonella infection; | 6.39 | 8.08 | 0.79 |
| Pholcodine | DB09209 | CXCR2;CXCR1;FPR1; | Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis;Salmonella infection; | 6.39 | 8.08 | 0.79 |
| Aluminum-acetate | DB14518 | ELA2;CTSG;LTF; | Th1 and Th2 cell differentiation;NF-kappa B signaling pathway;Inflammatory bowel disease; | 5.50 | 9.65 | 0.57 |
| Ibutilide | DB00308 | CA2;KCNJ1;CACNB3; | Aminoacyl-tRNA biosynthesis;Complement and coagulation cascades;Ascorbate and aldarate metabolism; | 4.97 | 4.14 | 1.2 |
| Prednicarbate | DB01130 | RAF1;G6PD;FNTA; | Cushing syndrome;Aldosterone synthesis and secretion;Calcium signaling pathway; | 59.29 | 16.52 | 3.59 |
| Phenylephrine | DB00388 | RAF1;DRD2;ADRB2; | Natural killer cell mediated cytotoxicity;Antigen processing and presentation;T cell receptor signaling pathway; | 47.09 | 14.06 | 3.35 |
| Sulfamethizole | DB00576 | PIK3CB;PRKCA;CA2; | Intestinal immune network for IgA production;Sphingolipid signaling pathway;Neutrophil extracellular trap formation; | 42.16 | 10.92 | 3.86 |
| Raltegravir | DB06817 | ELA2;CYP2C9;HSP90AB1; | Transcriptional misregulation in cancer;Neutrophil extracellular trap formation;Human immunodeficiency virus 1 infection; | 40.06 | 11.85 | 3.38 |
| Fluconazole | DB00196 | CYP19A1;ABCB1;CYP2C9; | Kaposi sarcoma-associated herpesvirus infection;Human immunodeficiency virus 1 infection;Human cytomegalovirus infection; | 34.57 | 10.23 | 3.38 |
| Voriconazole | DB00582 | CYP19A1;ABCB1;CYP2C9; | Kaposi sarcoma-associated herpesvirus infection;Human immunodeficiency virus 1 infection;Human cytomegalovirus infection; | 34.57 | 10.23 | 3.38 |
| Enzalutamide | DB08899 | HDAC2;HDAC1;MAPK14; | RNA transport;Amoebiasis;Systemic lupus erythematosus; | 31.98 | 6.69 | 4.78 |
| Oxtriphylline | DB01303 | HDAC2;HDAC1;ADRB2; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Amoebiasis; | 31.78 | 9.87 | 3.22 |
| Rivastigmine | DB00989 | HDAC1;HSP90AA1;SLC6A4; | Ribosome;Coronavirus disease - COVID-19;Thyroid hormone synthesis; | 30.76 | 9.76 | 3.15 |
| Mirabegron | DB08893 | HDAC1;ADRB2;CYP2C9; | Natural killer cell mediated cytotoxicity;Amoebiasis;Systemic lupus erythematosus; | 29.50 | 7.78 | 3.79 |
| Azithromycin | DB00207 | HDAC1;ABCB1;ALB; | Th1 and Th2 cell differentiation;Amoebiasis;T cell receptor signaling pathway; | 29.35 | 8.58 | 3.42 |
| Rimegepant | DB12457 | MAPK14;IGF1R;PDGFRB; | Pathways of neurodegeneration - multiple diseases;Complement and coagulation cascades;Cushing syndrome; | 27.23 | 6.96 | 3.91 |
| Pipotiazine | DB01621 | JAK1;DRD2;ADRB2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 26.90 | 6.81 | 3.95 |
| Carindacillin | DB09319 | ELA2;EGLN1;CTSS; | Platelet activation;Transcriptional misregulation in cancer;NF-kappa B signaling pathway; | 23.90 | 7.74 | 3.09 |
| Ethynodiol-diacetate | DB00823 | CYP19A1;NR3C2;AKR1C3; | NF-kappa B signaling pathway;Th1 and Th2 cell differentiation;Inflammatory bowel disease; | 22.40 | 5.91 | 3.79 |
| Prucalopride | DB06480 | DRD2;ADRB2;CYP2C9; | Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus;Pentose phosphate pathway; | 22.31 | 6.16 | 3.62 |
| Lorcaserin | DB04871 | DRD2;ADRB2;SLC6A4; | Pentose phosphate pathway;Neutrophil extracellular trap formation;Natural killer cell mediated cytotoxicity; | 21.97 | 6.10 | 3.6 |
| Celiprolol | DB04846 | DRD2;ABCB1;ADRB2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Sphingolipid signaling pathway; | 21.24 | 6.34 | 3.35 |
| Hexachlorophene | DB00756 | AKR1B1;SIRT1;HSPA8; | Th1 and Th2 cell differentiation;Th17 cell differentiation;RNA transport; | 20.94 | 9.65 | 2.17 |
| Mepyramine | DB06691 | MAPK14;DRD2;PTK2; | Non-alcoholic fatty liver disease;VEGF signaling pathway;Thermogenesis; | 20.26 | 4.80 | 4.22 |
| Tubocurarine | DB01199 | HDAC1;ABCB1;NMUR1; | Th1 and Th2 cell differentiation;Amoebiasis;Viral protein interaction with cytokine and cytokine receptor; | 20.07 | 8.26 | 2.43 |
| Sulfacetamide | DB00634 | MMP9;CA2;F2; | Complement and coagulation cascades;Neutrophil extracellular trap formation;Sphingolipid signaling pathway; | 19.66 | 5.77 | 3.41 |
| Oxprenolol | DB01580 | ABCB1;ADRB2;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 19.60 | 5.10 | 3.84 |
| Mepenzolate | DB04843 | PIK3CB;MAP2K1;SLC22A1; | Glyoxylate and dicarboxylate metabolism;Spliceosome;Neutrophil extracellular trap formation; | 19.48 | 5.47 | 3.56 |
| Asenapine | DB06216 | DRD2;ADRB2;LTA4H; | Necroptosis;Pentose phosphate pathway;Natural killer cell mediated cytotoxicity; | 19.39 | 5.30 | 3.66 |
| Metaraminol | DB00610 | DRD2;CA2;ADRB2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 18.87 | 5.92 | 3.19 |
| Practolol | DB01297 | ABCB1;ADRB2;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 18.68 | 5.10 | 3.66 |
| Sparfloxacin | DB01208 | GSK3B;CYP2C9;EGLN1; | Systemic lupus erythematosus;Fluid shear stress and atherosclerosis;Alcoholism; | 18.43 | 4.85 | 3.8 |
| Ulipristal | DB08867 | CYP19A1;CYP2C9;NR3C2; | Systemic lupus erythematosus;Phagosome;Leishmaniasis; | 18.35 | 5.54 | 3.31 |
| Olodaterol | DB09080 | DRD2;ADRB2;SLC6A4; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 18.10 | 5.35 | 3.38 |
| Lornoxicam | DB06725 | MMP9;CA2;G6PD; | Inflammatory bowel disease;Leishmaniasis;Pentose phosphate pathway; | 17.65 | 6.02 | 2.93 |
| Thiothixene | DB01623 | DRD2;ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 17.32 | 4.85 | 3.57 |
| Edoxudine | DB13421 | ALB;G6PD;TK1; | Rap1 signaling pathway;NF-kappa B signaling pathway;Drug metabolism - other enzymes; | 17.25 | 9.58 | 1.8 |
| Tegaserod | DB01079 | ADRB2;CYP2C9;HTR1F; | Natural killer cell mediated cytotoxicity;Amoebiasis;Antigen processing and presentation; | 16.66 | 7.24 | 2.3 |
| Mephentermine | DB01365 | DRD2;ADRB2;SLC6A4; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 16.65 | 5.25 | 3.17 |
| Procainamide | DB01035 | DRD2;SLC22A1;MPO; | Graft-versus-host disease;Neutrophil extracellular trap formation;Transcriptional misregulation in cancer; | 16.31 | 5.33 | 3.06 |
| Zalcitabine | DB00943 | ALB;CXCR4;TK1; | Necroptosis;Tuberculosis;Non-alcoholic fatty liver disease; | 16.10 | 8.85 | 1.82 |
| Nisoldipine | DB00401 | ABCB1;NR3C2;NR1I2; | Salmonella infection;Inflammatory bowel disease;Thiamine metabolism; | 16.02 | 5.58 | 2.87 |
| Nitrendipine | DB01054 | ABCB1;NR3C2;NR1I2; | Salmonella infection;Inflammatory bowel disease;Thiamine metabolism; | 16.02 | 5.58 | 2.87 |
| Finafloxacin | DB09047 | PIK3CB;SLC6A4;EGLN1; | B cell receptor signaling pathway;Cholinergic synapse;Thermogenesis; | 15.78 | 4.38 | 3.6 |
| Acetophenazine | DB01063 | DRD2;ABCB1;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Thiamine metabolism; | 15.74 | 4.30 | 3.66 |
| Benzocaine | DB01086 | ITK;PLCG1;XBP1; | Glycosaminoglycan degradation;Inflammatory bowel disease;Amyotrophic lateral sclerosis; | 15.60 | 9.93 | 1.57 |
| Etafedrine | DB11587 | CA2;ADRB2;SLC6A4; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 15.57 | 4.93 | 3.16 |
| Famotidine | DB00927 | CA2;ADRB2;SLC22A1; | Neutrophil extracellular trap formation;Pentose phosphate pathway;Natural killer cell mediated cytotoxicity; | 15.23 | 5.16 | 2.95 |
| D-Methionine | DB02893 | DRD2;SLC6A4;KIF11; | Primary immunodeficiency;PD-L1 expression and PD-1 checkpoint pathway in cancer;Non-alcoholic fatty liver disease; | 14.95 | 5.28 | 2.83 |
| Cimetidine | DB00501 | ABCB1;ADRB2;SLC22A1; | Natural killer cell mediated cytotoxicity;Antigen processing and presentation;Amoebiasis; | 14.83 | 5.93 | 2.5 |
| Rifamycin | DB11753 | ALB;NR1I2;GSTO1; | Necroptosis;Pertussis;IL-17 signaling pathway; | 14.39 | 6.48 | 2.22 |
| Rifapentine | DB01201 | ALB;NR1I2;GSTO1; | Necroptosis;Pertussis;IL-17 signaling pathway; | 14.39 | 6.48 | 2.22 |
| Quinidine-barbiturate | DB01346 | MMP9;ADRB2;GABRB3; | Graft-versus-host disease;Thiamine metabolism;Inflammatory bowel disease; | 14.00 | 6.39 | 2.19 |
| Azelaic-acid | DB00548 | MMP9;AKR1C3;PIM2; | Inflammatory bowel disease;Th1 and Th2 cell differentiation;T cell receptor signaling pathway; | 14.00 | 5.58 | 2.51 |
| Tirofiban | DB00775 | MMP9;ITGA2B;ITGB2; | Platelet activation;Tight junction;Regulation of actin cytoskeleton; | 13.79 | 6.13 | 2.25 |
| Ezetimibe | DB00973 | HSP90AA1;KIF11;ANPEP; | PI3K-Akt signaling pathway;Glyoxylate and dicarboxylate metabolism;Insulin secretion; | 13.13 | 5.86 | 2.24 |
| Propylhexedrine | DB06714 | DRD2;ADRB2;SLC6A4; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 13.02 | 5.25 | 2.48 |
| Etidronic-acid | DB01077 | CA2;CA4;SLC25A5; | Ribosome;Coronavirus disease - COVID-19;Pyrimidine metabolism; | 12.75 | 4.47 | 2.85 |
| Triclocarban | DB11155 | CDK1;CA2;CXCR2; | Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis;Malaria; | 12.46 | 3.97 | 3.14 |
| Citalopram | DB00215 | DRD2;SLC6A4;SLC22A1; | Neutrophil extracellular trap formation;Alcoholism;Non-alcoholic fatty liver disease; | 12.42 | 4.14 | 3 |
| Fluciclovine-(18F) | DB13146 | GRIN2D;GRIA4;SLC1A3; | Complement and coagulation cascades;Calcium signaling pathway;Thiamine metabolism; | 12.08 | 12.08 | 1 |
| Isradipine | DB00270 | ABCB1;PDE4B;CYP2C9; | Systemic lupus erythematosus;Cytosolic DNA-sensing pathway;Alcoholism; | 11.96 | 3.40 | 3.52 |
| Secobarbital | DB00418 | GABRA4;GABRB3;GABRE; | Calcium signaling pathway;Morphine addiction;Adherens junction; | 11.88 | 6.32 | 1.88 |
| Nilvadipine | DB06712 | ABCB1;NR3C2;NR1I2; | Salmonella infection;Fat digestion and absorption;Cytosolic DNA-sensing pathway; | 11.62 | 4.24 | 2.74 |
| Flutamide | DB00499 | CYP19A1;NR1I2;CTSS; | VEGF signaling pathway;Gastric cancer;Biosynthesis of amino acids; | 11.55 | 4.09 | 2.82 |
| Alfuzosin | DB00346 | ADRB2;PDE4B;SLC22A1; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 11.33 | 4.27 | 2.65 |
| Deserpidine | DB01089 | DRD2;ABCB1;SLC6A1; | Thiamine metabolism;Galactose metabolism;Pantothenate and CoA biosynthesis; | 11.19 | 4.21 | 2.66 |
| Ephedrine | DB01364 | ADRB2;SLC6A4;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 10.86 | 4.60 | 2.36 |
| Dextrothyroxine | DB00509 | NR1I2;MPO;NR1H3; | Calcium signaling pathway;Cortisol synthesis and secretion;Cushing syndrome; | 10.59 | 6.54 | 1.62 |
| Mycophenolic-acid | DB01024 | GSK3B;CYP19A1;MC3R; | Fluid shear stress and atherosclerosis;VEGF signaling pathway;Notch signaling pathway; | 10.49 | 3.82 | 2.75 |
| Glycyrrhizic-acid | DB13751 | CA2;TNF;TOP2A; | Staphylococcus aureus infection;Platelet activation;Pertussis; | 10.31 | 3.97 | 2.6 |
| Methazolamide | DB00703 | DRD2;CA2;CA4; | Complement and coagulation cascades;African trypanosomiasis;Neutrophil extracellular trap formation; | 10.27 | 3.52 | 2.92 |
| Eszopiclone | DB00402 | KIF11;GABRA4;GABRB3; | Morphine addiction;Adherens junction;Thiamine metabolism; | 10.27 | 4.08 | 2.52 |
| Lactose | DB04465 | CA2;GLB1;MGAM; | Aminoacyl-tRNA biosynthesis;Th17 cell differentiation;Natural killer cell mediated cytotoxicity; | 10.05 | 6.32 | 1.59 |
| Floxuridine | DB00322 | G6PD;TYMS;TK1; | Pyrimidine metabolism;Tuberculosis;p53 signaling pathway; | 9.90 | 6.27 | 1.58 |
| Tipranavir | DB00932 | CYP2C9;F2R;NR1H3; | Systemic lupus erythematosus;Alcoholism;Salivary secretion; | 9.82 | 4.41 | 2.23 |
| Reserpine | DB00206 | DRD2;ABCB1;FKBP1A; | Thiamine metabolism;Galactose metabolism;Pantothenate and CoA biosynthesis; | 9.74 | 3.90 | 2.5 |
| Trovafloxacin | DB00685 | PDE4B;CYP2C9;PIM2; | Systemic lupus erythematosus;Alcoholism;Cushing syndrome; | 9.58 | 3.11 | 3.08 |
| Aripiprazole-lauroxil | DB14185 | DRD2;ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 9.47 | 4.47 | 2.12 |
| Miglustat | DB00419 | ITGA2B;GLB1;MGAM; | Platelet activation;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 9.12 | 6.61 | 1.38 |
| Isoniazid | DB00951 | CYP2C9;SLC6A4;MPO; | Systemic lupus erythematosus;Alcoholism;Pathways of neurodegeneration - multiple diseases; | 9.03 | 4.99 | 1.81 |
| Sibutramine | DB01105 | DRD2;SLC6A4;PSMB5; | Non-alcoholic fatty liver disease;Complement and coagulation cascades;Glycosphingolipid biosynthesis - ganglio series; | 8.87 | 3.24 | 2.74 |
| Ceruletide | DB00403 | JARID1A;CXCR2;KCNJ1; | Antigen processing and presentation;Glyoxylate and dicarboxylate metabolism;Fluid shear stress and atherosclerosis; | 8.84 | 4.99 | 1.77 |
| Lindane | DB00431 | NR1I2;GABRA4;GABRB3; | Morphine addiction;Adherens junction;Wnt signaling pathway; | 8.72 | 4.74 | 1.84 |
| Dapagliflozin | DB06292 | CA2;SELP;ENPP2; | Platelet activation;Thiamine metabolism;Malaria; | 8.66 | 4.89 | 1.77 |
| Diethylpropion | DB00937 | DRD2;SLC6A4;CDK8; | Oxidative phosphorylation;Non-alcoholic fatty liver disease;Complement and coagulation cascades; | 8.58 | 3.43 | 2.5 |
| Fenfluramine | DB00574 | ADRB2;SLC6A4;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 8.42 | 4.60 | 1.83 |
| Doxazosin | DB00590 | ADRB2;SLC22A1;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 8.32 | 4.78 | 1.74 |
| Etacrynic-acid | DB00903 | GSTP1;GSTO1;GSTA3; | Ribosome;Pentose and glucuronate interconversions;Coronavirus disease - COVID-19; | 7.92 | 5.50 | 1.44 |
| Levoleucovorin | DB11596 | ITGA2B;TYMS;DHFR; | Platelet activation;RNA transport;Pyrimidine metabolism; | 7.07 | 4.98 | 1.42 |
| Meticillin | DB01603 | G6PD;EGLN1;ITGA4; | "Valine, leucine and isoleucine degradation;Th1 and Th2 cell differentiation;Pentose phosphate pathway;" | 6.66 | 2.74 | 2.43 |
| Methyldopa | DB00968 | DRD2;HTR1F;EGLN1; | Base excision repair;Taste transduction;Pantothenate and CoA biosynthesis; | 5.51 | 2.49 | 2.21 |
| Amoxicillin | DB01060 | CA2;TEK;G6PD; | Complement and coagulation cascades;Malaria;Renin secretion; | 5.00 | 1.86 | 2.69 |
| Cephalexin | DB00567 | CA2;F2;TEK; | Complement and coagulation cascades;African trypanosomiasis;Pertussis; | 4.97 | 1.62 | 3.08 |
| Nafarelin | DB00666 | TLR2;MC3R;MGAM; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 4.64 | 3.52 | 1.32 |
| Gluconolactone | DB04564 | TYMS;PYGL;SLC5A1; | Pyrimidine metabolism;Inflammatory bowel disease;Transcriptional misregulation in cancer; | 4.55 | 4.78 | 0.95 |
| Rosiglitazone | DB00412 | CYP2C9;RARB;ACSL6; | Systemic lupus erythematosus;Fatty acid biosynthesis;Neutrophil extracellular trap formation; | 4.16 | 3.61 | 1.15 |
| Canagliflozin | DB08907 | PYGL;ENPP2;SLC5A1; | Thiamine metabolism;Inflammatory bowel disease;Transcriptional misregulation in cancer; | 4.08 | 3.74 | 1.09 |
| Pidolic-acid | DB03088 | CCL2;CCL4L2;CCL8; | Human cytomegalovirus infection;RNA polymerase;Cytokine-cytokine receptor interaction; | 4.06 | 7.38 | 0.55 |
| Naloxegol | DB09049 | CXCR2;CXCR1;FPR1; | Natural killer cell mediated cytotoxicity;Aminoacyl-tRNA biosynthesis;RNA transport; | 4.05 | 5.00 | 0.81 |
| Solriamfetol | DB14754 | SLC6A4;SLC6A1;CSK; | Complement and coagulation cascades;Glycosphingolipid biosynthesis - ganglio series;Thermogenesis; | 3.73 | 2.52 | 1.48 |
| Topotecan | DB01030 | TOP2A;EIF2AK3;KCNJ1; | Salivary secretion;Basal transcription factors;Spliceosome; | 3.61 | 2.46 | 1.47 |
| Alprostadil | DB00770 | FPR1;AGTR2;LTB4R; | Spliceosome;Sphingolipid signaling pathway;Phagosome; | 2.84 | 6.45 | 0.44 |
| Dinoprost | DB12789 | FPR1;AGTR2;LTB4R; | Spliceosome;Sphingolipid signaling pathway;Phagosome; | 2.84 | 6.45 | 0.44 |
| Dinoprostone | DB00917 | FPR1;AGTR2;LTB4R; | Spliceosome;Sphingolipid signaling pathway;Phagosome; | 2.84 | 6.45 | 0.44 |
| Thiamylal | DB01154 | GABRB3;GABRE;KCNJ1; | Aminoacyl-tRNA biosynthesis;Thiamine metabolism;Starch and sucrose metabolism; | 2.43 | 4.12 | 0.59 |
| Ethanolamine-oleate | DB06689 | CTSG;AZU1;PRTN3; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;Amoebiasis; | 2.21 | 7.37 | 0.3 |
| D-Serine | DB03929 | GABRB3;GABRE;SERPINA7; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Arginine biosynthesis; | 1.93 | 4.48 | 0.43 |
| Tropicamide | DB00809 | HDAC1;RAF1;AKR1C3; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Natural killer cell mediated cytotoxicity; | 56.72 | 13.97 | 4.06 |
| Beclomethasone-dipropionate | DB00394 | RAF1;NR3C2;FNTA; | Cushing syndrome;Aldosterone synthesis and secretion;Calcium signaling pathway; | 54.20 | 15.62 | 3.47 |
| Levosalbutamol | DB13139 | RAF1;ADRB2;SLC22A1; | Natural killer cell mediated cytotoxicity;Neutrophil extracellular trap formation;Alcoholism; | 46.52 | 13.18 | 3.53 |
| Salbutamol | DB01001 | RAF1;ADRB2;SLC22A1; | Natural killer cell mediated cytotoxicity;Neutrophil extracellular trap formation;Alcoholism; | 46.52 | 13.18 | 3.53 |
| Thiamine | DB00152 | CA2;HSP90AA1;SLC22A1; | Kaposi sarcoma-associated herpesvirus infection;Protein processing in endoplasmic reticulum;Insulin secretion; | 33.75 | 9.48 | 3.56 |
| Rofecoxib | DB00533 | GSK3B;CYP19A1;ALOX5; | Spliceosome;Th17 cell differentiation;Th1 and Th2 cell differentiation; | 33.56 | 8.03 | 4.18 |
| Acetyl-sulfisoxazole | DB14033 | CA2;AKT2;CA4; | C-type lectin receptor signaling pathway;Glioma;Alzheimer disease; | 31.20 | 10.16 | 3.07 |
| Cabergoline | DB00248 | HDAC1;DRD2;ADRB2; | Natural killer cell mediated cytotoxicity;Amoebiasis;Th1 and Th2 cell differentiation; | 27.77 | 7.01 | 3.96 |
| Aminophylline | DB01223 | HDAC2;HDAC1;ADRB2; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Amoebiasis; | 26.25 | 9.87 | 2.66 |
| Methsuximide | DB05246 | CYP19A1;ELA2;CA2; | Human immunodeficiency virus 1 infection;Transcriptional misregulation in cancer;NF-kappa B signaling pathway; | 24.62 | 6.55 | 3.76 |
| Elexacaftor | DB15444 | HDAC2;HDAC1;FNTA; | RNA transport;Th1 and Th2 cell differentiation;Amoebiasis; | 24.61 | 6.09 | 4.04 |
| Latanoprost | DB00654 | HDAC2;HDAC1;AKR1C3; | Th1 and Th2 cell differentiation;RNA transport;Th17 cell differentiation; | 24.47 | 6.84 | 3.58 |
| Eugenol | DB09086 | IGF1R;CA2;CA4; | Transcriptional misregulation in cancer;Hematopoietic cell lineage;Th17 cell differentiation; | 24.33 | 7.88 | 3.09 |
| Deflazacort | DB11921 | NR3C2;G6PD;FNTA; | Cushing syndrome;Aldosterone synthesis and secretion;Calcium signaling pathway; | 23.85 | 7.84 | 3.04 |
| Dequalinium | DB04209 | PRKCA;BIRC4;C5AR1; | RNA polymerase;Leishmaniasis;Tuberculosis; | 23.07 | 9.61 | 2.4 |
| Drospirenone | DB01395 | CYP19A1;NR3C2;AKR1C3; | NF-kappa B signaling pathway;Th1 and Th2 cell differentiation;Inflammatory bowel disease; | 22.96 | 6.67 | 3.44 |
| Cefalotin | DB00456 | ELA2;ALB;G6PD; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Necroptosis; | 22.79 | 7.86 | 2.9 |
| Hydrocortamate | DB00769 | G6PD;FNTA;AKR1B1; | Cushing syndrome;Aldosterone synthesis and secretion;Calcium signaling pathway; | 22.70 | 7.94 | 2.86 |
| Linaclotide | DB08890 | HDAC1;CA2;CA4; | Th1 and Th2 cell differentiation;Amoebiasis;Th17 cell differentiation; | 21.98 | 6.21 | 3.54 |
| Procaterol | DB01366 | DRD2;ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 21.86 | 8.04 | 2.72 |
| Novobiocin | DB01051 | ALB;HSP90AB1;RPS6KA3; | Kaposi sarcoma-associated herpesvirus infection;Necroptosis;Apelin signaling pathway; | 21.83 | 8.36 | 2.61 |
| Encorafenib | DB11718 | RAF1;TTK;CCND2; | Choline metabolism in cancer;GnRH secretion;Bladder cancer; | 21.73 | 10.86 | 2 |
| Bromocriptine | DB01200 | DRD2;ABCB1;ADRB2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Sphingolipid signaling pathway; | 21.34 | 5.14 | 4.15 |
| Dihydro-alpha-ergocryptine | DB11274 | DRD2;ABCB1;ADRB2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Sphingolipid signaling pathway; | 21.34 | 5.14 | 4.15 |
| Epicriptine | DB11275 | DRD2;ABCB1;ADRB2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Sphingolipid signaling pathway; | 21.34 | 5.14 | 4.15 |
| Physostigmine | DB00981 | HDAC1;PBEF1;DYRK1A; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Amoebiasis; | 20.91 | 7.58 | 2.76 |
| Sulfameter | DB06821 | PIK3CB;CYP19A1;CA2; | Inflammatory bowel disease;B cell receptor signaling pathway;Graft-versus-host disease; | 20.55 | 5.65 | 3.64 |
| Sulfametopyrazine | DB00664 | PIK3CB;CYP19A1;CA2; | Inflammatory bowel disease;B cell receptor signaling pathway;Graft-versus-host disease; | 20.55 | 5.65 | 3.64 |
| Pramocaine | DB09345 | DRD2;ADRB2;LTA4H; | Necroptosis;Pentose phosphate pathway;Diabetic cardiomyopathy; | 20.46 | 5.61 | 3.65 |
| Niacin | DB00627 | HDAC2;HDAC1;LCK; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Amoebiasis; | 20.43 | 5.52 | 3.7 |
| Glycopyrronium | DB00986 | PIK3CB;CYP19A1;SLC22A1; | Glyoxylate and dicarboxylate metabolism;Spliceosome;Neutrophil extracellular trap formation; | 19.72 | 5.12 | 3.85 |
| Fluorescein | DB00693 | MMP9;HSP90AB1;TYMS; | Kaposi sarcoma-associated herpesvirus infection;Pathways in cancer;Pyrimidine metabolism; | 19.39 | 7.88 | 2.46 |
| Capsaicin | DB06774 | DRD2;ALB;SIRT1; | Necroptosis;RNA transport;Non-alcoholic fatty liver disease; | 18.75 | 7.10 | 2.64 |
| Zucapsaicin | DB09120 | DRD2;ALB;SIRT1; | Necroptosis;RNA transport;Non-alcoholic fatty liver disease; | 18.75 | 7.10 | 2.64 |
| Oseltamivir | DB00198 | HDAC2;ABCB1;LTA4H; | Platelet activation;RNA transport;Tight junction; | 18.11 | 4.80 | 3.77 |
| Salmeterol | DB00938 | DRD2;ADRB2;CYP2C9; | Systemic lupus erythematosus;Pentose phosphate pathway;Natural killer cell mediated cytotoxicity; | 17.79 | 5.28 | 3.37 |
| Acebutolol | DB01193 | ABCB1;ADRB2;SLC22A1; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Sphingolipid signaling pathway; | 16.66 | 4.96 | 3.36 |
| Itraconazole | DB01167 | CYP19A1;ABCB1;CYP2C9; | Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus;Thiamine metabolism; | 16.55 | 4.72 | 3.51 |
| Posaconazole | DB01263 | CYP19A1;ABCB1;CYP2C9; | Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus;Thiamine metabolism; | 16.55 | 4.72 | 3.51 |
| Cloxacillin | DB01147 | MAPK14;ITGA2B;PYGL; | Th1 and Th2 cell differentiation;Platelet activation;NF-kappa B signaling pathway; | 16.51 | 6.80 | 2.43 |
| Moxisylyte | DB09205 | HDAC1;DRD2;ADRB2; | Natural killer cell mediated cytotoxicity;Amoebiasis;Th1 and Th2 cell differentiation; | 16.27 | 7.01 | 2.32 |
| Clofibrate | DB00636 | ELA2;BCL2;BCL2L1; | Human immunodeficiency virus 1 infection;Transcriptional misregulation in cancer;Phagosome; | 16.24 | 5.89 | 2.76 |
| Perindopril | DB00790 | DRD2;SIRT1;ITGA2B; | Platelet activation;RNA transport;Tight junction; | 15.99 | 5.71 | 2.8 |
| Atenolol | DB00335 | ABCB1;ADRB2;CYP2C9; | Systemic lupus erythematosus;Pentose phosphate pathway;Natural killer cell mediated cytotoxicity; | 15.88 | 4.74 | 3.35 |
| Bisoprolol | DB00612 | ABCB1;ADRB2;CYP2C9; | Systemic lupus erythematosus;Pentose phosphate pathway;Natural killer cell mediated cytotoxicity; | 15.88 | 4.74 | 3.35 |
| Acetylcysteine | DB06151 | HDAC1;CDK1;GRIN2D; | Calcium signaling pathway;Amoebiasis;Th1 and Th2 cell differentiation; | 14.74 | 6.49 | 2.27 |
| Sofosbuvir | DB08934 | MMP9;CYP2C9;TYMS; | Neutrophil extracellular trap formation;Inflammatory bowel disease;Systemic lupus erythematosus; | 14.65 | 5.51 | 2.66 |
| Budesonide | DB01222 | NR3C2;SLC22A1;ANXA3; | Th1 and Th2 cell differentiation;Amoebiasis;Neutrophil extracellular trap formation; | 14.33 | 7.28 | 1.97 |
| Telbivudine | DB01265 | ALB;G6PD;TK1; | NF-kappa B signaling pathway;Drug metabolism - other enzymes;Necroptosis; | 14.22 | 7.22 | 1.97 |
| Aminobenzoic-acid | DB02362 | CA2;TNF;PADI4; | Malaria;Staphylococcus aureus infection;Inflammatory bowel disease; | 13.71 | 5.51 | 2.49 |
| Miltefosine | DB09031 | CDK1;ABCB1;CYP2C9; | Cell cycle;Systemic lupus erythematosus;Th1 and Th2 cell differentiation; | 13.57 | 3.81 | 3.56 |
| Acamprosate | DB00659 | GABRA4;GABRB3;GABRE; | Calcium signaling pathway;Morphine addiction;Adherens junction; | 13.52 | 5.83 | 2.32 |
| Nimodipine | DB00393 | ABCB1;NR3C2;NR1I2; | Salmonella infection;Fat digestion and absorption;Cytosolic DNA-sensing pathway; | 12.80 | 4.05 | 3.16 |
| Aprepitant | DB00673 | PARP1;DRD2;CYP2C9; | Systemic lupus erythematosus;RNA transport;Alcoholism; | 12.55 | 3.26 | 3.85 |
| Diphemanil | DB13720 | PDGFRB;CYP19A1;CA2; | Complement and coagulation cascades;ABC transporters;Arrhythmogenic right ventricular cardiomyopathy; | 12.49 | 3.16 | 3.96 |
| Hydroflumethiazide | DB00774 | CA2;ALB;CA4; | Necroptosis;Complement and coagulation cascades;Prion disease; | 12.10 | 4.17 | 2.9 |
| Trichlormethiazide | DB01021 | CA2;ALB;CA4; | Necroptosis;Complement and coagulation cascades;Prion disease; | 12.10 | 4.17 | 2.9 |
| Arbutin | DB11217 | CA2;CYP2C9;KIF11; | Systemic lupus erythematosus;Primary immunodeficiency;Complement and coagulation cascades; | 11.98 | 4.26 | 2.81 |
| Chlorothiazide | DB00880 | CA2;ALB;CA4; | Necroptosis;Complement and coagulation cascades;Prion disease; | 11.39 | 4.17 | 2.73 |
| Rolapitant | DB09291 | SLC6A4;NR1I2;PIM2; | Thermogenesis;Carbon metabolism;Pentose phosphate pathway; | 11.36 | 3.81 | 2.98 |
| Amiloride | DB00594 | SLC22A1;CDK8;GZMM; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Amoebiasis; | 11.23 | 7.24 | 1.55 |
| Scopolamine | DB00747 | SLC6A4;SLC22A1;CDK8; | Th1 and Th2 cell differentiation;Th17 cell differentiation;Oxidative phosphorylation; | 11.04 | 4.35 | 2.54 |
| Clofedanol | DB04837 | BCL2;SLC6A4;BCL2L1; | Phagosome;Oxidative phosphorylation;Renin secretion; | 10.73 | 3.65 | 2.94 |
| Telotristat-ethyl | DB12095 | PIK3CB;PDE4B;TNF; | Staphylococcus aureus infection;B cell receptor signaling pathway;Epstein-Barr virus infection; | 10.49 | 3.28 | 3.2 |
| Pentamidine | DB00738 | F2;C5AR1;C1S; | Amoebiasis;Calcium signaling pathway;Antigen processing and presentation; | 10.48 | 6.35 | 1.65 |
| Pyrantel | DB11156 | ADRB2;YES1;P2RY5; | Pentose phosphate pathway;Amoebiasis;Natural killer cell mediated cytotoxicity; | 10.32 | 5.43 | 1.9 |
| Norgestimate | DB00957 | CYP19A1;PSEN1;KIF11; | Primary immunodeficiency;VEGF signaling pathway;Human immunodeficiency virus 1 infection; | 10.28 | 3.15 | 3.26 |
| Alclofenac | DB13167 | CA2;BCL2;BCL2L1; | Phagosome;Complement and coagulation cascades;Ether lipid metabolism; | 10.24 | 3.55 | 2.88 |
| Ciprofloxacin | DB00537 | CYP2C9;EGLN1;MPO; | Systemic lupus erythematosus;Alcoholism;Graft-versus-host disease; | 10.19 | 3.45 | 2.95 |
| Lomefloxacin | DB00978 | CYP2C9;EGLN1;MPO; | Systemic lupus erythematosus;Alcoholism;Graft-versus-host disease; | 10.19 | 3.45 | 2.95 |
| Edoxaban | DB09075 | SLC6A4;F2;SIRT1; | RNA transport;Oxidative phosphorylation;Basal transcription factors; | 10.06 | 4.23 | 2.38 |
| Stiripentol | DB09118 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Graft-versus-host disease; | 10.03 | 4.75 | 2.11 |
| Ranitidine | DB00863 | ABCB1;ADRB2;HTR1F; | Pentose phosphate pathway;Olfactory transduction;Natural killer cell mediated cytotoxicity; | 10.00 | 5.78 | 1.73 |
| Enoxacin | DB00467 | CYP2C9;PIM2;MPO; | Systemic lupus erythematosus;Alcoholism;Graft-versus-host disease; | 9.99 | 3.31 | 3.02 |
| Brinzolamide | DB01194 | DRD2;CA2;CA4; | African trypanosomiasis;Complement and coagulation cascades;Neutrophil extracellular trap formation; | 9.85 | 3.19 | 3.09 |
| Guanadrel | DB00226 | HDAC1;SLC6A4;SLC6A1; | Th1 and Th2 cell differentiation;Amoebiasis;Th17 cell differentiation; | 9.77 | 4.68 | 2.09 |
| Indigotindisulfonic-acid | DB11577 | DRD2;INSR;ADRB2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 9.68 | 4.79 | 2.02 |
| Pirbuterol | DB01291 | ADRB2;HTR1F;GLB1; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 9.48 | 4.86 | 1.95 |
| Ixabepilone | DB04845 | TUBA1A;TUBB2C;TUBB3; | Salmonella infection;Pathways in cancer;Necroptosis; | 9.48 | 6.87 | 1.38 |
| Phenylpropanolamine | DB00397 | DRD2;ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 9.40 | 4.52 | 2.08 |
| Methyprylon | DB01107 | PARP1;GABRA4;GABRB3; | Morphine addiction;Adherens junction;Wnt signaling pathway; | 9.12 | 3.00 | 3.04 |
| Dicloxacillin | DB00485 | MAPK14;ITGA4;PYGL; | Thiamine metabolism;Th1 and Th2 cell differentiation;T cell receptor signaling pathway; | 9.08 | 3.74 | 2.43 |
| Succinic-acid | DB00139 | EGLN1;CXCR4;ALDH1A1; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;PI3K-Akt signaling pathway; | 9.02 | 5.34 | 1.69 |
| Carbetocin | DB01282 | PARP1;CYP2C9;ITGA2B; | Platelet activation;Tight junction;Systemic lupus erythematosus; | 8.90 | 3.00 | 2.97 |
| Pargyline | DB01626 | DRD2;CA2;CDK8; | RNA polymerase;Huntington disease;African trypanosomiasis; | 8.50 | 2.84 | 2.99 |
| Protokylol | DB06814 | ADRB2;HTR1F;G6PD; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 8.10 | 3.35 | 2.42 |
| Argatroban | DB00278 | F2;ITGA2B;NRP1; | Platelet activation;Tight junction;Complement and coagulation cascades; | 8.06 | 3.26 | 2.47 |
| Baclofen | DB00181 | HSP90AA1;CSK;ANPEP; | Insulin secretion;Cushing syndrome;Thyroid hormone synthesis; | 7.97 | 4.26 | 1.87 |
| Butabarbital | DB00237 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Thiamine metabolism; | 7.78 | 3.49 | 2.23 |
| Rilmenidine | DB11738 | DRD2;CYP2C9;HTR1F; | Systemic lupus erythematosus;Alcoholism;Drug metabolism - cytochrome P450; | 7.53 | 3.73 | 2.02 |
| Guanabenz | DB00629 | DRD2;SLC22A1;HTR1F; | Neutrophil extracellular trap formation;Alcoholism;African trypanosomiasis; | 7.52 | 3.07 | 2.45 |
| Pitolisant | DB11642 | DRD2;SLC6A4;PSMB5; | Non-alcoholic fatty liver disease;Thermogenesis;Pantothenate and CoA biosynthesis; | 7.04 | 2.38 | 2.96 |
| Proguanil | DB01131 | CA2;SLC22A1;TYMS; | Alcoholism;Pyrimidine metabolism;Neutrophil extracellular trap formation; | 6.93 | 2.72 | 2.55 |
| Butalbital | DB00241 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Thiamine metabolism; | 6.91 | 3.49 | 1.98 |
| Sevoflurane | DB01236 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Thiamine metabolism; | 6.91 | 3.49 | 1.98 |
| Talbutal | DB00306 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Thiamine metabolism; | 6.91 | 3.49 | 1.98 |
| Liothyronine | DB00279 | NR1I2;NR1H3;RARB; | Calcium signaling pathway;Cushing syndrome;Parkinson disease; | 6.88 | 4.81 | 1.43 |
| Pioglitazone | DB01132 | CYP2C9;PIM2;RARB; | Systemic lupus erythematosus;Alcoholism;Toxoplasmosis; | 6.87 | 3.35 | 2.05 |
| Bupropion | DB01156 | DRD2;SLC6A4;SLC6A1; | Non-alcoholic fatty liver disease;Complement and coagulation cascades;Glycosphingolipid biosynthesis - ganglio series; | 6.82 | 3.07 | 2.22 |
| Phenmetrazine | DB00830 | DRD2;SLC6A4;SLC6A1; | Non-alcoholic fatty liver disease;Complement and coagulation cascades;Glycosphingolipid biosynthesis - ganglio series; | 6.82 | 3.07 | 2.22 |
| Xanthinol | DB09092 | GAPDH;MDH2;IDH3A; | Prion disease;Calcium signaling pathway;Alzheimer disease; | 6.28 | 5.28 | 1.19 |
| Fluvoxamine | DB00176 | CYP2C9;SLC6A4;SLC6A1; | Systemic lupus erythematosus;Neutrophil extracellular trap formation;Complement and coagulation cascades; | 5.97 | 2.56 | 2.33 |
| Degarelix | DB06699 | BIRC4;BIRC3;MC3R; | RNA polymerase;Human immunodeficiency virus 1 infection;Cholinergic synapse; | 5.85 | 3.90 | 1.5 |
| Minoxidil | DB00350 | PIK3CB;KCNJ1;KCNJ10; | Glyoxylate and dicarboxylate metabolism;B cell receptor signaling pathway;Aminoacyl-tRNA biosynthesis; | 5.85 | 3.50 | 1.67 |
| Betazole | DB00272 | ADRB2;HTR1F;QPCT; | Natural killer cell mediated cytotoxicity;Antigen processing and presentation;Amoebiasis; | 5.59 | 5.76 | 0.97 |
| Histamine | DB05381 | ADRB2;HTR1F;QPCT; | Natural killer cell mediated cytotoxicity;Antigen processing and presentation;Amoebiasis; | 5.59 | 5.76 | 0.97 |
| Amobarbital | DB01351 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Thiamine metabolism; | 5.55 | 3.49 | 1.59 |
| Butobarbital | DB01353 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Thiamine metabolism; | 5.55 | 3.49 | 1.59 |
| Tolazamide | DB00839 | ALB;KCNJ1;KCNJ10; | Aminoacyl-tRNA biosynthesis;Necroptosis;IL-17 signaling pathway; | 5.54 | 4.90 | 1.13 |
| Tiagabine | DB00906 | CA2;SLC6A4;SLC6A1; | Complement and coagulation cascades;Collecting duct acid secretion;ABC transporters; | 5.37 | 2.14 | 2.51 |
| Levamisole | DB00848 | CYP19A1;ALPL;CRHBP; | VEGF signaling pathway;Natural killer cell mediated cytotoxicity;Human immunodeficiency virus 1 infection; | 5.26 | 2.96 | 1.78 |
| Acetazolamide | DB00819 | CA2;CA4;CRHBP; | Complement and coagulation cascades;Neutrophil extracellular trap formation;African trypanosomiasis; | 4.81 | 2.14 | 2.25 |
| Fondaparinux | DB00569 | F2;PROZ;SERPINB1; | Th17 cell differentiation;Th1 and Th2 cell differentiation;PI3K-Akt signaling pathway; | 4.63 | 5.03 | 0.92 |
| Dotatate-gallium-Ga-68 | DB13925 | CXCR4;AGTR2;C5AR1; | Transcriptional misregulation in cancer;Apoptosis;Viral protein interaction with cytokine and cytokine receptor; | 4.43 | 6.81 | 0.65 |
| Thiopental | DB00599 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Thiamine metabolism; | 4.36 | 3.49 | 1.25 |
| Quinethazone | DB01325 | CA2;CA4;PSEN1; | Complement and coagulation cascades;RNA transport;Neutrophil extracellular trap formation; | 4.09 | 1.86 | 2.2 |
| Zopiclone | DB01198 | KIF11;GABRB3;GABRE; | Thiamine metabolism;Primary immunodeficiency;Cell cycle; | 3.78 | 2.76 | 1.37 |
| Gonadorelin | DB00644 | GSK3B;MC3R;CBX7; | Fluid shear stress and atherosclerosis;Starch and sucrose metabolism;Notch signaling pathway; | 3.74 | 1.87 | 2 |
| Viloxazine | DB09185 | PDE4B;SLC6A4;SLC6A1; | Complement and coagulation cascades;Glycosphingolipid biosynthesis - ganglio series;Thermogenesis; | 3.64 | 1.68 | 2.16 |
| Cefaclor | DB00833 | CA2;TEK;G6PD; | Complement and coagulation cascades;Sulfur relay system;Sulfur metabolism; | 3.52 | 1.33 | 2.65 |
| Cyclacillin | DB01000 | CA2;TEK;G6PD; | Complement and coagulation cascades;Sulfur relay system;Sulfur metabolism; | 3.52 | 1.33 | 2.65 |
| Dalfampridine | DB06637 | KCNA3;KCNA6;KCNS2; | RNA polymerase;Ribosome;Huntington disease; | 2.94 | 3.63 | 0.81 |
| Fructose | DB04173 | PYGL;SLC5A1;SLC2A5; | Inflammatory bowel disease;Transcriptional misregulation in cancer;Carbohydrate digestion and absorption; | 2.90 | 4.27 | 0.68 |
| Dexfenfluramine | DB01191 | SLC6A4;HTR1F;SLC6A1; | Complement and coagulation cascades;Glycosphingolipid biosynthesis - ganglio series;Thermogenesis; | 2.88 | 1.68 | 1.71 |
| Cephaloglycin | DB00689 | CA2;TEK;DNMT1; | "Complement and coagulation cascades;Valine, leucine and isoleucine degradation;Sulfur relay system;" | 2.74 | 1.17 | 2.34 |
| Cefprozil | DB01150 | CA2;TEK;ANPEP; | Complement and coagulation cascades;Malaria;Renin secretion; | 2.67 | 1.17 | 2.28 |
| Pregabalin | DB00230 | ALPL;CACNB3;SLC36A1; | Complement and coagulation cascades;Th17 cell differentiation;Th1 and Th2 cell differentiation; | 2.47 | 2.74 | 0.9 |
| Hydroxocobalamin | DB00200 | MTR;TCN1;NOTCH2NL; | Phagosome;Th1 and Th2 cell differentiation;Human immunodeficiency virus 1 infection; | 2.20 | 7.32 | 0.3 |
| Ferric-maltol | DB15598 | ITGB2;ITGB8;SLC11A2; | Malaria;Natural killer cell mediated cytotoxicity;T cell receptor signaling pathway; | 2.10 | 3.14 | 0.67 |
| Triptorelin | DB06825 | TLR2;MC3R;CBX7; | Notch signaling pathway;Neutrophil extracellular trap formation;Terpenoid backbone biosynthesis; | 1.74 | 1.43 | 1.22 |
| Amifampridine | DB11640 | KCNA3;KCNA6;KCNS2; | RNA polymerase;Ribosome;Huntington disease; | 1.09 | 3.63 | 0.3 |
| Difluprednate | DB06781 | RAF1;FNTA;IL1B; | Cushing syndrome;Aldosterone synthesis and secretion;Calcium signaling pathway; | 45.48 | 15.21 | 2.99 |
| Lercanidipine | DB00528 | ABCB1;CYP2C9;MDH1; | Kaposi sarcoma-associated herpesvirus infection;Alcoholism;Systemic lupus erythematosus; | 24.46 | 9.16 | 2.67 |
| Ciclopirox | DB01188 | HDAC1;MAPK14;MMP9; | Amoebiasis;Th1 and Th2 cell differentiation;T cell receptor signaling pathway; | 22.87 | 5.56 | 4.11 |
| Quinestrol | DB04575 | HDAC2;HDAC1;PLA2G7; | RNA transport;Th1 and Th2 cell differentiation;Amoebiasis; | 19.46 | 6.01 | 3.24 |
| Mestranol | DB01357 | HDAC2;HDAC1;CYP2C9; | RNA transport;Systemic lupus erythematosus;Th1 and Th2 cell differentiation; | 19.40 | 4.79 | 4.05 |
| Romidepsin | DB06176 | HDAC2;HDAC1;PAK1; | RNA transport;Amoebiasis;Th1 and Th2 cell differentiation; | 19.12 | 4.45 | 4.3 |
| Upadacitinib | DB15091 | JAK1;MAPK14;CYP2C9; | Systemic lupus erythematosus;NF-kappa B signaling pathway;Alcoholism; | 18.91 | 4.36 | 4.34 |
| Torasemide | DB00214 | CA2;ADRB2;PBEF1; | Malaria;Pentose phosphate pathway;Natural killer cell mediated cytotoxicity; | 18.38 | 6.03 | 3.05 |
| Cefapirin | DB01139 | ELA2;ALB;DNMT1; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Necroptosis; | 18.36 | 7.29 | 2.52 |
| Desogestrel | DB00304 | IGF1R;CYP19A1;INSR; | Rap1 signaling pathway;Ovarian steroidogenesis;VEGF signaling pathway; | 18.06 | 4.74 | 3.81 |
| Rosuvastatin | DB01098 | HDAC2;HDAC1;ITGAM; | Th1 and Th2 cell differentiation;RNA transport;Th17 cell differentiation; | 18.05 | 5.71 | 3.16 |
| Grazoprevir | DB11575 | ELA2;CTSS;JARID1A; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Human immunodeficiency virus 1 infection; | 17.47 | 6.64 | 2.63 |
| Orlistat | DB01083 | PRKCA;PRKCE;LIPA; | Tuberculosis;Autoimmune thyroid disease;Phagosome; | 17.22 | 8.32 | 2.07 |
| Simeprevir | DB06290 | HDAC1;CTSS;JARID1A; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Amoebiasis; | 16.26 | 5.38 | 3.02 |
| Terlipressin | DB02638 | HDAC1;PARP1;CYP2C9; | Systemic lupus erythematosus;Amoebiasis;Th1 and Th2 cell differentiation; | 15.81 | 3.97 | 3.98 |
| Tolcapone | DB00323 | ALOX5;HSP90AB1;ALOX5AP; | Spliceosome;Fc epsilon RI signaling pathway;Apelin signaling pathway; | 15.39 | 6.66 | 2.31 |
| Boceprevir | DB08873 | ELA2;F2;CTSS; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Human immunodeficiency virus 1 infection; | 14.73 | 5.30 | 2.78 |
| Oxetacaine | DB12532 | HDAC1;SIRT1;UBE2N; | RNA transport;Amoebiasis;Th1 and Th2 cell differentiation; | 13.54 | 4.59 | 2.95 |
| Amylmetacresol | DB13908 | ALOX5;CA2;ALOX12; | Spliceosome;Platelet activation;Tight junction; | 12.98 | 4.75 | 2.73 |
| Oxyphencyclimine | DB00383 | PIK3CB;SLC22A1;JARID1A; | Glyoxylate and dicarboxylate metabolism;Spliceosome;Neutrophil extracellular trap formation; | 12.89 | 4.00 | 3.22 |
| Guaiacol | DB11359 | CA2;ALB;CA4; | Necroptosis;Complement and coagulation cascades;Prion disease; | 12.62 | 4.02 | 3.14 |
| Tetracaine | DB09085 | HDAC1;SLC22A1;RYR2; | Th1 and Th2 cell differentiation;Amoebiasis;Neutrophil extracellular trap formation; | 12.62 | 4.25 | 2.97 |
| Pramipexole | DB00413 | DRD2;ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 12.30 | 4.30 | 2.86 |
| Huperzine-A | DB04864 | LCK;SIRT1;NLGN2; | Th1 and Th2 cell differentiation;Th17 cell differentiation;RNA transport; | 12.22 | 5.63 | 2.17 |
| Carteolol | DB00521 | DRD2;ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 12.08 | 4.30 | 2.81 |
| Vilanterol | DB09082 | DRD2;ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 12.08 | 4.30 | 2.81 |
| Cilazapril | DB01340 | DRD2;ITGA2B;F2R; | Platelet activation;Tight junction;Regulation of actin cytoskeleton; | 12.03 | 4.91 | 2.45 |
| Hydrochlorothiazide | DB00999 | CA2;ALB;CA4; | Necroptosis;Complement and coagulation cascades;Prion disease; | 11.70 | 4.02 | 2.91 |
| Chlorpropamide | DB00672 | CYP2C9;ALB;F2; | Systemic lupus erythematosus;Necroptosis;Alcoholism; | 11.53 | 3.91 | 2.95 |
| Glucosamine | DB01296 | MMP9;TNF;PSMD10; | Staphylococcus aureus infection;NOD-like receptor signaling pathway;Inflammatory bowel disease; | 11.37 | 4.15 | 2.74 |
| Clodronic-acid | DB00720 | MMP9;SLC25A5;SLC25A6; | Ribosome;Coronavirus disease - COVID-19;Inflammatory bowel disease; | 11.22 | 4.60 | 2.44 |
| Omadacycline | DB12455 | ALB;PADI4;GRK6; | Necroptosis;Th1 and Th2 cell differentiation;Inflammatory bowel disease; | 10.77 | 6.22 | 1.73 |
| Clindamycin | DB01190 | ALB;PADI4;TTRAP; | Necroptosis;Salivary secretion;Inflammatory bowel disease; | 10.41 | 5.88 | 1.77 |
| Lincomycin | DB01627 | ALB;PADI4;TTRAP; | Necroptosis;Salivary secretion;Inflammatory bowel disease; | 10.41 | 5.88 | 1.77 |
| Rasagiline | DB01367 | DRD2;BCL2;BCL2L1; | Phagosome;Ubiquitin mediated proteolysis;Tuberculosis; | 10.38 | 3.57 | 2.91 |
| Testolactone | DB00894 | CYP19A1;AKR1B1;F2R; | Glutathione metabolism;VEGF signaling pathway;Chemical carcinogenesis; | 10.35 | 3.59 | 2.88 |
| Mefloquine | DB00358 | ADRB2;CYP2C9;UBE2N; | Systemic lupus erythematosus;Pentose phosphate pathway;Natural killer cell mediated cytotoxicity; | 10.14 | 4.70 | 2.16 |
| Clenbuterol | DB01407 | ADRB2;TNF;HTR1F; | Natural killer cell mediated cytotoxicity;Pentose phosphate pathway;Antigen processing and presentation; | 10.08 | 3.45 | 2.92 |
| Thonzylamine | DB11235 | DRD2;CYP2C9;SLC6A4; | Systemic lupus erythematosus;Neutrophil extracellular trap formation;Non-alcoholic fatty liver disease; | 9.95 | 3.09 | 3.22 |
| Metocurine | DB01336 | HDAC1;NMUR1;XPA; | Th1 and Th2 cell differentiation;Amoebiasis;Viral protein interaction with cytokine and cytokine receptor; | 9.69 | 5.10 | 1.9 |
| Metocurine-iodide | DB00416 | HDAC1;NMUR1;XPA; | Th1 and Th2 cell differentiation;Amoebiasis;Viral protein interaction with cytokine and cytokine receptor; | 9.69 | 5.10 | 1.9 |
| Vecuronium | DB01339 | CA2;ABCB1;SLC22A1; | Neutrophil extracellular trap formation;Alcoholism;Complement and coagulation cascades; | 9.61 | 2.88 | 3.34 |
| Quinagolide | DB09097 | DRD2;ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Graft-versus-host disease; | 9.46 | 4.30 | 2.2 |
| Ulobetasol | DB00596 | ABCB1;CYP2C9;NR3C2; | Systemic lupus erythematosus;Cytosolic DNA-sensing pathway;Alcoholism; | 9.45 | 2.92 | 3.24 |
| Ornithine | DB00129 | KIF11;ARG1;OAZ1; | Th1 and Th2 cell differentiation;Influenza A;Primary immunodeficiency; | 9.40 | 7.90 | 1.19 |
| Isopropamide | DB01625 | DRD2;ABCB1;SOAT1; | B cell receptor signaling pathway;Glyoxylate and dicarboxylate metabolism;Thiamine metabolism; | 9.22 | 3.45 | 2.67 |
| Dapsone | DB00250 | CYP19A1;CA2;CA4; | Complement and coagulation cascades;VEGF signaling pathway;Human immunodeficiency virus 1 infection; | 9.11 | 2.86 | 3.18 |
| Emtricitabine | DB00879 | ALB;CXCR4;DCK; | Necroptosis;Non-alcoholic fatty liver disease;Herpes simplex virus 1 infection; | 8.90 | 4.78 | 1.86 |
| Lamivudine | DB00709 | ALB;CXCR4;DCK; | Necroptosis;Non-alcoholic fatty liver disease;Herpes simplex virus 1 infection; | 8.90 | 4.78 | 1.86 |
| Clidinium | DB00771 | SLC22A1;JARID1A;FKBP1A; | Neutrophil extracellular trap formation;Alcoholism;NF-kappa B signaling pathway; | 8.73 | 3.91 | 2.23 |
| Cyclopentolate | DB00979 | BCL2;SLC6A4;BCL2L1; | Phagosome;Oxidative phosphorylation;Thermogenesis; | 8.69 | 3.01 | 2.89 |
| Fluocinolone-acetonide | DB00591 | NR3C2;ANXA3;ANXA5; | Th1 and Th2 cell differentiation;Amoebiasis;T cell receptor signaling pathway; | 8.60 | 6.37 | 1.35 |
| Olsalazine | DB01250 | AKR1C3;PTPN6;DNMT1; | "Valine, leucine and isoleucine degradation;Th1 and Th2 cell differentiation;Inflammatory bowel disease;" | 8.55 | 4.28 | 2 |
| Cefotaxime | DB00493 | ALB;SLC22A1;DNMT1; | Necroptosis;Neutrophil extracellular trap formation;Alcoholism; | 8.44 | 4.18 | 2.02 |
| Resorcinol | DB11085 | CA2;CA4;MPO; | Transcriptional misregulation in cancer;Sphingolipid signaling pathway;Complement and coagulation cascades; | 7.84 | 3.27 | 2.4 |
| Diethylcarbamazine | DB00711 | ALOX5;ALOX12;ALOX12B; | Spliceosome;Platelet activation;Tight junction; | 7.79 | 4.53 | 1.72 |
| Levamlodipine | DB09237 | ABCB1;NR3C2;UBE2N; | Cytosolic DNA-sensing pathway;NF-kappa B signaling pathway;Thiamine metabolism; | 7.77 | 2.73 | 2.84 |
| Rescinnamine | DB01180 | DRD2;ABCB1;FKBP5; | Thiamine metabolism;Galactose metabolism;Pantothenate and CoA biosynthesis; | 7.73 | 3.10 | 2.49 |
| Sitagliptin | DB01261 | ANPEP;DPP8;PEPD; | cAMP signaling pathway;Human cytomegalovirus infection;Regulation of lipolysis in adipocytes; | 7.67 | 10.65 | 0.72 |
| Selegiline | DB01037 | CDK1;DRD2;CDK8; | Cell cycle;Oxidative phosphorylation;Leishmaniasis; | 7.43 | 2.41 | 3.08 |
| Gallium-nitrate | DB05260 | IL1B;RRM2B;RRM2; | Pyrimidine metabolism;Cushing syndrome;Human cytomegalovirus infection; | 7.31 | 6.20 | 1.18 |
| Desonide | DB01260 | CYP2C9;NR3C2;SLC22A1; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 7.15 | 2.23 | 3.2 |
| Citrulline | DB00155 | INSR;PADI4;CHKA; | Inflammatory bowel disease;Graft-versus-host disease;T cell receptor signaling pathway; | 7.09 | 3.46 | 2.05 |
| Esketamine | DB11823 | SLC6A4;GRIN2D;EEF2; | Ribosome;Coronavirus disease - COVID-19;Calcium signaling pathway; | 6.78 | 3.85 | 1.76 |
| Troleandomycin | DB13179 | ABCB1;NR1I2;RARB; | Thiamine metabolism;Thyroid hormone signaling pathway;Hepatitis B; | 6.71 | 2.79 | 2.41 |
| Methoxamine | DB00723 | ADRB2;LTA4H;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 6.66 | 3.72 | 1.79 |
| Midodrine | DB00211 | ADRB2;LTA4H;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 6.66 | 3.72 | 1.79 |
| Lactulose | DB00581 | CA2;MGAM;QPCT; | Natural killer cell mediated cytotoxicity;Amoebiasis;Th1 and Th2 cell differentiation; | 6.58 | 4.04 | 1.63 |
| Benzodiazepine | DB12537 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Wnt signaling pathway; | 6.30 | 3.00 | 2.1 |
| Ethchlorvynol | DB00189 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Wnt signaling pathway; | 6.30 | 3.00 | 2.1 |
| Meprobamate | DB00371 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Wnt signaling pathway; | 6.30 | 3.00 | 2.1 |
| Quazepam | DB01589 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Wnt signaling pathway; | 6.30 | 3.00 | 2.1 |
| Taurine | DB01956 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Wnt signaling pathway; | 6.30 | 3.00 | 2.1 |
| Etoposide | DB00773 | ABCB1;TOP2A;NCOA1; | Lysosome;Thiamine metabolism;Thyroid hormone signaling pathway; | 6.30 | 2.92 | 2.16 |
| Teniposide | DB00444 | ABCB1;TOP2A;NCOA1; | Lysosome;Thiamine metabolism;Thyroid hormone signaling pathway; | 6.30 | 2.92 | 2.16 |
| Dabigatran-etexilate | DB06695 | F2;ITGA2B;NQO2; | Platelet activation;Tight junction;Complement and coagulation cascades; | 6.17 | 2.80 | 2.2 |
| Amcinonide | DB00288 | AKR1B1;ANXA3;ANXA5; | Glutathione metabolism;Amoebiasis;Th1 and Th2 cell differentiation; | 6.15 | 6.34 | 0.97 |
| Miglitol | DB00491 | ITGA2B;MGAM;AGL; | Platelet activation;Th1 and Th2 cell differentiation;Th17 cell differentiation; | 5.96 | 4.70 | 1.27 |
| Mecamylamine | DB00657 | DRD2;SLC6A4;GNA15; | Non-alcoholic fatty liver disease;Ubiquitin mediated proteolysis;Thermogenesis; | 5.93 | 2.43 | 2.44 |
| Manidipine | DB09238 | CA2;ABCB1;CACNB3; | Complement and coagulation cascades;Thiamine metabolism;Thyroid hormone signaling pathway; | 5.71 | 2.16 | 2.64 |
| Ceftriaxone | DB01212 | CA2;CYP2C9;SLC22A1; | Systemic lupus erythematosus;Alcoholism;Neutrophil extracellular trap formation; | 5.05 | 1.98 | 2.55 |
| Cystine | DB00138 | DRD2;SLC6A4;SLC7A6; | Non-alcoholic fatty liver disease;Thermogenesis;Pantothenate and CoA biosynthesis; | 4.91 | 2.21 | 2.22 |
| Atazanavir | DB01072 | ABCB1;F2;PSEN1; | Complement and coagulation cascades;Thiamine metabolism;Thyroid hormone signaling pathway; | 4.86 | 1.69 | 2.88 |
| Camphor | DB01744 | EGLN1;TRPV2;PSMD10; | Hematopoietic cell lineage;Th17 cell differentiation;Th1 and Th2 cell differentiation; | 4.61 | 4.61 | 1 |
| Trifluridine | DB00432 | G6PD;TYMS;TK1; | Pyrimidine metabolism;p53 signaling pathway;Drug metabolism - other enzymes; | 4.50 | 2.59 | 1.74 |
| Teriflunomide | DB08880 | CYP2C9;CTSS;DHFR; | Systemic lupus erythematosus;Alcoholism;Biosynthesis of amino acids; | 4.47 | 2.02 | 2.22 |
| Cyclothiazide | DB00606 | CA2;CA4;CA11; | Complement and coagulation cascades;Neutrophil extracellular trap formation;African trypanosomiasis; | 4.33 | 1.80 | 2.4 |
| Diclofenamide | DB01144 | CA2;CA4;CA11; | Complement and coagulation cascades;Neutrophil extracellular trap formation;African trypanosomiasis; | 4.33 | 1.80 | 2.4 |
| Lenalidomide | DB00480 | CYP19A1;CDH24;CRBN; | VEGF signaling pathway;Legionellosis;Human immunodeficiency virus 1 infection; | 4.16 | 2.97 | 1.4 |
| Gemcitabine | DB00441 | TYMS;DCK;CDA; | Tuberculosis;Pyrimidine metabolism;Herpes simplex virus 1 infection; | 3.97 | 4.67 | 0.85 |
| Brivudine | DB03312 | G6PD;TK1;DCK; | Tuberculosis;Drug metabolism - other enzymes;Herpes simplex virus 1 infection; | 3.91 | 3.13 | 1.25 |
| Pyrazinamide | DB00339 | PARP1;SIRT1;CAPN1; | RNA transport;Staphylococcus aureus infection;Axon guidance; | 3.81 | 1.45 | 2.62 |
| Silodosin | DB06207 | ADRB2;HTR1F;SCD; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 3.77 | 3.56 | 1.06 |
| Guanfacine | DB01018 | DRD2;HTR1F;NISCH; | Taste transduction;Pantothenate and CoA biosynthesis;Hepatitis C; | 3.44 | 2.75 | 1.25 |
| Moxonidine | DB09242 | DRD2;HTR1F;NISCH; | Taste transduction;Pantothenate and CoA biosynthesis;Hepatitis C; | 3.44 | 2.75 | 1.25 |
| Lipoic-acid | DB00166 | AKR1B1;LIPT1;LIAS; | Glutathione metabolism;RIG-I-like receptor signaling pathway;Malaria; | 3.30 | 2.80 | 1.18 |
| Fospropofol | DB06716 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Wnt signaling pathway; | 3.30 | 3.00 | 1.1 |
| Ivermectin | DB00602 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Wnt signaling pathway; | 3.30 | 3.00 | 1.1 |
| Ethinamate | DB01031 | CA2;CA4;CA11; | Complement and coagulation cascades;Neutrophil extracellular trap formation;African trypanosomiasis; | 3.08 | 1.80 | 1.71 |
| Sodium-sulfate | DB09472 | CA2;CA4;CA11; | Complement and coagulation cascades;Neutrophil extracellular trap formation;African trypanosomiasis; | 3.08 | 1.80 | 1.71 |
| Pyridoxal-phosphate | DB00114 | PYGL;GADL1;ALAS2; | Inflammatory bowel disease;Transcriptional misregulation in cancer;Mitophagy - animal; | 2.88 | 4.00 | 0.72 |
| Lisdexamfetamine | DB01255 | ADRB2;HTR1F;ERAP2; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 2.61 | 3.23 | 0.81 |
| Isoflurophate | DB00677 | NLGN2;CTSA;LTF; | Endocytosis;Necroptosis;Olfactory transduction; | 2.14 | 4.37 | 0.49 |
| Carisoprodol | DB00395 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Wnt signaling pathway; | 2.01 | 3.00 | 0.67 |
| gamma-Hydroxybutyric-acid | DB01440 | GABRA4;GABRB3;GABRE; | Morphine addiction;Adherens junction;Wnt signaling pathway; | 2.01 | 3.00 | 0.67 |
| Creatine | DB00148 | SLC6A4;SLC6A1;SLC6A8; | Complement and coagulation cascades;Glycosphingolipid biosynthesis - ganglio series;Thermogenesis; | 1.89 | 1.68 | 1.12 |
| Hexocyclium | DB06787 | SLC6A4;NRP1;NMUR1; | Thermogenesis;Pathways of neurodegeneration - multiple diseases;Diabetic cardiomyopathy; | 1.78 | 0.99 | 1.79 |
| Phylloquinone | DB01022 | EGLN1;SOAT1;POLM; | B cell receptor signaling pathway;Glyoxylate and dicarboxylate metabolism;PI3K-Akt signaling pathway; | 1.74 | 1.40 | 1.24 |
| N-Acetylglucosamine | DB00141 | B4GALT1;B4GALT6;B4GALT5; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Hematopoietic cell lineage; | 1.57 | 4.03 | 0.39 |
| Guanethidine | DB01170 | SLC6A4;SLC6A1;SLC6A8; | Complement and coagulation cascades;Glycosphingolipid biosynthesis - ganglio series;Thermogenesis; | 1.57 | 1.68 | 0.93 |
| Ivosidenib | DB14568 | CTSS;PTGES;ENPP2; | Thiamine metabolism;Biosynthesis of amino acids;Arginine biosynthesis; | 1.54 | 0.83 | 1.86 |
| Benzylpenicilloyl-polylysine | DB00895 | FCGR3B;FCGR3A;FCGR2C; | RNA transport;Osteoclast differentiation;Natural killer cell mediated cytotoxicity; | 1.51 | 2.75 | 0.55 |
| Dactinomycin | DB00970 | TOP2A;SLC1A3;SLC1A1; | Complement and coagulation cascades;Glycerophospholipid metabolism;Malaria; | 1.45 | 1.50 | 0.97 |
| Glimepiride | DB00222 | KCNJ1;KCNJ10;KCNJ15; | Aminoacyl-tRNA biosynthesis;Thiamine metabolism;Starch and sucrose metabolism; | 1.45 | 2.54 | 0.57 |
| Riboflavin | DB00140 | ASAH1;RFK;BLVRB; | RNA transport;Autophagy - other;Malaria; | 1.45 | 2.54 | 0.57 |
| Streptozocin | DB00428 | MGEA5;SLC2A3;SLC2A5; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Th17 cell differentiation; | 1.45 | 4.02 | 0.36 |
| Cefadroxil | DB01140 | CA2;TEK;TST; | Complement and coagulation cascades;Sulfur relay system;Sulfur metabolism; | 1.42 | 0.64 | 2.23 |
| Cefradine | DB01333 | CA2;TEK;TST; | Complement and coagulation cascades;Sulfur relay system;Sulfur metabolism; | 1.42 | 0.64 | 2.23 |
| Taurocholic-acid | DB04348 | CA2;NR1H3;RARB; | Complement and coagulation cascades;African trypanosomiasis;Circadian rhythm; | 1.20 | 0.81 | 1.48 |
| Dimethyl-fumarate | DB08908 | KEAP1;IPP;KLHL20; | Salmonella infection;Hepatitis C;Asthma; | 1.10 | 3.05 | 0.36 |
| Sodium-tetradecyl-sulfate | DB00464 | PROZ;PRTN3;GZMM; | Amoebiasis;NF-kappa B signaling pathway;Th1 and Th2 cell differentiation; | 1.00 | 8.29 | 0.12 |
| Epoprostenol | DB01240 | CYP8B1;CYP7A1;GPR171; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;RNA polymerase; | 0.73 | 4.87 | 0.15 |
| Pilocarpine | DB01085 | PRKCA;PRKCE; | Tuberculosis;Autoimmune thyroid disease;Phagosome; | 15.57 | 6.51 | 2.39 |
| Pravastatin | DB00175 | HDAC2;HDAC1; | RNA transport;Th1 and Th2 cell differentiation;Amoebiasis; | 15.01 | 3.81 | 3.94 |
| Glycol-salicylate | DB11323 | CA2;HSP90AB1; | Kaposi sarcoma-associated herpesvirus infection;Apelin signaling pathway;Chemokine signaling pathway; | 13.20 | 5.52 | 2.39 |
| Asunaprevir | DB11586 | ELA2;PPP3CB; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Human immunodeficiency virus 1 infection; | 10.39 | 5.25 | 1.98 |
| Cefdinir | DB00535 | ALB;MPO; | Necroptosis;Prion disease;Graft-versus-host disease; | 10.21 | 4.27 | 2.39 |
| Bimatoprost | DB00905 | CA2;AKR1C3; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;Complement and coagulation cascades; | 9.56 | 3.81 | 2.51 |
| Latanoprostene-bunod | DB11660 | CA2;AKR1C3; | Th1 and Th2 cell differentiation;Inflammatory bowel disease;Complement and coagulation cascades; | 9.56 | 3.81 | 2.51 |
| Zanamivir | DB00558 | CYP19A1;FNTA; | Calcium signaling pathway;RNA transport;VEGF signaling pathway; | 9.50 | 3.61 | 2.63 |
| Pentostatin | DB00552 | DRD2;RNASE2; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Amoebiasis; | 9.28 | 6.14 | 1.51 |
| Acyclovir | DB00787 | HSP90AB1;TK1; | Phagosome;Kaposi sarcoma-associated herpesvirus infection;Drug metabolism - other enzymes; | 9.15 | 6.23 | 1.47 |
| Bromfenac | DB00963 | AKR1C3;AKR1B1; | Glutathione metabolism;Th1 and Th2 cell differentiation;Inflammatory bowel disease; | 8.44 | 3.92 | 2.15 |
| Fosinopril | DB00492 | HDAC1;FKBP1A; | Th1 and Th2 cell differentiation;Amoebiasis;NF-kappa B signaling pathway; | 8.28 | 3.66 | 2.26 |
| Atovaquone | DB01117 | HSP90AB1;PTPRC; | Kaposi sarcoma-associated herpesvirus infection;Apelin signaling pathway;Chemokine signaling pathway; | 8.09 | 5.39 | 1.5 |
| Cinoxacin | DB00827 | MMP9;CA2; | Complement and coagulation cascades;Inflammatory bowel disease;T cell receptor signaling pathway; | 7.93 | 2.84 | 2.79 |
| Daclatasvir | DB09102 | CYP2C9;BCL2; | Systemic lupus erythematosus;Phagosome;Alcoholism; | 7.31 | 2.81 | 2.6 |
| Elbasvir | DB11574 | CYP2C9;BCL2; | Systemic lupus erythematosus;Phagosome;Alcoholism; | 7.31 | 2.81 | 2.6 |
| Ledipasvir | DB09027 | CYP2C9;BCL2; | Systemic lupus erythematosus;Phagosome;Alcoholism; | 7.31 | 2.81 | 2.6 |
| Velpatasvir | DB11613 | CYP2C9;BCL2; | Systemic lupus erythematosus;Phagosome;Alcoholism; | 7.31 | 2.81 | 2.6 |
| Pyridostigmine | DB00545 | ALB;NLGN2; | Necroptosis;Prion disease;Endocytosis; | 7.15 | 4.52 | 1.58 |
| Oxandrolone | DB00621 | CYP19A1;F2R; | VEGF signaling pathway;Human immunodeficiency virus 1 infection;Oocyte meiosis; | 6.30 | 2.84 | 2.22 |
| Isosorbide | DB09401 | BCL2;BCL2L1; | Phagosome;Tuberculosis;Human immunodeficiency virus 1 infection; | 6.13 | 2.18 | 2.81 |
| Triflusal | DB08814 | CA2;ITGA2B; | Platelet activation;Complement and coagulation cascades;Tight junction; | 6.13 | 2.77 | 2.21 |
| Rapacuronium | DB04834 | ABCB1;SLC22A1; | Neutrophil extracellular trap formation;Alcoholism;Thiamine metabolism; | 6.12 | 2.24 | 2.73 |
| Nadolol | DB01203 | ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 5.89 | 2.92 | 2.02 |
| Nebivolol | DB04861 | ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 5.89 | 2.92 | 2.02 |
| Timolol | DB00373 | ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 5.89 | 2.92 | 2.02 |
| Cinacalcet | DB01012 | DRD2;SLC6A4; | Non-alcoholic fatty liver disease;Thermogenesis;Pantothenate and CoA biosynthesis; | 5.77 | 2.21 | 2.61 |
| Ticagrelor | DB08816 | CYP2C9;GPR171; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Systemic lupus erythematosus; | 5.70 | 4.25 | 1.34 |
| Venetoclax | DB11581 | BCL2;BCL2L1; | Phagosome;Tuberculosis;Human immunodeficiency virus 1 infection; | 5.57 | 2.18 | 2.55 |
| Meropenem | DB00760 | ITGA2B;F2R; | Platelet activation;Tight junction;Regulation of actin cytoskeleton; | 5.56 | 3.52 | 1.58 |
| Protirelin | DB09421 | PARP1;ITGA2B; | Platelet activation;Tight junction;Regulation of actin cytoskeleton; | 5.52 | 2.14 | 2.58 |
| Spirapril | DB01348 | DRD2;SIRT1; | RNA transport;Staphylococcus aureus infection;Pantothenate and CoA biosynthesis; | 5.45 | 2.28 | 2.39 |
| Flurandrenolide | DB00846 | NR3C2;SLC22A1; | Neutrophil extracellular trap formation;Alcoholism;Cytosolic DNA-sensing pathway; | 5.43 | 2.09 | 2.6 |
| Dyphylline | DB00651 | ADRB2;PDE4B; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 5.41 | 2.64 | 2.05 |
| Anastrozole | DB01217 | CYP19A1;CTSS; | VEGF signaling pathway;Biosynthesis of amino acids;Human immunodeficiency virus 1 infection; | 5.24 | 1.89 | 2.77 |
| Oxybutynin | DB01062 | LTA4H;SLC22A1; | Neutrophil extracellular trap formation;Alcoholism;Necroptosis; | 5.22 | 2.00 | 2.61 |
| Ceftibuten | DB01415 | ALB;DNMT1; | "Necroptosis;Prion disease;Valine, leucine and isoleucine degradation;" | 5.21 | 2.98 | 1.75 |
| Clevidipine | DB04920 | NR3C2;PYGL; | Inflammatory bowel disease;Transcriptional misregulation in cancer;NF-kappa B signaling pathway; | 5.11 | 2.86 | 1.79 |
| Flunisolide | DB00180 | ABCB1;NR3C2; | Cytosolic DNA-sensing pathway;NF-kappa B signaling pathway;Thiamine metabolism; | 5.11 | 1.94 | 2.64 |
| Acarbose | DB00284 | CDK1;MGAM; | Th1 and Th2 cell differentiation;Th17 cell differentiation;T cell receptor signaling pathway; | 5.07 | 2.56 | 1.98 |
| Xamoterol | DB13781 | ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 5.05 | 2.92 | 1.73 |
| Pivampicillin | DB01604 | FNTA;ANPEP; | Calcium signaling pathway;RNA transport;MicroRNAs in cancer; | 4.98 | 3.04 | 1.64 |
| Thonzonium | DB09552 | NR1I2;UBE2N; | Hepatitis B;Glutamatergic synapse;Chronic myeloid leukemia; | 4.93 | 2.54 | 1.94 |
| Rufinamide | DB06201 | PARP1;MPO; | Graft-versus-host disease;Cortisol synthesis and secretion;NF-kappa B signaling pathway; | 4.93 | 1.82 | 2.7 |
| Decamethonium | DB01245 | SLC22A1;NLGN2; | Alcoholism;Neutrophil extracellular trap formation;Endocytosis; | 4.87 | 3.29 | 1.48 |
| Glycine-betaine | DB06756 | BCL2;BCL2L1; | Phagosome;Tuberculosis;Human immunodeficiency virus 1 infection; | 4.67 | 2.18 | 2.14 |
| 2-mercaptobenzothiazole | DB11496 | CA2;MPO; | Complement and coagulation cascades;Graft-versus-host disease;Cortisol synthesis and secretion; | 4.65 | 2.46 | 1.89 |
| Benserazide | DB12783 | ALPL;UBE2I; | Calcium signaling pathway;Gastric acid secretion;Insulin secretion; | 4.63 | 3.73 | 1.24 |
| Cefditoren | DB01066 | CA2;CYP2C9; | Systemic lupus erythematosus;Complement and coagulation cascades;Alcoholism; | 4.33 | 1.62 | 2.68 |
| Cefmenoxime | DB00267 | CA2;CYP2C9; | Systemic lupus erythematosus;Complement and coagulation cascades;Alcoholism; | 4.33 | 1.62 | 2.68 |
| Ceforanide | DB00923 | CA2;CYP2C9; | Systemic lupus erythematosus;Complement and coagulation cascades;Alcoholism; | 4.33 | 1.62 | 2.68 |
| Aminoglutethimide | DB00357 | PARP1;CYP19A1; | VEGF signaling pathway;Human immunodeficiency virus 1 infection;Oocyte meiosis; | 4.31 | 1.21 | 3.55 |
| Ospemifene | DB04938 | CYP19A1;FKBP1A; | VEGF signaling pathway;NF-kappa B signaling pathway;Human immunodeficiency virus 1 infection; | 4.08 | 2.10 | 1.94 |
| Saxagliptin | DB06335 | CYP2C9;DPP8; | Systemic lupus erythematosus;Alcoholism;Cushing syndrome; | 4.07 | 2.61 | 1.56 |
| Vildagliptin | DB04876 | CYP2C9;DPP8; | Systemic lupus erythematosus;Alcoholism;Cushing syndrome; | 4.07 | 2.61 | 1.56 |
| Deslanoside | DB01078 | CA2;CA4; | Complement and coagulation cascades;Neutrophil extracellular trap formation;African trypanosomiasis; | 3.96 | 1.65 | 2.4 |
| Hydroquinone | DB09526 | CA2;CA4; | Complement and coagulation cascades;Neutrophil extracellular trap formation;African trypanosomiasis; | 3.96 | 1.65 | 2.4 |
| Ertapenem | DB00303 | PTGES;ITGA2B; | Platelet activation;Tight junction;Regulation of actin cytoskeleton; | 3.90 | 2.18 | 1.79 |
| Fesoterodine | DB06702 | LTA4H;UBE2N; | Necroptosis;Herpes simplex virus 1 infection;Glutamatergic synapse; | 3.38 | 1.60 | 2.11 |
| Ipratropium | DB00332 | SLC22A1;CDK8; | Neutrophil extracellular trap formation;Alcoholism;Oxidative phosphorylation; | 3.35 | 1.56 | 2.15 |
| Terbinafine | DB00857 | DRD2;RLBP1; | Leishmaniasis;Pantothenate and CoA biosynthesis;Hepatitis C; | 3.15 | 2.00 | 1.57 |
| Idoxuridine | DB00249 | G6PD;TK1; | Drug metabolism - other enzymes;Pyrimidine metabolism;Phagosome; | 3.13 | 2.16 | 1.45 |
| Metformin | DB00331 | SLC22A1;PRKAB1; | Neutrophil extracellular trap formation;Alcoholism;JAK-STAT signaling pathway; | 3.11 | 1.60 | 1.95 |
| Amprenavir | DB00701 | ABCB1;KCNA3; | RNA polymerase;Huntington disease;Thiamine metabolism; | 3.06 | 1.51 | 2.03 |
| Darunavir | DB01264 | ABCB1;KCNA3; | RNA polymerase;Huntington disease;Thiamine metabolism; | 3.06 | 1.51 | 2.03 |
| Fosamprenavir | DB01319 | ABCB1;KCNA3; | RNA polymerase;Huntington disease;Thiamine metabolism; | 3.06 | 1.51 | 2.03 |
| Moxidectin | DB11431 | CYP2C9;CAPN1; | Systemic lupus erythematosus;Alcoholism;Drug metabolism - cytochrome P450; | 3.02 | 1.63 | 1.85 |
| Cyclophosphamide | DB00531 | NR1I2;RARB; | Hepatitis B;Chronic myeloid leukemia;AGE-RAGE signaling pathway in diabetic complications; | 2.72 | 1.74 | 1.56 |
| Ifosfamide | DB01181 | NR1I2;RARB; | Hepatitis B;Chronic myeloid leukemia;AGE-RAGE signaling pathway in diabetic complications; | 2.72 | 1.74 | 1.56 |
| Permethrin | DB04930 | NR1I2;RARB; | Hepatitis B;Chronic myeloid leukemia;AGE-RAGE signaling pathway in diabetic complications; | 2.72 | 1.74 | 1.56 |
| Rilpivirine | DB08864 | NR1I2;RARB; | Hepatitis B;Chronic myeloid leukemia;AGE-RAGE signaling pathway in diabetic complications; | 2.72 | 1.74 | 1.56 |
| Isometheptene | DB06706 | ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 2.68 | 2.92 | 0.92 |
| Methantheline | DB00940 | ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 2.68 | 2.92 | 0.92 |
| Nizatidine | DB00585 | ADRB2;HTR1F; | Pentose phosphate pathway;Natural killer cell mediated cytotoxicity;Antigen processing and presentation; | 2.68 | 2.92 | 0.92 |
| L-Lysine | DB00123 | KIF11;KARS; | Primary immunodeficiency;Cell cycle;Th17 cell differentiation; | 2.65 | 2.28 | 1.16 |
| Estramustine | DB01196 | PTPN11;PTPN6; | Vibrio cholerae infection;Pathogenic Escherichia coli infection;Renal cell carcinoma; | 2.62 | 1.48 | 1.77 |
| Acetyldigitoxin | DB00511 | TNF;KCNA3; | RNA polymerase;Huntington disease;Staphylococcus aureus infection; | 2.61 | 1.36 | 1.92 |
| Digoxin | DB00390 | TNF;KCNA3; | RNA polymerase;Huntington disease;Staphylococcus aureus infection; | 2.61 | 1.36 | 1.92 |
| Valbenazine | DB11915 | PDE4B;CYP2C9; | Systemic lupus erythematosus;Alcoholism;Drug metabolism - cytochrome P450; | 2.61 | 0.98 | 2.66 |
| Aminolevulinic-acid | DB00855 | PEPD;ALAD; | cAMP signaling pathway;Human cytomegalovirus infection;Regulation of lipolysis in adipocytes; | 2.50 | 8.61 | 0.29 |
| Enasidenib | DB13874 | CDK1;EGLN1; | Cell cycle;Antifolate resistance;Vasopressin-regulated water reabsorption; | 2.29 | 0.90 | 2.55 |
| Cerivastatin | DB00439 | PSMB5;LTB4R; | Sphingolipid signaling pathway;Transcriptional misregulation in cancer;GnRH signaling pathway; | 2.26 | 1.87 | 1.21 |
| Ouabain | DB01092 | STAT1;KLF5; | Phosphatidylinositol signaling system;Spliceosome;Choline metabolism in cancer; | 2.26 | 3.18 | 0.71 |
| Cobimetinib | DB05239 | MAP2K1;MAP2K4; | Glycosphingolipid biosynthesis - globo and isoglobo series;VEGF signaling pathway;Oocyte meiosis; | 2.13 | 1.12 | 1.91 |
| Etravirine | DB06414 | ABCB1;AMD1; | Thiamine metabolism;Thyroid hormone signaling pathway;Galactose metabolism; | 2.12 | 1.20 | 1.77 |
| Empagliflozin | DB09038 | BCL2A1;SLC5A1; | Inflammatory bowel disease;Pentose phosphate pathway;Th1 and Th2 cell differentiation; | 2.03 | 3.39 | 0.6 |
| Ertugliflozin | DB11827 | BCL2A1;SLC5A1; | Inflammatory bowel disease;Pentose phosphate pathway;Th1 and Th2 cell differentiation; | 2.03 | 3.39 | 0.6 |
| Ticarcillin | DB01607 | G6PD;DNMT1; | "Valine, leucine and isoleucine degradation;Pentose phosphate pathway;Central carbon metabolism in cancer;" | 1.96 | 1.22 | 1.6 |
| Chlormerodrin | DB00534 | ALDH1A1;ALDH5A1; | Natural killer cell mediated cytotoxicity;Th1 and Th2 cell differentiation;T cell receptor signaling pathway; | 1.53 | 3.25 | 0.47 |
| Cysteine | DB00151 | GCLC;GADL1; | Cocaine addiction;Viral myocarditis;Thermogenesis; | 1.47 | 3.86 | 0.38 |
| Flucytosine | DB01099 | DNMT1;TYMS; | "Pyrimidine metabolism;Valine, leucine and isoleucine degradation;Antifolate resistance;" | 1.13 | 1.06 | 1.07 |
| Choline | DB00122 | NLGN2;PHOSPHO1; | Endocytosis;Necroptosis;Olfactory transduction; | 0.98 | 2.22 | 0.44 |
| Lusutrombopag | DB13125 | ITGA4;CTSA; | Th1 and Th2 cell differentiation;T cell receptor signaling pathway;Sulfur relay system; | 0.92 | 0.87 | 1.05 |
| Ribostamycin | DB03615 | PDIA3;NMUR1; | Pathways in cancer;Glyoxylate and dicarboxylate metabolism;Spliceosome; | 0.89 | 1.69 | 0.53 |
| Biotin | DB00121 | PCCB;MCCC2; | Leishmaniasis;Proteoglycans in cancer;ErbB signaling pathway; | 0.89 | 1.90 | 0.47 |
| Methohexital | DB00474 | GABRB3;GABRE; | Ubiquitin mediated proteolysis;Morphine addiction;Proteasome; | 0.86 | 1.68 | 0.51 |
| Avatrombopag | DB11995 | SLC22A1;ABCG1; | Neutrophil extracellular trap formation;Alcoholism;Viral carcinogenesis; | 0.85 | 1.80 | 0.47 |
| Chloramphenicol | DB00446 | TOP2A;SLC5A1; | Glycerophospholipid metabolism;PPAR signaling pathway;Choline metabolism in cancer; | 0.82 | 0.81 | 1.01 |
| Pamidronic-acid | DB00282 | TRIM24;CASP2; | Apoptosis;Platinum drug resistance;Hepatitis C; | 0.74 | 2.75 | 0.27 |
| Gentamicin | DB00798 | DHFR;LRP8; | Alcoholism;Folate biosynthesis;One carbon pool by folate; | 0.33 | 0.61 | 0.55 |
| Thimerosal | DB11590 | MTR;SLC7A6; | RNA transport;Metabolic pathways;Phagosome; | 0.28 | 0.72 | 0.39 |
| Dantrolene | DB01219 | PDE4B;RYR2; | Axon guidance;Histidine metabolism;Proteasome; | 0.27 | 0.16 | 1.64 |
| Asparagine | DB00174 | SLC1A3;SLC1A1; | Complement and coagulation cascades;Malaria;Pertussis; | 0.21 | 1.17 | 0.18 |
| Sucralfate | DB00364 | ANGPT2;FGL2; | Viral protein interaction with cytokine and cytokine receptor;Human cytomegalovirus infection;Cholesterol metabolism; | 0.16 | 1.22 | 0.13 |
| Lomustine | DB01206 | STMN1;STMN2; | p53 signaling pathway;Non-homologous end-joining;Vasopressin-regulated water reabsorption; | 0.14 | 0.64 | 0.22 |
| Liotrix | DB01583 | NR1H3;RARB; | Circadian rhythm;Platinum drug resistance;Adipocytokine signaling pathway; | 0.08 | 0.17 | 0.46 |
| Loteprednol-etabonate | DB14596 | RAF1; | GnRH secretion;Bladder cancer;Non-small cell lung cancer; | 22.53 | 9.79 | 2.3 |
| Voxilaprevir | DB12026 | ELA2; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Human immunodeficiency virus 1 infection; | 8.32 | 4.40 | 1.89 |
| Nepafenac | DB06802 | HDAC1; | Th1 and Th2 cell differentiation;Amoebiasis;Th17 cell differentiation; | 7.69 | 2.99 | 2.57 |
| Paritaprevir | DB09297 | HDAC1; | Th1 and Th2 cell differentiation;Amoebiasis;Th17 cell differentiation; | 7.69 | 2.99 | 2.57 |
| Procarbazine | DB01168 | HDAC1; | Th1 and Th2 cell differentiation;Amoebiasis;Th17 cell differentiation; | 7.69 | 2.99 | 2.57 |
| Gemeprost | DB08964 | POLB; | Phospholipase D signaling pathway;Ras signaling pathway;Phosphatidylinositol signaling system; | 5.78 | 6.42 | 0.9 |
| Misoprostol | DB00929 | POLB; | Phospholipase D signaling pathway;Ras signaling pathway;Phosphatidylinositol signaling system; | 5.78 | 6.42 | 0.9 |
| Nitisinone | DB00348 | ALOX5; | Spliceosome;Chemokine signaling pathway;Pathways in cancer; | 5.13 | 2.54 | 2.02 |
| Phenacemide | DB01121 | ALOX5; | Spliceosome;Chemokine signaling pathway;Pathways in cancer; | 5.13 | 2.54 | 2.02 |
| Patent-Blue | DB13967 | ALB; | Necroptosis;Prion disease;Non-alcoholic fatty liver disease; | 5.02 | 2.45 | 2.05 |
| Phenol | DB03255 | ALB; | Necroptosis;Prion disease;Non-alcoholic fatty liver disease; | 5.02 | 2.45 | 2.05 |
| Chlormezanone | DB01178 | MMP9; | Inflammatory bowel disease;T cell receptor signaling pathway;Th1 and Th2 cell differentiation; | 4.48 | 2.21 | 2.03 |
| Cefixime | DB00671 | ALB; | Necroptosis;Prion disease;Non-alcoholic fatty liver disease; | 4.04 | 2.45 | 1.65 |
| Cefpodoxime | DB01416 | ALB; | Necroptosis;Prion disease;Non-alcoholic fatty liver disease; | 4.04 | 2.45 | 1.65 |
| Ceftizoxime | DB01332 | ALB; | Necroptosis;Prion disease;Non-alcoholic fatty liver disease; | 4.04 | 2.45 | 1.65 |
| Didanosine | DB00900 | ALB; | Necroptosis;Prion disease;Non-alcoholic fatty liver disease; | 4.04 | 2.45 | 1.65 |
| Clobetasone | DB13158 | FNTA; | Calcium signaling pathway;RNA transport;MicroRNAs in cancer; | 3.86 | 2.40 | 1.61 |
| Fosphenytoin | DB01320 | CTSG; | Inflammatory bowel disease;Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity; | 3.63 | 3.21 | 1.13 |
| Almitrine | DB01430 | MAPK14; | Starch and sucrose metabolism;Epithelial cell signaling in Helicobacter pylori infection;Fluid shear stress and atherosclerosis; | 3.52 | 1.40 | 2.52 |
| Guaifenesin | DB00874 | GRIN2D; | Calcium signaling pathway;Spliceosome;Phosphatidylinositol signaling system; | 3.06 | 3.03 | 1.01 |
| Magnesium-acetate-tetrahydrate | DB09409 | GRIN2D; | Calcium signaling pathway;Spliceosome;Phosphatidylinositol signaling system; | 3.06 | 3.03 | 1.01 |
| Efinaconazole | DB09040 | DRD2; | Pantothenate and CoA biosynthesis;Hepatitis C;Type I diabetes mellitus; | 2.99 | 1.48 | 2.02 |
| Luliconazole | DB08933 | DRD2; | Pantothenate and CoA biosynthesis;Hepatitis C;Type I diabetes mellitus; | 2.99 | 1.48 | 2.02 |
| Streptomycin | DB01082 | PADI4; | Inflammatory bowel disease;Graft-versus-host disease;T cell receptor signaling pathway; | 2.98 | 2.82 | 1.06 |
| Mexiletine | DB00379 | CYP19A1; | VEGF signaling pathway;Human immunodeficiency virus 1 infection;Oocyte meiosis; | 2.57 | 1.21 | 2.12 |
| Peramivir | DB06614 | CYP19A1; | VEGF signaling pathway;Human immunodeficiency virus 1 infection;Oocyte meiosis; | 2.57 | 1.21 | 2.12 |
| 5-O-phosphono-alpha-D-ribofuranosyl-diphosphate | DB01632 | ITPR1; | Transcriptional misregulation in cancer;NF-kappa B signaling pathway;Neutrophil extracellular trap formation; | 2.57 | 3.05 | 0.84 |
| Hydralazine | DB01275 | MPO; | Graft-versus-host disease;Cortisol synthesis and secretion;NF-kappa B signaling pathway; | 2.52 | 1.82 | 1.38 |
| Cetrimonium | DB01718 | SLC22A1; | Neutrophil extracellular trap formation;Alcoholism;Viral carcinogenesis; | 2.27 | 1.20 | 1.9 |
| Didecyldimethylammonium | DB04221 | SLC22A1; | Neutrophil extracellular trap formation;Alcoholism;Viral carcinogenesis; | 2.27 | 1.20 | 1.9 |
| Irinotecan | DB00762 | SLC22A1; | Neutrophil extracellular trap formation;Alcoholism;Viral carcinogenesis; | 2.27 | 1.20 | 1.9 |
| Pancuronium | DB01337 | SLC22A1; | Neutrophil extracellular trap formation;Alcoholism;Viral carcinogenesis; | 2.27 | 1.20 | 1.9 |
| Pipecuronium | DB01338 | SLC22A1; | Neutrophil extracellular trap formation;Alcoholism;Viral carcinogenesis; | 2.27 | 1.20 | 1.9 |
| Rocuronium | DB00728 | SLC22A1; | Neutrophil extracellular trap formation;Alcoholism;Viral carcinogenesis; | 2.27 | 1.20 | 1.9 |
| Dipyrithione | DB11327 | EHMT2; | Apelin signaling pathway;Pathways in cancer;Glutamatergic synapse; | 2.24 | 3.66 | 0.61 |
| Fluticasone | DB13867 | NR3C2; | Cytosolic DNA-sensing pathway;NF-kappa B signaling pathway;Salmonella infection; | 1.88 | 0.89 | 2.11 |
| Fluticasone-furoate | DB08906 | NR3C2; | Cytosolic DNA-sensing pathway;NF-kappa B signaling pathway;Salmonella infection; | 1.88 | 0.89 | 2.11 |
| Fluticasone-propionate | DB00588 | NR3C2; | Cytosolic DNA-sensing pathway;NF-kappa B signaling pathway;Salmonella infection; | 1.88 | 0.89 | 2.11 |
| Anidulafungin | DB00362 | CYP2C9; | Systemic lupus erythematosus;Alcoholism;Drug metabolism - cytochrome P450; | 1.84 | 0.98 | 1.88 |
| Bicalutamide | DB01128 | CYP2C9; | Systemic lupus erythematosus;Alcoholism;Drug metabolism - cytochrome P450; | 1.84 | 0.98 | 1.88 |
| Doravirine | DB12301 | CYP2C9; | Systemic lupus erythematosus;Alcoholism;Drug metabolism - cytochrome P450; | 1.84 | 0.98 | 1.88 |
| Lefamulin | DB12825 | CYP2C9; | Systemic lupus erythematosus;Alcoholism;Drug metabolism - cytochrome P450; | 1.84 | 0.98 | 1.88 |
| Micafungin | DB01141 | CYP2C9; | Systemic lupus erythematosus;Alcoholism;Drug metabolism - cytochrome P450; | 1.84 | 0.98 | 1.88 |
| Retapamulin | DB01256 | CYP2C9; | Systemic lupus erythematosus;Alcoholism;Drug metabolism - cytochrome P450; | 1.84 | 0.98 | 1.88 |
| Flucloxacillin | DB00301 | PYGL; | Inflammatory bowel disease;Transcriptional misregulation in cancer;Th1 and Th2 cell differentiation; | 1.69 | 2.22 | 0.76 |
| Fluocinonide | DB01047 | NR3C2; | Cytosolic DNA-sensing pathway;NF-kappa B signaling pathway;Salmonella infection; | 1.58 | 0.89 | 1.77 |
| Halcinonide | DB06786 | NR3C2; | Cytosolic DNA-sensing pathway;NF-kappa B signaling pathway;Salmonella infection; | 1.58 | 0.89 | 1.77 |
| Parachlorophenol | DB13154 | ALOX12; | Platelet activation;Tight junction;Pathogenic Escherichia coli infection; | 1.41 | 1.77 | 0.8 |
| Carbimazole | DB00389 | MPO; | Graft-versus-host disease;Cortisol synthesis and secretion;NF-kappa B signaling pathway; | 1.39 | 1.82 | 0.76 |
| Methimazole | DB00763 | MPO; | Graft-versus-host disease;Cortisol synthesis and secretion;NF-kappa B signaling pathway; | 1.39 | 1.82 | 0.76 |
| Propylthiouracil | DB00550 | MPO; | Graft-versus-host disease;Cortisol synthesis and secretion;NF-kappa B signaling pathway; | 1.39 | 1.82 | 0.76 |
| Anagrelide | DB00261 | PDE3B; | Choline metabolism in cancer;Herpes simplex virus 1 infection;Kaposi sarcoma-associated herpesvirus infection; | 1.34 | 3.94 | 0.34 |
| Phenazopyridine | DB01438 | CDK1; | Cell cycle;Antifolate resistance;Hematopoietic cell lineage; | 1.25 | 0.57 | 2.18 |
| Auranofin | DB00995 | CA2; | Complement and coagulation cascades;African trypanosomiasis;Malaria; | 1.22 | 0.64 | 1.91 |
| Isocarboxazid | DB01247 | CA2; | Complement and coagulation cascades;African trypanosomiasis;Malaria; | 1.22 | 0.64 | 1.91 |
| Metamizole | DB04817 | CA2; | Complement and coagulation cascades;African trypanosomiasis;Malaria; | 1.22 | 0.64 | 1.91 |
| Paramethadione | DB00617 | CA2; | Complement and coagulation cascades;African trypanosomiasis;Malaria; | 1.22 | 0.64 | 1.91 |
| Polythiazide | DB01324 | CA2; | Complement and coagulation cascades;African trypanosomiasis;Malaria; | 1.22 | 0.64 | 1.91 |
| Risedronic-acid | DB00884 | CA2; | Complement and coagulation cascades;African trypanosomiasis;Malaria; | 1.22 | 0.64 | 1.91 |
| Tavaborole | DB09041 | CA2; | Complement and coagulation cascades;African trypanosomiasis;Malaria; | 1.22 | 0.64 | 1.91 |
| Tetradecyl-hydrogen-sulfate-(ester) | DB11328 | CA2; | Tetradecyl-hydrogen-sulfate-ester | 1.22 | 0.64 | 1.91 |
| Trimethadione | DB00347 | CA2; | Complement and coagulation cascades;African trypanosomiasis;Malaria; | 1.22 | 0.64 | 1.91 |
| Zoledronic-acid | DB00399 | CA2; | Complement and coagulation cascades;African trypanosomiasis;Malaria; | 1.22 | 0.64 | 1.91 |
| Trospium | DB00209 | SIRT1; | RNA transport;Staphylococcus aureus infection;Oxidative phosphorylation; | 1.09 | 0.80 | 1.36 |
| Sapropterin | DB00360 | TH; | Influenza A;Ribosome;Epstein-Barr virus infection; | 0.96 | 1.40 | 0.69 |
| Halofantrine | DB01218 | UBE2N; | Glutamatergic synapse;Morphine addiction;Arginine biosynthesis; | 0.95 | 0.80 | 1.19 |
| Ganciclovir | DB01004 | TK1; | Drug metabolism - other enzymes;Pyrimidine metabolism;Phagosome; | 0.90 | 1.47 | 0.61 |
| Penciclovir | DB00299 | TK1; | Drug metabolism - other enzymes;Pyrimidine metabolism;Phagosome; | 0.90 | 1.47 | 0.61 |
| Methocarbamol | DB00423 | CA2; | Complement and coagulation cascades;African trypanosomiasis;Malaria; | 0.88 | 0.64 | 1.38 |
| Amifostine | DB01143 | ALPL; | Th17 cell differentiation;Th1 and Th2 cell differentiation;Starch and sucrose metabolism; | 0.70 | 1.02 | 0.69 |
| Proparacaine | DB00807 | PPID; | Metabolic pathways;Oxidative phosphorylation;Pancreatic secretion; | 0.54 | 0.99 | 0.55 |
| Propoxycaine | DB09342 | PPID; | Metabolic pathways;Oxidative phosphorylation;Pancreatic secretion; | 0.54 | 0.99 | 0.55 |
| Mercaptopurine | DB01033 | IMPDH1; | Notch signaling pathway;Biosynthesis of amino acids;Metabolic pathways; | 0.54 | 1.04 | 0.52 |
| Mycophenolate-mofetil | DB00688 | IMPDH1; | Notch signaling pathway;Biosynthesis of amino acids;Metabolic pathways; | 0.54 | 1.04 | 0.52 |
| Ribavirin | DB00811 | IMPDH1; | Notch signaling pathway;Biosynthesis of amino acids;Metabolic pathways; | 0.54 | 1.04 | 0.52 |
| L-Glutamine | DB00130 | GLUL; | Spliceosome;GABAergic synapse;Glutamatergic synapse; | 0.52 | 1.04 | 0.5 |
| Capecitabine | DB01101 | TYMS; | Pyrimidine metabolism;Antifolate resistance;Cell cycle; | 0.51 | 0.53 | 0.96 |
| Fluorouracil | DB00544 | TYMS; | Pyrimidine metabolism;Antifolate resistance;Cell cycle; | 0.51 | 0.53 | 0.96 |
| Tegafur | DB09256 | TYMS; | Pyrimidine metabolism;Antifolate resistance;Cell cycle; | 0.51 | 0.53 | 0.96 |
| Tegafur-uracil | DB09327 | TYMS; | Pyrimidine metabolism;Antifolate resistance;Cell cycle; | 0.51 | 0.53 | 0.96 |
| Besifloxacin | DB06771 | EGLN1; | Vasopressin-regulated water reabsorption;Endocytosis; | 0.46 | 0.33 | 1.42 |
| Gemifloxacin | DB01155 | EGLN1; | Vasopressin-regulated water reabsorption;Endocytosis; | 0.46 | 0.33 | 1.42 |
| Cefoxitin | DB01331 | DNMT1; | "Valine, leucine and isoleucine degradation;Staphylococcus aureus infection;RNA transport;" | 0.44 | 0.53 | 0.82 |
| Cefuroxime | DB01112 | DNMT1; | "Valine, leucine and isoleucine degradation;Staphylococcus aureus infection;RNA transport;" | 0.44 | 0.53 | 0.82 |
| Acetylcholine | DB03128 | NLGN2; | Endocytosis;Necroptosis;Olfactory transduction; | 0.42 | 2.22 | 0.19 |
| Ambenonium | DB01122 | NLGN2; | Endocytosis;Necroptosis;Olfactory transduction; | 0.42 | 2.22 | 0.19 |
| Carbamoylcholine | DB00411 | NLGN2; | Endocytosis;Necroptosis;Olfactory transduction; | 0.42 | 2.22 | 0.19 |
| Choline-salicylate | DB14006 | NLGN2; | Endocytosis;Necroptosis;Olfactory transduction; | 0.42 | 2.22 | 0.19 |
| Demecarium | DB00944 | NLGN2; | Endocytosis;Necroptosis;Olfactory transduction; | 0.42 | 2.22 | 0.19 |
| Edrophonium | DB01010 | NLGN2; | Endocytosis;Necroptosis;Olfactory transduction; | 0.42 | 2.22 | 0.19 |
| Gallamine-triethiodide | DB00483 | NLGN2; | Endocytosis;Necroptosis;Olfactory transduction; | 0.42 | 2.22 | 0.19 |
| Neostigmine | DB01400 | NLGN2; | Endocytosis;Necroptosis;Olfactory transduction; | 0.42 | 2.22 | 0.19 |
| Pralidoxime | DB00733 | NLGN2; | Endocytosis;Necroptosis;Olfactory transduction; | 0.42 | 2.22 | 0.19 |
| Digitoxin | DB01396 | KCNA3; | RNA polymerase;Huntington disease;Bacterial invasion of epithelial cells; | 0.42 | 0.46 | 0.9 |
| Dexrazoxane | DB00380 | TOP2A; | Glycerophospholipid metabolism;PPAR signaling pathway;Choline metabolism in cancer; | 0.39 | 0.32 | 1.22 |
| Mitoxantrone | DB01204 | TOP2A; | Glycerophospholipid metabolism;PPAR signaling pathway;Choline metabolism in cancer; | 0.39 | 0.32 | 1.22 |
| Valrubicin | DB00385 | TOP2A; | Glycerophospholipid metabolism;PPAR signaling pathway;Choline metabolism in cancer; | 0.39 | 0.32 | 1.22 |
| Dacarbazine | DB00851 | PGD; | Pentose phosphate pathway;Vasopressin-regulated water reabsorption;Fc epsilon RI signaling pathway; | 0.34 | 0.53 | 0.65 |
| Gadopentetic-acid | DB00789 | PGD; | Pentose phosphate pathway;Vasopressin-regulated water reabsorption;Fc epsilon RI signaling pathway; | 0.34 | 0.53 | 0.65 |
| Lacidipine | DB09236 | CACNB3; | Complement and coagulation cascades;Glycosphingolipid biosynthesis - ganglio series;Melanoma; | 0.33 | 0.48 | 0.69 |
| Selinexor | DB11942 | XPO1; | RNA transport;Amyotrophic lateral sclerosis;MicroRNAs in cancer; | 0.29 | 0.48 | 0.6 |
| Cyanocobalamin | DB00115 | MTR; | RNA transport;Metabolic pathways;Phagosome; | 0.28 | 0.72 | 0.39 |
| Mecobalamin | DB03614 | MTR; | RNA transport;Metabolic pathways;Phagosome; | 0.28 | 0.72 | 0.39 |
| Omacetaxine-mepesuccinate | DB04865 | RPL8; | DNA replication;Ribosome;Coronavirus disease - COVID-19; | 0.27 | 1.08 | 0.25 |
| Etelcalcetide | DB12865 | FURIN; | Transcriptional misregulation in cancer;Neutrophil extracellular trap formation;Sphingolipid signaling pathway; | 0.26 | 1.25 | 0.21 |
| Brivaracetam | DB05541 | SCN2B; | Spliceosome;Phototransduction;Alcoholism; | 0.26 | 1.30 | 0.2 |
| Dichlorobenzyl-alcohol | DB13269 | SCN2B; | Spliceosome;Phototransduction;Alcoholism; | 0.26 | 1.30 | 0.2 |
| Bacitracin | DB00626 | NRD1; | Calcium signaling pathway;Melanogenesis;GnRH signaling pathway; | 0.26 | 3.20 | 0.08 |
| Ethosuximide | DB00593 | CRBN; | Legionellosis;Viral carcinogenesis;Longevity regulating pathway - multiple species; | 0.23 | 1.27 | 0.18 |
| Betahistine | DB06698 | PSMB5; | Proteasome;Spinocerebellar ataxia; | 0.22 | 0.17 | 1.32 |
| Azlocillin | DB01061 | PTGES; | Glycosaminoglycan biosynthesis - keratan sulfate;2-Oxocarboxylic acid metabolism;Glycosphingolipid biosynthesis - lacto and neolacto series; | 0.20 | 0.15 | 1.32 |
| Fosfomycin | DB00828 | CBX7; | Notch signaling pathway;Thyroid hormone signaling pathway;Metabolic pathways; | 0.15 | 0.30 | 0.49 |
| Pyridoxine | DB00165 | PDXK; | Neutrophil extracellular trap formation;Drug metabolism - other enzymes;Phagosome; | 0.12 | 0.53 | 0.23 |
| Isosorbide-mononitrate | DB01020 | GUCY1B3; | Transcriptional misregulation in cancer;Circadian entrainment;GABAergic synapse; | 0.12 | 0.61 | 0.19 |
| Methylene-blue | DB09241 | GUCY1B3; | Transcriptional misregulation in cancer;Circadian entrainment;GABAergic synapse; | 0.12 | 0.61 | 0.19 |
| Molsidomine | DB09282 | GUCY1B3; | Transcriptional misregulation in cancer;Circadian entrainment;GABAergic synapse; | 0.12 | 0.61 | 0.19 |
| Plecanatide | DB13170 | GUCY1B3; | Transcriptional misregulation in cancer;Circadian entrainment;GABAergic synapse; | 0.12 | 0.61 | 0.19 |
| Flecainide | DB01195 | RYR2; | Axon guidance;Histidine metabolism;One carbon pool by folate; | 0.11 | 0.16 | 0.67 |
| Kanamycin | DB01172 | NMUR1; | D-Glutamine and D-glutamate metabolism;AMPK signaling pathway;Protein export; | 0.09 | 0.17 | 0.51 |
| Tobramycin | DB00684 | NMUR1; | D-Glutamine and D-glutamate metabolism;AMPK signaling pathway;Protein export; | 0.09 | 0.17 | 0.51 |
| Mitotane | DB00648 | FDX1; | RNA transport;Leishmaniasis;IL-17 signaling pathway; | 0.08 | 1.04 | 0.08 |
| Inositol-nicotinate | DB08949 | HCAR3; | Leishmaniasis;RNA transport;Inflammatory bowel disease; | 0.08 | 1.31 | 0.06 |
| Cangrelor | DB06441 | GPR171; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 0.07 | 3.27 | 0.02 |
| Treprostinil | DB00374 | GPR171; | Th1 and Th2 cell differentiation;Natural killer cell mediated cytotoxicity;Th17 cell differentiation; | 0.07 | 3.27 | 0.02 |
| Riluzole | DB00740 | SLC7A6; | Non-homologous end-joining;Protein export;cAMP signaling pathway; | 0.00 | 0.00 | 0.16 |
| Ciprofibrate | DB09064 | RARB; | Circadian rhythm;Adipocytokine signaling pathway; | 0.00 | 0.00 | 0.3 |
| Drotaverine | DB06751 | PDE4B; | Proteasome; | 0.00 | 0.00 | 1.74 |
| Allopurinol | DB00437 | PARP1; | Aminoacyl-tRNA biosynthesis;Non-homologous end-joining; | 0.00 | 0.00 | 2.44 |
| Dolutegravir | DB08930 | PARP1; | Aminoacyl-tRNA biosynthesis;Non-homologous end-joining; | 0.00 | 0.00 | 2.44 |
| D-alpha-Tocopherol-acetate | DB14002 | ALOX5;PRKCA;PRKACA; | Spliceosome;Platelet activation;Coronavirus disease - COVID-19; | 0.00 | 0.00 | 0 |
